Compositions of human heart-derived extracellular vesicles and their uses

Extracellular vesicles derived from human cardiac cells provide a novel treatment for atrial arrhythmias by targeting multiple underlying mechanisms, reducing inflammation and fibrosis to decrease atrial fibrillation incidence and duration.

JP2024543456APending Publication Date: 2024-11-21UNIVERSITY OF OTTAWA HEART INSTITUTE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024527770
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-12
Filing Date
2022-11-11
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for atrial arrhythmias, such as atrial fibrillation, are limited by serious side effects and limited efficacy, as they primarily target heart rate without addressing underlying mechanisms like inflammation and fibrosis.

Method used

Compositions comprising extracellular vesicles derived from human cardiac cells, which can reduce atrial fibrosis, inflammation, and fibroblast proliferation, thereby addressing multiple mechanisms contributing to atrial arrhythmias.

Benefits of technology

The extracellular vesicles effectively reduce atrial inflammation and fibrosis, leading to a decrease in atrial fibrillation incidence and duration, with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543456000001_ABST
    Figure 2024543456000001_ABST
Patent Text Reader

Abstract

Compositions of human heart-derived extracellular vesicles are provided. These compositions can include extracellular vesicles and biologically or pharma- ceutical acceptable adjuvants or carriers, and the extracellular vesicles can include one or more of the following characteristics: extracellular vesicles isolated from human heart cells, a polydisperse population of particles, one or more cytoplasmic markers, one or more transmembrane markers, acetylcholinesterase activity, substantially absent or absent one or more contaminants, unique miRNA transcripts, and unit doses of extracellular vesicles. Also provided is the use of the compositions of human heart-derived extracellular vesicles in the treatment and prevention of atrial arrhythmias, atrial inflammation, atrial fibrosis, and atrial fibroblast proliferation.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates generally to the treatment or prevention of atrial arrhythmias. More specifically, the present invention relates to compositions comprising extracellular vesicles, and uses and methods for the treatment of atrial arrhythmias. [Background technology]

[0002] Atrial arrhythmias, including atrial fibrillation, are the most common heart rhythm disorder in the world, affecting approximately 38 million people worldwide (Benjamin, Levy et al. 1994; Furberg, Psaty et al. 1994; Go, Hylek et al. 2001). Patients with atrial arrhythmias may present with symptoms that can significantly impact their quality of life, including but not limited to general fatigue, rapid heart rate, irregular heartbeat, dizziness, shortness of breath, anxiety, weakness, confusion, fainting, sweating, chest pain, chest pressure, syncope, palpitations, and palpitations. Atrial arrhythmias occur when the upper chambers of the heart (atria) beat irregularly and out of sync with the lower chambers of the heart (ventricles), resulting in an irregular heartbeat. Ventricular arrhythmias also occur when the ventricles do not beat in sync with the atria, but such arrhythmias differ significantly from atrial arrhythmias in underlying causes, treatment, symptoms, and mortality. Therefore, many therapies that suppress ventricular arrhythmias are ineffective against atrial arrhythmias (Ledan 2020). Specifically, drugs that reduce electrical conductivity are contraindicated in patients with ventricular arrhythmias because they increase the risk of death (Friberg 2018).

[0003] Although atrial arrhythmias are not inherently life-threatening, they do increase the risk of blood clots and stroke by fivefold (McRae, Kapoor et al. 2019). Without significant advances in the treatment or prevention of atrial arrhythmias, this will also lead to increased hospitalizations and strokes (Go, Hylek et al. 2001;Seo,michie et al. 2020). Rhythm and rate-controlling drugs are common pharmacological treatments for atrial arrhythmias, but they are often ineffective and off-target effects on blood pressure and cardiac function limit their use.

[0004] Due to limitations in the treatment and prevention of atrial arrhythmias with current therapies, recent preclinical research has focused on biologic therapies targeting mechanisms thought to drive atrial arrhythmias, such as reducing inflammation and modifying atrial electrophysiology (McRae, Kapoor et al. 2019; Seo, Michie et al. 2020).

[0005] Alternative, additional, and / or improved therapies for atrial arrhythmias are desirable. Summary of the Invention [Problem to be solved by the invention]

[0006] Traditionally, atrial arrhythmias have been treated with drugs that control the heartbeat and return it to a normal rhythm. These drugs are only moderately effective, have significant side effects, and become less effective over time. Other treatment options include electrical cardioversion, catheter procedures, and surgical procedures. Catheter ablation is commonly used, but success rates vary widely and serious complications can occur (Lycke, O'Neill et al. 2021). A limitation of current drug approaches is that they can only target heart rate but do not address other mechanisms that may cause atrial arrhythmias, such as fibrosis, fibroblast proliferation, and inflammation (Jost, Christ et al. 2021). Biologically based therapeutic options are emerging to treat atrial arrhythmias, but to date have not progressed to clinical trials.

[0007] Extracellular vesicles are naturally secreted, non-replicative particles bound by lipid bilayers that carry heterogeneous components, including but not limited to organelles, nucleic acids, proteins, lipids, metabolites, etc., and may target multiple mechanisms related to the suppression of atrial arrhythmias. The composition of extracellular vesicles varies depending on the tissue, cell, and physiological parameters. Thus, it has proven difficult to obtain compositions that are effective for the treatment of specific diseases, although clinical trials have been initiated for several extracellular vesicle-related therapeutics (Ciferri, Quarto et al. 2021). The inventors hypothesized that extracellular vesicles secreted by human cardiac cells may treat or prevent atrial fibrosis and atrial inflammation, which may contribute to the development of atrial arrhythmias. Therefore, the studies described herein below were conducted to investigate whether extracellular vesicles derived from human cardiac cells could provide a treatment for atrial arrhythmias, such as atrial fibrillation. [Means for solving the problem]

[0008] The teachings herein provide compositions and methods comprising extracellular vesicles derived from human cardiac cells and their use in the treatment and prevention of atrial arrhythmias, atrial inflammation, atrial fibrosis and atrial fibroblast proliferation.

[0009] In one embodiment, provided herein is a composition comprising an extracellular vesicle and a biologically or pharma- ceutically acceptable adjuvant or carrier, wherein the extracellular vesicle may comprise one or more of the following characteristics:

[0010] Extracellular vesicles isolated from human cardiac cells;

[0011] a polydisperse population of particles ranging from about 1 nm to about 1000 nm, or any value defining that range;

[0012] one or more cytoplasmic markers defined by ALIX, any ANXA polypeptide, any ACT polypeptide, TSG101, any CHMP polypeptide, PDCD6IP, VPS4A, VPS4B, ARRDC1, any CAV polypeptide, any EHD polypeptide, RHOA, HSPA8, HSPA1A, any actin polypeptide, any tubulin polypeptide, GAPDH, HSP90AB1, ARF6, SDCBP, MAPT, HSC70, HSP70, HSP84, HSPA8 and TSG101, or a combination thereof;

[0013] one or more transmembrane markers defined by CD3, CD9, CD14, CD37, CD41, CD45, CD47, CD53, CD55, CD59, CD61, CD63, CD73, CD81, CD82, CD90, any GNA polypeptide, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DQ, any H2-A, H2-K, H2-D, H2-Q polypeptides, any ITGA polypeptide, any ITGB polypeptide, TFR2, LAMP1, LAMP2, any SDC polypeptide, BSG, ADAM10, SHH, TSPAN8, PECAM1, ERBB2, EPCAM, CDC42a, GYPA, AChE-S, AChE-E, AβA4, APP, ABCC1, FLOT1, FLOT2, ICAM1, EpCam, or a combination thereof;

[0014] Acetylcholinesterase activity;

[0015] Substantially absent or absent one or more of the following groups: GM130, APOA1, APOA2, APOB, APOB100, ALB, ribosomal proteins, UMOD, and protein / nucleic acid aggregates, and 1-1000 unique miRNA transcripts.

[0016] and about 10 per milliliter 2 From 10 to 10 20 A unit dose of extracellular vesicles containing particles, or any value defining a range thereof.

[0017] In another embodiment of the composition, the human cardiac cells can be autologous or allogeneic to the subject to which the composition is administered.

[0018] In another embodiment of the composition, the extracellular vesicles can be absorbed by immune cells, including, but not limited to, lymphocytes, T cells, B cells, NK cells, monocytes, macrophages, and neutrophils. In certain embodiments, the extracellular vesicles can reduce the activation of inflammasomes in immune cells. In certain embodiments, the extracellular vesicles can reduce the activation of inflammasomes in immune cells.

[0019] In another embodiment of any of the above compositions, the extracellular vesicles may be absorbed by human cardiac cells. In another embodiment, the human cardiac cells that absorb the extracellular vesicles may be cardiomyocytes, endothelial cells, immune cells and / or fibroblasts. In certain embodiments, absorption by human cardiac cells may be determined by the transport of proteins from the extracellular vesicles to the human cardiac cells. In certain embodiments, it is contemplated that the transport of proteins from the extracellular vesicles to the human cardiac cells may be the transport of one or more proteins, including exogenous proteins, fluorescent proteins, luminescent proteins, proteins capable of undergoing a colorimetric reaction, proteins tagged with a group capable of fluorescence, proteins tagged with a group capable of luminescence, proteins tagged with a group capable of a colorimetric reaction, proteins that are not detectable or are not present in the human cardiac cells, or any combination thereof. In certain further embodiments, the protein tagged with a group capable of fluorescence may be CD63. In certain embodiments, absorption by human cardiac cells may be determined by the transport of membrane lipids from the extracellular vesicles to the human cardiac cells. In further embodiments, the transport of membrane lipids from extracellular vesicles to human cardiac cells can be measured using one or more of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil), KH67 PKH26, any membrane-localizable fluorescent dye, any membrane-localizable luminescent dye, any membrane-localizable colorimetric dye, any functional equivalent, and any combination thereof. In yet further embodiments, the transport of membrane lipids from extracellular vesicles to human cardiac cells can be measured using DiI.

[0020] In another embodiment of any of the above compositions, the human cardiac cells may be derived from a cardiac biopsy. In certain embodiments, the biopsy may include one or more of the following cardiac layers: endocardium, myocardium, epicardium, or any combination thereof. In another embodiment, the human cardiac cells may be derived from myocardial tissue. In certain embodiments, the human cardiac cells may be derived from the atrial appendage. In certain embodiments, the human cardiac cells may be derived from the left atrial appendage. In certain embodiments, the human cardiac cells may be derived from ventricular tissue. In certain embodiments, the human cardiac cells may be derived from the whole heart.

[0021] In another embodiment of any of the above compositions, the extracellular vesicles may be isolated from one or more of the following: atrial explant-derived stem cells, atrial explant-derived cells, cardiac explant-derived stem cells; human cardiac explant-derived cells, cardiac explant-derived cells; cardiac explant-derived stem cells; cardiac explant-derived cells; cardiac cells differentiated from induced pluripotent stem cells; cardiac cells differentiated from ES cells; or cardiac cells derived from any cell type capable of differentiating into cardiac cells.

[0022] In another embodiment of any of the above compositions, the human cardiac cells may be cryopreserved.

[0023] In another embodiment of any of the above compositions, the extracellular vesicles can be isolated from immortalized cell lines.In a further embodiment of any of the above compositions, the extracellular vesicles can be isolated from immortalized cardiac explant-derived cells.In certain embodiments, cardiac explant-derived cells can be immortalized using one or more of the following techniques: viral genes, viral gene products, genetic mutations, telomerase reverse transcriptase expression, SV40, or equivalent techniques.

[0024] In another embodiment of any of the above compositions, the human cardiac cells may be grown in vitro. In a further embodiment, the human cardiac cells may be expanded in vitro. In yet another embodiment, the human cardiac cells may be grown in vitro using Good Manufacturing Practice (GMP) conditions including:

[0025] Controlled physiological cell culture conditions, said conditions including a continuous atmosphere of about 5% oxygen, about 5% carbon dioxide, about 80% relative humidity, and a temperature of about 37°C;

[0026] Serum-free, xeno-free growth medium; and fetal bovine serum depleted of extracellular vesicles.

[0027] In certain embodiments, human cardiac cells may be grown in vitro using GMP conditions, hi another embodiment, human cardiac cells may be grown in vitro using GMP compliant enzymes to detach the cells from the culture plate, where the enzymes may be one or more of TrypLE™ Select, Collagenase I, and Collagenase II.

[0028] In another embodiment of any of the above compositions, the extracellular vesicles can be isolated after about 1 hour to about 196 hours of incubation. In certain embodiments, the extracellular vesicles can be isolated after about 48 hours or more of incubation.

[0029] In another embodiment of any of the above compositions, the composition may be substantially immunologically inert.

[0030] In another embodiment of any of the above compositions, the extracellular vesicles can be a polydisperse population of particles ranging from about 75 nm to about 500 nm, including, but not limited to, any value defining the range of about 95 nm to about 250 nm. In certain embodiments, the extracellular vesicles can be a polydisperse population comprising an average diameter of about 75 nm to about 200 nm. In further embodiments, the extracellular vesicles can be a polydisperse population comprising an average diameter of about 132 nm.

[0031] In another embodiment of any of the above compositions, the one or more cytoplasmic markers may be ALIX, ANXA5, and TSG101, or any combination thereof.

[0032] In another embodiment of any of the above compositions, the one or more transmembrane markers can be CD9, CD61, CD63, CD81, FLOT1, ICAM1, EpCam, or any combination thereof. In further embodiments, CD81 can be expressed on an equal or fewer number of particles than those expressing CD9 or CD63. In certain further embodiments, CD81 can be expressed on about half or less number of particles compared to the number of particles expressing CD63.

[0033] In another embodiment of any of the above compositions, acetylcholinesterase activity can be measured using FluoroCet exosome quantification kit or equivalent methodology. In certain embodiments, acetylcholinesterase activity can be used to quantify the number of extracellular vesicle particles.

[0034] In another embodiment of any of the above compositions, the extracellular vesicles may be substantially devoid of GM130 or may be devoid of GM130.

[0035] In another embodiment of any of the above compositions, the miRNA may be between 10 and 250 unique transcripts. In a particular embodiment, the miRNA may be between 60 and 85 unique transcripts.In a further embodiment, the miRNA can be miR-23a-3p, miR-199a-3p+miR-199b-3p, miR-4454+miR-7975, let-7a-5p, let-7b-5p, miR-125b-5p, miR-100-5P, miR-29b-3p, miR-21-5p, miR-191-5p, miR-199b-5p, miR-29a-3p, miR-22-3P, let-7i-5p, miR-181a-5p, miR-25-3p, miR-127-3p, let-7g-5p, miR-15b-5p, miR-320e, miR-221-3p, let-7d-5p, miR-16-5p, miR-424-5p, miR-3180, miR-374a-5p, miR-15a-5p, miR-130a-3p, miR-376a-3p, miR-199a-5p, miR-222-3p, miR-4286, miR-4516, miR-34a-5p, miR-1255a, miR-365a-3p+miR-365b-3p, miR-323a-3p, let-7c-5p, miR-27b-3p, miR-134-3p, miR-451a, miR-23b-3p, miR-423-5p, miR-28-5p, miR-125a-5p, miR-24-3p, miR-382-5p, miR-1228-3p, miR-20a-5p+miR-20b-5p, let-7e-5p, miR-18a-5p, miR-337-5p, miR-320e, miR-106a-5p+miR-17-5p, miR-19b-3p, miR-140-5p, let-7f-5p, miR-323a-5p, miR-148a-3p, miR-132-3p, miR-136-5p, miR-376c-3p, miR-379-5p, miR-26a-5p, miR-202-3p, miR-1290, miR-154-5p, miR-214-3p, miR-377-3p, miR-381-3p, miR-188-5p, miR-26b-5p, miR-363-3p, miR-337-3p, miR-137, miR-1973, miR-193a-5p+miR-193b-5p, miR-411-5p, functional equivalents, or combinations thereof.In certain embodiments, the miRNA transcript may substantially lack or lack one or more of miR-1, miR-133, miR-328, miR-590, or any combination thereof. In certain embodiments, the miRNA transcript may substantially lack or lack one or more of miR-210, miR-146a, or any combination thereof.

[0036] In another embodiment of any of the above compositions, the unit dose of the extracellular vesicles is 10 per milliliter 8 ~10 15 In a further embodiment, the unit dose of the extracellular vesicles may be 10 per milliliter. 10 It may be a particle.

[0037] In another embodiment of any of the above compositions, the unit dose of extracellular vesicles is 10 2 ~10 20 It may be a particle.

[0038] In another embodiment, any of the compositions described above can be used for treating atrial arrhythmia.In one embodiment, atrial arrhythmia can be selected from the group consisting of atrial fibrillation, postoperative atrial fibrillation, postinfarction atrial fibrillation, thyrotoxicosis, postviral atrial fibrillation, alcohol-related atrial fibrillation, drug-induced atrial fibrillation, viral atrial fibrillation, atrial fibrillation, postviral atrial fibrillation, COVID-19 atrial fibrillation, post-COVID-19 atrial fibrillation, paroxysmal atrial fibrillation, permanent atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, atrial tachycardia, atrial flutter, familial atrial fibrillation, idiopathic atrial fibrillation, isolated atrial fibrillation, and orphan atrial arrhythmia.

[0039] In certain embodiments of any of the above compositions, the extracellular vesicles may be delivered systemically. In other embodiments, the extracellular vesicles may be delivered locally. In certain embodiments, the extracellular vesicles may be delivered intramyocardially. In certain embodiments, the extracellular vesicles may be delivered intraatrium. In certain embodiments, the extracellular vesicles may be delivered by a catheter. In another embodiment, the extracellular vesicles may be delivered by a central venous access device. In another embodiment, the extracellular vesicles may be delivered by a peripherally inserted central catheter.

[0040] In another embodiment of any of the above compositions, the extracellular vesicles may reduce or prevent atrial inflammation. In certain embodiments, the reduction in atrial inflammation may be quantified histologically, including a reduction in the number of inflammatory cells in the atria of the heart when compared to an untreated subject. In further embodiments, the number of inflammatory cells in the atria may be quantified using one or more markers including hematoxylin and eosin staining, activated T lymphocytes, macrophage infiltration, macrophage polarization, mast cells, neutrophils, or any combination thereof. In certain embodiments, the histological reduction in the number of inflammatory cells in the atria may include a reduction in inflammatory cells in the atria ranging from about 1% to about 100% when compared to an untreated subject. In another embodiment, the reduction in atrial inflammation may be a reduction in the levels of cytokines in the heart when compared to an untreated subject. In certain embodiments, the one or more cytokines include IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-11, IL-13, IL-16, IL-17, IL-18, G-CSF, GM-CSF, MCP-1, PDGF-AB, TNF-α, any type I IFN, any type II IFN, any type III IFN, or any combination thereof. In another embodiment, the reduction in cytokine levels can be quantified using a multiplex Luminex® assay, including a reduction in the amount of one or more cytokines by 1% to about 100% when compared to an untreated subject. In another embodiment, the reduction in cytokine levels can be quantified using an enzyme-linked immunosorbent assay (ELISA), including a reduction in the amount of one or more cytokines by 1% to about 100% when compared to an untreated subject.

[0041] In another embodiment of any of the above compositions, the extracellular vesicles can reduce or prevent atrial fibrosis. In certain embodiments, the composition can reduce atrial fibrosis by reducing atrial collagen levels when compared to untreated subjects, and atrial collagen levels can be quantified using hydroxyproline, including about a 1% to about a 100% reduction in hydroxyproline levels when compared to untreated subjects.

[0042] In another embodiment of any of the above compositions, the extracellular vesicles can reduce atrial fibroblast proliferation. In certain embodiments, the reduction in atrial fibroblast proliferation can be a reduction in the relative atrial fibroblast number over time when compared to an untreated subject, including a reduction in the relative atrial fibroblast number by about 1% to about 100% over time when compared to an untreated subject. In certain embodiments, the reduction in atrial fibroblast proliferation can include a reduction in the number of cells in the S phase of the cell cycle when compared to an untreated subject. In other embodiments, the number of cells in the S phase of the cell cycle can be measured using one or more of the following: flow cytometry, Western blot, ELISA, bromodeoxyuridine (BrDU), 5-ethynyl-2'deoxyuridine (EdU), phosphorylation of retinoblastoma protein, cyclin D, cyclin E, cyclin A, cyclin B, any equivalent method, or any combination thereof. In further embodiments, the reduction in the number of cells in the S phase of the cell cycle can include from about 1% to about 100% when compared to untreated subjects.

[0043] In certain embodiments, said decrease in atrial fibroblast proliferation can be an increase in the number of cells in G0 or G1 of the cell cycle compared to an untreated subject, which can be measured using one or more of the following: flow cytometry, Western blot, ELISA, Ki67, BrDU, EdU, propidium iodide, phosphorylation of retinoblastoma protein, cyclin D, cyclin E, any equivalent method or combination thereof, including an increase of about 1% to about 100% or more compared to an untreated subject.

[0044] In certain embodiments, the reduction in atrial fibroblast proliferation may include a reduction in the number of cells in the G2 or M phase of the cell cycle compared to an untreated subject, where the reduction in the number of cells in the G2 or M phase of the cell cycle compared to an untreated subject is measured using one or more of the following: flow cytometry, Western blot, ELISA, phosphorylation of histone H3, propidium iodide, cyclin B, cyclin B, cyclin A, cyclin D, CDK1, CDK2, DAPI, Hoechst, Ki67, any equivalent method or combination thereof. Including a reduction of about 1% to about 100% when compared to an untreated subject. In some embodiments, the proliferation of atrial fibroblasts can be measured in vitro. In some embodiments, the proliferation of atrial fibroblasts can be measured in vivo.

[0045] In another embodiment of any of the above compositions, the reduction in atrial fibroblast proliferation may comprise a reduction in the transcription of a positive cell cycle regulatory gene as compared to an untreated subject. In another embodiment of any of the above compositions, the reduction in atrial fibroblast proliferation may comprise an increase in the transcription of a negative cell cycle regulatory gene as compared to an untreated subject.

[0046] In another embodiment of any of the above compositions, the extracellular vesicles can reduce the relative mass of the atria when compared to an untreated subject, including comparing the ratio of atrial mass to total body weight (relative mass = atrial mass / total body weight). Between a subject treated with extracellular vesicles and an untreated subject, the reduction can include about 1% to about 100% less relative mass when compared to an untreated subject.

[0047] In another embodiment of any of the above compositions, the biologically or pharma- ceutical acceptable adjuvant or carrier may be suitable for systemic delivery. In certain embodiments, the biologically or pharma- ceutical acceptable adjuvant or carrier may be suitable for localized delivery. In other embodiments, the biologically or pharma- ceutical acceptable adjuvant or carrier may be suitable for intramyocardial delivery. In other embodiments, the biologically or pharma- ceutical acceptable adjuvant or carrier may be suitable for intraatrial delivery. In other embodiments, the biologically or pharma- ceutical acceptable adjuvant or carrier may be suitable for catheter delivery.

[0048] In another embodiment of any of the above compositions, the extracellular vesicles may improve one or more symptoms including general fatigue, elevated heart rate, irregular heart rate, dizziness, shortness of breath, anxiety, fainting, heart failure, throbbing in the neck, weakness, confusion, fainting, sweating, chest pain, chest pressure, chest pounding, or a combination thereof. In certain embodiments, the extracellular vesicles may reduce the duration of atrial fibrillation, and the reduction in the duration of atrial fibrillation is determined using an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest exam, an x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or a combination thereof.

[0049] In another embodiment of any of the above compositions, the extracellular vesicles are capable of reducing the incidence of atrial fibrillation, and the reduction in the incidence of atrial fibrillation is determined using an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or a combination thereof.

[0050] In another embodiment of any of the above compositions, the extracellular vesicles can be solubilized by the addition of a detergent, including a solution of about 0.01% to about 10.0% Triton™ X-100, and solubilization can be measured by a reduction in the number of extracellular vesicle particles compared to a sample that is not treated with the detergent.

[0051] In another embodiment, a method for the treatment or prevention of atrial arrhythmia is provided, which may comprise administering to a subject in need thereof any of the compositions described above.

[0052] In another embodiment, a method is provided for reducing or preventing atrial fibrosis, which may comprise administering to a subject in need thereof any of the compositions described above.

[0053] In another embodiment, a method is provided for reducing or preventing atrial inflammation, which may comprise administering to a subject in need thereof any of the compositions described above.

[0054] In another embodiment, a method is provided for reducing or preventing atrial fibroblast proliferation, which may comprise administering to a subject in need thereof any of the compositions described above.

[0055] In another embodiment of any of the above methods, the atrial arrhythmia may be diagnosed using one or more technologies including an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technologies, or a combination thereof. In another embodiment, the subject having atrial arrhythmia may have one or more symptoms including general fatigue, rapid heartbeat, irregular heartbeat, dizziness, shortness of breath, anxiety, fainting, heart failure, pounding in the neck, weakness, confusion, fainting, sweating, chest pain, chest pressure, pounding in the chest, or a combination thereof.

[0056] In another embodiment of any of the above methods, the extracellular vesicles may be administered systemically. In certain embodiments, the extracellular vesicles may be administered locally. In certain embodiments, the extracellular vesicles may be administered intramyocardially. In certain embodiments, the extracellular vesicles may be administered intraatrium. In another embodiment, the local administration may comprise an injection. In certain embodiments, the injection may comprise 1 to 500 injections. In a further embodiment, the local administration including injection may comprise a dose of about 0.10 cm 2 Approximately 10.00cm from each 2 The intra-atrial administration may include injections every 1 to 500 injections, and the surface area may be based on the tissue being injected, for example, the surface area of ​​the atrium of the heart, the surface area of ​​the left atrium of the heart, the surface area of ​​the right atrium, the surface area of ​​the ventricle of the heart, the surface area of ​​the left ventricle of the heart, the surface area of ​​the right ventricle of the heart, or the surface area of ​​the entire heart. In a preferred embodiment, the intra-atrial administration may include injections, which may further include 1 to 500 injections, and the intra-atrial administration may include injections every 1 to 500 injections, and the surface area may be based on the tissue being injected, for example, the surface area of ​​the atrium of the heart, the surface area of ​​the left atrium of the heart, the surface area of ​​the right ventricle of the heart, or the surface area of ​​the entire heart. 2 ~Approx. 10.0cm 2 This may include an injection every 24 hours.

[0057] In another embodiment of any of the above methods, the extracellular vesicles may be administered by catheter. In certain embodiments, the extracellular vesicles may be administered by catheter into a small blood vessel that perfuses the atrium. In certain embodiments, the extracellular vesicles may be administered using a biomaterial that surrounds the atrium.

[0058] In another embodiment of any of the above methods, the extracellular vesicles may reduce atrial inflammation. In certain embodiments, the reduction in atrial inflammation may be quantified histologically, including a reduction in the number of inflammatory cells in the atria of the heart when compared to an untreated subject. In certain embodiments, the number of inflammatory cells in the atria is quantified using one or more markers, which may include hematoxylin and eosin staining, activated T lymphocytes, macrophage infiltration, macrophage polarization, mast cells, neutrophils, or any combination thereof. In certain embodiments, the histological reduction in the number of inflammatory cells in the atria may include a reduction in inflammatory cells in the atria ranging from about 1% to about 100% when compared to an untreated subject. In certain embodiments, the reduction in atrial inflammation can be a reduction in the levels of cytokines in the heart as compared to an untreated subject, where one or more of said cytokines can be IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-11, IL-13, IL-16, IL-17, IL-18, G-CSF, GM-CSF, MCP-1, PDGF-AB, TNF-α, any type I IFN, any type II IFN, any type III IFN, or any combination thereof. In certain embodiments, the reduction in the cytokine levels can be quantified using a multiplex Luminex-based assay or equivalent technology and can include about a 1% to about 100% reduction in one or more cytokines as compared to an untreated subject.

[0059] In another embodiment of any of the above methods, the extracellular vesicles can reduce atrial fibrosis. In certain embodiments, the extracellular vesicles can reduce atrial fibrosis by reducing atrial collagen, and atrial collagen levels can be quantified using hydroxyproline, any equivalent, or any combination thereof, including about 1% to about 100% reduction in hydroxyproline levels when compared to untreated subjects. In certain embodiments, it is contemplated that atrial fibrosis can be quantified by comparing the ratio of atrial mass to total body weight (relative mass = atrial mass / total body weight) between subjects treated with extracellular vesicles and untreated subjects, where a higher value indicates increased fibrosis and a lower value indicates decreased fibrosis.

[0060] In another embodiment of any of the above methods, the extracellular vesicles can reduce the proliferation of atrial fibroblasts. In certain embodiments, the reduction in atrial fibroblast proliferation can include a reduction in the number of cells in the S phase of the cell cycle compared to an untreated subject, the number of cells in the S phase of the cell cycle can be measured using one or more of the following: flow cytometry, Western blot, ELISA, bromodeoxyuridine (BrDU), 5-ethynyl-2'deoxyuridine (EdU), any nucleoside analog, phosphorylation of retinoblastoma protein, cyclin D, cyclin E, cyclin A, cyclin B, any equivalent method, or any combination thereof, including a reduction of about 1% to about 100% in the number of cells in the S phase of the cell cycle compared to an untreated subject. In certain embodiments, the reduction in atrial fibroblast proliferation can include a reduction in the number of cells in the S phase of the cell cycle compared to an untreated subject, measured using flow cytometry or an equivalent method. In certain other embodiments, said decrease in atrial fibroblast proliferation may be an increase in the number of cells in G0 or G1 of the cell cycle compared to an untreated subject, and the number of cells in G0 or G1 of the cell cycle may be measured using one or more of the following: flow cytometry, Western blot, ELISA, Ki67, BrDU, EdU, propidium iodide, phosphorylation of retinoblastoma protein, cyclin D, cyclin E, any equivalent method, or any combination thereof, and the number of cells in G0 or G1 of the cell cycle may include an increase of about 1% to about 100% or more when compared to an untreated subject. In certain other embodiments, the reduction in atrial fibroblast proliferation can include a reduction in the number of cells in the G2 or M phase of the cell cycle as compared to untreated subjects, where the reduction in the number of cells in the G2 or M phase of the cell cycle as compared to untreated subjects can be measured using one or more of the following: flow cytometry, western blot, ELISA, phosphorylation of histone H3, propidium iodide, cyclin B, cyclin B, cyclin A, cyclin D, CDK1, CDK2, DAPI, Hoechst, Ki67, any equivalent method or combination thereof, and includes a reduction of about 1% to about 100% as compared to untreated subjects.

[0061] In another embodiment of any of the above methods, the reduction in atrial fibroblast proliferation may comprise a reduction in the transcription of a positive cell cycle regulatory gene as compared to an untreated subject. In another embodiment of any of the above methods, the reduction in atrial fibroblast proliferation may comprise an increase in the transcription of a negative cell cycle regulatory gene as compared to an untreated subject.

[0062] In another embodiment of any of the above methods, the extracellular vesicles may improve one or more symptoms including general fatigue, elevated heart rate, arrhythmia, dizziness, shortness of breath, anxiety, weakness, confusion, fainting, sweating, chest pain, chest pressure, chest pounding, or a combination thereof. In certain embodiments, the extracellular vesicles may reduce the duration of atrial fibrillation, and the reduction in the duration of atrial fibrillation may be determined using an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or a combination thereof. In certain embodiments, the extracellular vesicles can reduce the incidence of atrial fibrillation, and the reduction in the incidence of atrial fibrillation can be determined using an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure cuff, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or a combination thereof.

[0063] In yet another embodiment, provided herein is a method, use, cell, kit, or composition as described anywhere herein. [Brief description of the drawings]

[0064] [Figure 1] Figure 1 shows the experimental design for the derivation of extracellular vesicles (EVs) from cardiac explant-derived cells, the use of said extracellular vesicles in a rodent model of atrial arrhythmias, and the analysis of the effects of EVs on atrial inflammation, atrial fibrosis and atrial fibrillation. [Diagram 2]Figure 2 shows an exemplary proteomics array demonstrating the presence of transmembrane markers (CD63, CD81, FLOT1, ICAM1, EpCam) and cytoplasmic markers (ALIX, ANXA5 and TSG101) indicative of EV identity, while lacking cellular contaminants (GM130). [Diagram 3] Figure 3A-C shows the diameter and abundance of extracellular vesicles derived from human cardiac cells. (A) Flow cytometry showing the relationship between EV size and surface marker expression (n=3 biological replicates). (B) Quantification of the concentration (EV / mL) of extracellular vesicles expressing the surface markers CD81, CD9, or CD63 (n=3 biological replicates). One-way ANOVA with individual mean comparisons by Bonferroni's multiple two-tailed comparisons test. (C) Quantification of the diameter (nm) of extracellular vesicles expressing the surface markers CD81, CD9, or CD63 (n=3 biological replicates). One-way ANOVA with individual mean comparisons by Bonferroni's multiple two-tailed comparisons test. [Figure 4] Figure 4 shows representative flow cytometry images demonstrating the relationship between EV diameter and surface marker expression. EVs within the range of 100-500 nm in diameter are gated. Fluorescence intensity is quantified using a standard unit known as equivalent soluble fluorophores (MESFs). [Diagram 5] Figure 5A-B shows the abundance of miRNAs in extracellular vesicles derived from human cardiac cells. (A) miRNA content in EDC EVs was profiled using multiplex fluorescent oligonucleotide-based miRNA detection. The relative abundance of microRNA transcripts in EDC EVs is shown (n=3 biological replicates). (B) Pathway analysis of microRNA transcripts in EDC EVs is shown. Pathway analysis terms were extracted from the Reactome database for network analysis. EV, extracellular vesicles; FDR, false discovery rate; miR, microRNA. [Figure 6] FIG. 6 shows the relative abundance of proteins within extracellular vesicles derived from human cardiac cells (n=3 biological replicates). [Figure 7]Figure 7 shows human cardiac explant-derived cells cultured under serum-free and xeno-free culture conditions in a clinical cell manufacturing facility to produce extracellular vesicles containing anti-fibrotic / anti-inflammatory proteins. An enrichment map of the EDV EV proteome is shown showing the relationships between biological pathways that are expressed above those expected by chance. Red nodes indicate pathways predicted to have a positive effect and blue nodes indicate pathways predicted to have a negative effect. ECM, extracellular matrix; MMP2, matrix metalloproteinase 2. [Figure 8] Figure 8 shows flow cytometry quantification of in vitro uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil)-labeled EVs by rat atrial fibroblasts, cardiomyocytes and human umbilical vein endothelial cells. Cardiomyocytes, red line with squares; endothelial cells, black line with triangles; fibroblasts, blue line with circles. [Figure 9] Figure 9 shows a study schematic illustrating the study design, number of animals included, group assignment and results measured to determine the effects of extracellular vesicles derived from human cardiac cells in a rodent model of atrial arrhythmia. [Figure 10] Figure 10 shows representative tracings from electrocardiograms (ECGs) demonstrating the effect of EV treatment on talc-treated animals after burst pacing. EV, extracellular vesicles; veh, vehicle. [Figure 11] Figure 11 shows the effect of EV treatment on the probability of inducing atrial fibrillation (AF) after burst pacing. Superimposed numbers indicate the absolute number of female (lower grey bar + number) or male animals (upper black bar + number) that went into AF. Logistic regression using a generalized linear model with a binomial probability distribution and a logit link function was performed. AF, atrial fibrillation; EV, extracellular vesicles; veh, vehicle. [Figure 12] FIG. 12 shows the effect of EV treatment on the mean duration of AF episodes (n=2-25). AF, atrial fibrillation; EV, extracellular vesicles; veh, vehicle. [Figure 13]Figure 13A-B shows the effect of EV treatment on atrial fibrosis and atrial structure. (A) Atrial fibrosis was measured using hydroxyproline for the indicated experimental groups (n = 10). One-way ANOVA with individual mean comparisons with Bonferroni's two-tailed multiple comparisons test. (B) Relative atrial mass was measured using the ratio of atrial weight to body weight for the indicated experimental groups (n = 10-15). One-way ANOVA with individual mean comparisons with Bonferroni's two-tailed multiple comparisons test. AF, atrial fibrillation; EV, extracellular vesicles; veh, vehicle. [Figure 14] Figure 14A-B shows the effect of human cardiac extracellular vesicles (EVs) on inflammation. (A) Representative images of atrial tissue sections after hematoxylin and eosin staining showing the effect of talc and EVs on inflammatory cell infiltration. (B) Quantitative analysis of hematoxylin and eosin staining showing the effect of talc and EVs on inflammatory cell infiltration (n=5 biological replicates). [Figure 15] FIG. 15 shows the effect of talc and EVs on IL1β, IL2, IL6, IL18, monocyte chemotactic protein 1 (MCP1), platelet-derived growth factor AB (PDGF-AB) and tumor necrosis factor alpha (TNFα) levels (n=5 biological replicates). IL, interleukin. [Figure 16] Figure 16 shows the effect of human cardiac extracellular vesicles (EVs) on the proliferation of atrial fibroblasts. (A) The effect of cardiac explant-derived cell (EDC) EVs on relative cell number. (B) The effect of cardiac explant-derived cell (EDC) EVs on population doubling time. [Figure 17] Figure 17 shows the effect of cardiac explant-derived cell (EDC) extracellular vesicles (EVs) on atrial fibroblast proliferation. Representative images of atrial fibroblasts labeled with 5-ethynyl-2'deoxyuridine (EdU, shown in green) and 4',6-diamidino-2-phenylindole (DAPI, shown in blue) are shown untreated (baseline), after treatment with interleukin 6 (IL6), transforming growth factor β1 (TGFβ1) and / or EDC EVs. Scale bar 200 μM. [Figure 18]Figure 18 shows quantification of nuclear incorporation of the thymidine analog 5-ethynyl-2'-deoxyuridine (EdU) in atrial fibroblasts without treatment (baseline) and after treatment with interleukin 6 (IL6), transforming growth factor β1 (TGFβ1), and / or EDC EV (n=5 biological replicates). [Figure 19] FIG. 19 shows cell cycle analysis showing the effect of anaphase promoting complex (APC), IL6, TGFβ1 and / or EDC EVs on the percentage of atrial fibroblasts in G0 / G1 or S and G2 / M phases of the cell cycle (n=5 biological replicates). (A) Pie chart showing the percentage of cells in G0 / G1 (blue), S (red), or G2 / M (grey) phases of the cell cycle. (B) Shows the percentage of cells in G0 / G1 phase of the cell cycle. (C) Shows the percentage of cells in S+G2 / M of the cell cycle. [Figure 20] Figure 20 shows the effect of IL6, TGFβ1 and / or EDC EVs on the proteomic expression of cyclins that control the progression of atrial fibroblasts through the cell cycle (n=3 biological replicates). Cyclin A2, cyclin B1, cyclin D, and cyclin E protein levels were measured using enzyme-linked immunosorbent assay (ELISA). [Figure 21] Figure 21 shows representative images of flow cytometry demonstrating EV depletion after solubilization. Addition of 0.1% Triton X-100 solubilizes CD63 stained EVs. Numbers within gates represent percentage of gated population within all particles detected. PE-MSEF, equivalent soluble fluorescent dye phycoerythrin molecule. [Figure 22]Figure 22 shows the implementation and group size of the in vivo study. It was assumed that the incidence of atrial fibrillation (AF) after talc treatment was 0.6, and that extracellular vesicles (EV) treatment would reduce the incidence of AF to 0.2. Gender was not thought to change the incidence of inducible atrial fibrillation. Based on these assumptions, a group sample size of 34 rats (17 females + 17 males) would achieve a power of 83% to detect superiority using a two-tailed Mann-Whitney test (probability of a false positive result (α error) = 0.05). Animals that died due to an overdose of anesthetic drugs before the second procedure were not included in the analysis. One additional female rat received EVs due to an allocation error. To avoid data compromise, animals were also included in the analysis. Considering that the gender of the recipient did not affect the occurrence of the primary outcome (i.e., AF induction rate), secondary outcomes (e.g., histology, fibrosis, etc.) were not analyzed separately by recipient gender. EPS, electrophysiological studies; EV, extracellular vesicles; veh, vehicle. [Diagram 23] Figure 23 shows the effect of human heart-derived EVs on inflammasome activation using a luciferase reporter for caspase-1 activation. THP-1 cells were differentiated with phorbol 12-myristate 13-acetate (PMA) for 3 days. Medium was changed and EVs were added, followed by lipopolysaccharide (LPS). After 3 hours, half of the medium was removed and luciferase luminescence was tested using vehicle or the caspase inhibitor YVAD-CHO. RLU, relative light units. [Figure 24]Figure 24 shows the effect of human cardiac-derived EV dose on atrial fibrillation, fibrosis and inflammation. (A) Probability of atrial fibrillation (>0.5 s) was measured after burst pacing at the indicated EV concentrations. Logistic regression using a generalized linear model with a binomial probability distribution and logit link function was performed. (B) Atrial fibrosis was measured using hydroxyproline for the indicated experimental groups. ANOVA with Tukey's multiple comparison test. (C) Inflammation in atria treated with the indicated human cardiac-derived EVs was measured using enzyme-linked immunosorbent assay. ANOVA followed by Tukey's multiple comparison test was performed. IL, interleukin; MCP, monocyte chemoattractant protein; PDGF, platelet-derived growth factor. [Diagram 25] Figure 25 shows the effect of human cardiac-derived EVs and the effect of colchicine on atrial fibrillation, fibrosis and inflammation. (A) Probability of atrial fibrillation (>0.5 sec) was measured after burst pacing with the indicated treatments. Logistic regression using a generalized linear model with a binomial probability distribution and a logit link function was performed. (B) Atrial fibrosis was measured using hydroxyproline for the indicated experimental groups. ANOVA with Tukey's multiple comparison test. (C) Inflammation in atria treated as indicated was measured using enzyme-linked immunosorbent assay. ANOVA followed by Tukey's multiple comparison test was performed. IL, interleukin; MCP, monocyte chemoattractant protein. [Figure 26] FIG. 26 shows the effect of human cardiac-derived EVs on infarct-induced atrial fibrillation. Atrial fibrillation (>0.5 seconds) was measured for the indicated groups. Logistic regression using a generalized linear model with a binomial probability distribution and a logit link function was performed. [Figure 27] Figure 27 shows uptake of human cardiac-derived EVs. Flow cytometry showing uptake of labeled EVs by macrophages (Raw 264.7), primary cultured rat atrial fibroblasts (AF), human umbilical vein endothelial cells (HUVEC), primary human pulmonary microvascular endothelial cells (HPMEC), neonatal rat ventricular myocytes (NRVM), hepatic G2 cells (HepG2), and human embryonic kidney cells (HEK). [Figure 28] Figure 28 shows the experimental design for the derivation of extracellular vesicles (EVs) from the indicated tissues and the steps of miRNA and protein profiling from the EVs therefrom. [Figure 29] Figure 29A-B show (A) exemplary plots of EV tracking analysis, and (B) the concentration and size of EVs isolated from the indicated cell types. [Diagram 30] Figure 30 shows an exemplary proteomic array demonstrating the presence of transmembrane (CD63, CD81, FLOT1, ICAM1, EpCam) and cytoplasmic markers (ALIX, ANXA5 and TSG10) indicative of EV identity, while lacking cellular contaminants (GM130). [Diagram 31] Figure 31A-C shows EV miRNA cargo profile across tissues. (A) Venn diagram showing distinct numbers of miRNAs identified in three cell types. (B) Venn diagram showing highly abundant (above 99th percentile) miRNAs that differ across cell types. (C) Rank plot showing distinct numbers of miRNAs identified in three cell types. Highly abundant (above 99th percentile) miRNAs are highlighted in the rank plot. Data are shown as mean, n=3 biological replicates. Each circle on the rank plot represents one distinct miRNA. miRNA: microRNA, BM-MSC: bone marrow-derived mesenchymal stromal cells, HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Diagram 32] Figure 32A-C shows EV protein cargo profiles across tissues. (A) Venn diagram showing distinct number of proteins identified in the three cell types. (B) Venn diagram showing highly abundant (above 99th percentile) proteins that differ between cell types. (C) Rank plot showing distinct number of proteins identified in the three cell types. Highly abundant (above 99th percentile) proteins are highlighted in the rank plot. Data are shown as mean, n=3 biological replicates. Each circle on the rank plot represents one distinct protein. LFQ: label-free quantification; BM-MSC: bone marrow derived mesenchymal stromal cells, HDC: heart derived cells, UC-MSC: umbilical cord derived mesenchymal stromal cells. [Diagram 33] Figure 33 shows differential expression analysis of EV miRNA cargo in HDC vs. BM MSC. miRNAs were considered differentially expressed with log2 fold change >1.5 or <1.5 and p-value <0.05. Volcano plot showing 20 downregulated and 36 upregulated miRNA transcripts and heatmap showing significantly differentially expressed miRNAs in HDC EVs vs. BM-MSC EVs. List of differentially expressed miRNAs is shown in Table 3. n=3 biological replicates. BM-MSC: bone marrow derived mesenchymal stromal cells, HDC: cardiac derived cells. [Diagram 34] Figure 34 shows differential expression analysis of EV miRNA cargo in BM MSCs vs UC MSCs. miRNAs were considered differentially expressed with log2 fold change >1.5 or <1.5 and p-value <0.05. Volcano plot showing 12 downregulated and 164 upregulated miRNA transcripts and heatmap showing significantly differentially expressed miRNAs in BM-MSC EVs vs UC-MSC EVs. List of differentially expressed miRNAs is shown in Table 4. n=3 biological replicates. BM-MSC: bone marrow derived mesenchymal stromal cells, UC-MSC: umbilical cord derived mesenchymal stromal cells. [Diagram 35] Figure 35 shows differential expression analysis of EV miRNA cargo in HDC vs UC MSC. miRNAs were considered differentially expressed with log2 fold change >1.5 or <1.5 and p-value <0.05. Volcano plot showing 15 downregulated and 299 upregulated miRNA transcripts and heatmap showing significantly differentially expressed miRNAs in HDC EVs vs UC-MSC EVs. List of differentially expressed miRNAs is shown in Table 5. n=3 biological replicates. HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Diagram 36]Figure 36 shows differential protein expression analysis of EV cargo in HDC vs. BM MSC. Proteins identified in at least 2 out of 3 replicates were included in the analysis. Proteins were considered differentially expressed with a p-value <0.05. Volcano plot showing 9 downregulated and 14 upregulated proteins and heatmap showing significantly differentially expressed proteins in HDC vs. BM-MSC EVs. A list of differentially expressed proteins is shown in Table 6. n=3 biological replicates. BM-MSC: bone marrow-derived mesenchymal stromal cells, HDC: cardiac-derived cells. [Figure 37] Figure 37 shows differential protein expression analysis of EV cargo in BM MSCs vs. UC MSCs. Proteins identified in at least 2 out of 3 replicates were included in the analysis. Proteins were considered differentially expressed with a p-value <0.05. Volcano plot showing 198 downregulated and 107 upregulated proteins and heatmap showing significantly differentially expressed proteins in BM-MSC EVs vs. UC-MSC EVs. A list of differentially expressed proteins is shown in Table 7. n=3 biological replicates. BM-MSC: bone marrow derived mesenchymal stromal cells, UC-MSC: umbilical cord derived mesenchymal stromal cells. [Figure 38] Figure 38 shows differential protein expression analysis of EV cargo in HDC vs. UC MSC. Proteins identified in at least 2 out of 3 replicates were included in the analysis. Proteins were considered differentially expressed with a p-value <0.05. Volcano plot showing 141 downregulated and 119 upregulated proteins and heatmap showing significantly differentially expressed proteins in HDC EVs vs. UC-MSC EVs. A list of differentially expressed proteins is shown in Table 8. n=3 biological replicates. HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Figure 39]Figure 39A-B shows functional enrichment analysis of differentially expressed EV miRNA cargo of HDC vs BM MSC. (A) Top 10 significantly enriched biological functions and gene ontology biological processes of all differentially expressed miRNAs (DEMs) between HDC vs BM MSC. (B) Top 10 significantly enriched biological functions of enriched miRNAs in HDC compared to BM MSC and BM MSC compared to HDC. n=3 biological replicates. Activ: activity, BM-MSC: bone marrow-derived mesenchymal stromal cells, Dev: development, Diff: differentiation, HDC: cardiac-derived cells, MET: mesenchymal-epithelial transition, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Diagram 40] Figure 40A-B shows functional enrichment analysis of differentially expressed EV miRNA cargo in HDC vs. BM MSC. (A) Top 10 significantly enriched for transcription factors and tissue specificity of all differentially expressed miRNAs (DEMs) between HDC and BM MSC. (B) Top 10 significantly enriched for transcription factors and tissue specificity of enriched miRNAs in HDC compared to BM MSC and BM MSC compared to HDC. n=3 biological replicates. If the analysis yielded less than 10 enriched terms, all terms are displayed on the graph. BM-MSC: bone marrow-derived mesenchymal stromal cells, HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Diagram 41]Figure 41A-B shows functional enrichment analysis of differentially expressed EV miRNA cargo in BM MSC vs. UC MSC. (A) Top 10 significantly enriched biological functions and gene ontology biological processes of all differentially expressed miRNAs (DEMs) between BM MSC and UC MSC. (B) Top 10 significantly enriched biological functions of enriched miRNAs in BM USC compared to UC MSC and UC MSC compared to BM MSC. n=3 biological replicates. Activ: activity, BM-MSC: bone marrow-derived mesenchymal stromal cells, Dev: development, Diff: differentiation, HDC: cardiac-derived cells, MET: mesenchymal-epithelial transition, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Diagram 42] Figure 42A-B shows functional enrichment analysis of differentially expressed EV miRNA cargo in BM MSC vs. UC MSC. (A) Top 10 significantly enriched for transcription factors and tissue specificity of all differentially expressed miRNAs (DEMs) between BM MSC and UC MSC. (B) Top 10 significantly enriched for transcription factors and tissue specificity of enriched miRNAs in BM MSC compared to UC MSC and UC MSC compared to BM MSC. n=3 biological replicates. BM-MSC: bone marrow derived mesenchymal stromal cells, HDC: heart derived cells, UC-MSC: umbilical cord derived mesenchymal stromal cells. [Diagram 43] Figure 43A-B shows functional enrichment analysis of EV differentially expressed miRNA cargo in HDC vs UC MSC. (A) Top 10 significantly enriched biological functions and gene ontology biological processes of all differentially expressed miRNAs (DEMs) between HDC and UC MSC. (B) Top 10 significantly enriched biological functions of enriched miRNAs in HDC compared to UC MSC and UC MSC compared to HDC. n=3 biological replicates. Activ: activity, BM-MSC: bone marrow-derived mesenchymal stromal cells, Dev: development, Diff: differentiation, HDC: cardiac-derived cells, MET: mesenchymal-epithelial transition, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Diagram 44] Figure 44A-B shows functional enrichment analysis of differentially expressed EV miRNA cargo in HDC vs. UC MSC. (A) Top 10 significantly enriched for transcription factors and tissue specificity of all differentially expressed miRNAs (DEMs) between HDC and UC MSC. (B) Top 10 significantly enriched for transcription factors and tissue specificity of enriched miRNAs in HDC compared to UC MSC or UC MSC compared to HDC. n=3 biological replicates. BM-MSC: bone marrow-derived mesenchymal stromal cells, HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Diagram 45] Figure 45A-B shows functional enrichment analysis of differentially expressed EV protein cargo of HDC vs. BM MSC. (A) Top 10 significantly enriched molecular functions of all differentially expressed proteins (DEPs) between HDC vs. BM MSC. (B) Top 10 significantly enriched molecular functions of enriched proteins in HDC compared to BM MSC and BM MSC compared to HDC. n=3 biological replicates. BM-MSC: bone marrow-derived mesenchymal stromal cells, ECM: extracellular matrix, GDP: guanosine diphosphate, GTP: guanosine triphosphate, HDC: cardiac-derived cells, LDL: low density lipoprotein, Macromol.cmpx: macromolecular complex, MHC: myosin heavy chain, protein. Ppase: protein phosphatase, UC-MSC: umbilical cord-derived mesenchymal stromal cells. Cellular component (CC); biological process (BP) [Figure 46]Figure 46A-B shows functional enrichment analysis of differentially expressed EV protein cargo of HDC vs. BM MSC. (A) Top 10 significantly enriched biological processes (BPs) and cellular components (CCs) of all differentially expressed proteins (DEPs) between HDC vs. BM MSC. (B) Top 10 significantly enriched biological processes (BPs) and cellular components (CCs) of enriched proteins in HDC compared to BM MSC and BM MSC compared to HDC. n=3 biological replicates. BM-MSC: bone marrow-derived mesenchymal stromal cells, ER: endoplasmic reticulum, diff: differentiation, ECM: extracellular matrix, HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Figure 47] Figure 47A-B shows functional enrichment analysis of differentially expressed EV protein cargo of BM MSC vs. UC MSC. (A) Top 10 significantly enriched molecular functions of all differentially expressed proteins (DEPs) between BM MSC and UC MSC. (B) Top 10 significantly enriched molecular functions of enriched proteins in BM MSC compared to UC MSC and UC MSC compared to BM MSC. n=3 biological replicates. BM-MSC: bone marrow-derived mesenchymal stromal cells, ECM: extracellular matrix, GDP: guanosine diphosphate, GTP: guanosine triphosphate, HDC: cardiac-derived cells, LDL: low density lipoprotein, Macromol.cmpx: macromolecular complex, MHC: myosin heavy chain, protein. Ppase: protein phosphatase, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Figure 48]Figure 48A-B shows functional enrichment analysis of differentially expressed EV protein cargo of BM MSC vs. UC MSC. (A) Top 10 significantly enriched biological processes (BPs) and cellular components (CCs) of all differentially expressed proteins (DEPs) between BM MSC and UC MSC. (B) Top 10 significantly enriched biological processes (BPs) and cellular components (CCs) of enriched proteins in BM MSC compared to UC MSC and UC MSC compared to BM MSC. n=3 biological replicates. BM-MSC: bone marrow-derived mesenchymal stromal cells, ER: endoplasmic reticulum, diff: differentiation, ECM: extracellular matrix, HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Figure 49] Figure 49A-B shows functional enrichment analysis of differentially expressed EV protein cargo of HDC vs UC MSC. (A) Top 10 significantly enriched molecular functions of all differentially expressed proteins (DEPs) between HDC and UC MSC. (B) Top 10 significantly enriched molecular functions of enriched proteins in HDC compared to UC MSC and UC MSC compared to HDC. n=3 biological replicates. BM-MSC: bone marrow derived mesenchymal stromal cells, ECM: extracellular matrix, GDP: guanosine diphosphate, GTP: guanosine triphosphate, HDC: cardiac derived cells, LDL: low density lipoprotein, Macromol.cmpx: macromolecular complex, MHC: myosin heavy chain, protein. Ppase: protein phosphatase, UC-MSC: umbilical cord derived mesenchymal stromal cells. [Figure 50]Figure 50A-B shows functional enrichment analysis of differentially expressed EV protein cargo of HDC vs UC MSC. (A) Top 10 significantly enriched biological processes (BPs) and cellular components (CCs) of all differentially expressed proteins (DEPs) between HDC and UC MSC. (B) Top 10 significantly enriched biological processes (BPs) and cellular components (CCs) of enriched proteins in HDC compared to UC MSC and UC MSC compared to HDC. n=3 biological replicates. BM-MSC: bone marrow-derived mesenchymal stromal cells, ER: endoplasmic reticulum, diff: differentiation, ECM: extracellular matrix, HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Figure 51] Figure 51 shows protein-protein interaction network and GO-BP (Gene Ontology Biological Process) analysis of differentially expressed proteins in EVs from BM-MSCs and USC-MSCs differentially expressed proteins (DEPs). Significant clusters from PPI network and enriched GO-BP terms of BM-MSCs and UC-MSCs DEPs. Diamonds indicate nodes, grey lines indicate edges, and circles indicate hub node genes. [Figure 52] Figure 52 shows protein-protein interaction network and GO-BP (Gene Ontology-Biological Process) analysis of differentially expressed proteins in EVs from HDC vs UC MSC differentially expressed proteins (DEPs). Significant clusters from PPI network and enriched GO-BP terms of HDC and UC-MSC DEPs. Diamonds indicate nodes, grey lines indicate edges, and circles indicate hub node genes. [Figure 53]Figure 53A-B shows KEGG (Kyoto Encyclopedia of Genes and Genomes) functional enrichment analysis for all differentially expressed proteins (DEPs) or up- or down-regulated proteins between HDC vs. BM MSC EVs. (A) Top 10 significantly enriched KEGG pathways for all differentially expressed proteins between HDC vs. BM MSCs. (B) Top 10 significantly enriched KEGG pathways for enriched proteins in HDC vs. BM MSCs and BM MSC vs. HDCs. n=3 biological replicates. If the analysis yielded less than 10 enrichment terms, all terms are displayed in the graph. BM-MSC: bone marrow-derived mesenchymal stromal cells, HDC: cardiac-derived cells. [Figure 54] Figure 54A-B shows KEGG (Kyoto Encyclopedia of Genes and Genomes) functional enrichment analysis for all differentially expressed proteins (DEPs) or up-regulated or down-regulated proteins between BM MSC EVs and UC MSC EVs. (A) Top 10 significantly enriched KEGG pathways in UC MSCs and BM MSCs for all DEPs. (B) Top 10 significantly enriched KEGG pathways for enriched proteins in UC MSCs vs. BM MSCs and BM MSCs vs. UC MSCs. n=3 biological replicates. BM-MSC: bone marrow-derived mesenchymal stromal cells, E. Coli: Escherichia coli, UC-MSC: umbilical cord-derived mesenchymal stromal cells. [Figure 55]55A-B show KEGG (Kyoto Encyclopedia of Genes and Genomes) functional enrichment analysis for all differentially expressed proteins (DEPs) or up- or down-regulated proteins between HDC and UC MSC EVs. (A) Top 10 significantly enriched KEGG pathways of all DEPs between UC MSC vs HDC. (B) Top 10 significantly enriched KEGG pathways of enriched proteins in UC MSC vs HDC and HDC vs UC MSC. n=3 biological replicates. ECM: extracellular matrix, GDP: guanosine diphosphate, GTP: guanosine triphosphate, HDC: cardiac-derived cells, UC-MSC: umbilical cord-derived mesenchymal stromal cells.

[0065] These and other features of the present invention will be better understood with reference to the following description and accompanying drawings. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0066] Current pharmacological and surgical treatments for atrial arrhythmias can be limited by severe side effects and limited efficacy. Current drugs address a single mechanism of atrial arrhythmias, target heart rate, but atrial arrhythmias are believed to be caused by multiple mechanisms, including inflammation, fibrosis, and fibroblast proliferation. Identifying compositions that target multiple mechanisms that may cause atrial arrhythmias may improve the treatment and prevention of atrial arrhythmias.

[0067] As used herein, a "patient" or "subject" may include any vertebrate or cell, including mammals, but is not limited to humans, non-human primates, rats, dogs, pigs, and mice. In a preferred embodiment, the mammal may be a human. Additionally, a patient or subject "in need thereof" may include any of the above tissues diagnosed with atrial arrhythmia, experiencing symptoms of atrial arrhythmia, and / or experiencing symptoms associated with a condition that would benefit from administration of an extracellular vesicle composition. As used herein, an "untreated subject" may include any of the above organisms, cells, or materials to which any conditioning measures have been performed or administered, including but not limited to sham surgery, unconditioned medium only, vehicle, buffer only, untreated, and / or equivalent or suitable conditioning measures in place of the composition of extracellular vesicles. In certain embodiments, an "untreated subject" may be a patient or subject prior to administration of a composition of extracellular vesicles described herein.

[0068] As used herein, "in vitro" can encompass experiments or analyses performed on any vertebrate cells cultured outside of an organism, including, but not limited to, mammals, including humans, non-human primates, rats, dogs, pigs, and mice.

[0069] As used herein, "in vivo" can encompass experiments or analyses performed on any whole vertebrate animal, including mammals, but not limited to humans, non-human primates, rats, dogs, pigs and mice.

[0070] In the present specification, "about 1% to about 100%" refers to any value that defines the range, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%. , 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%.

[0071] Extracellular vesicles are naturally secreted, non-replicative particles that are surrounded by a lipid bilayer and can transport their components to other cells (Murphy, de Jong et al. 2019). As used herein, the term "components" refers to the molecular contents of extracellular vesicles, including but not limited to proteins, lipids, nucleic acids, metabolites, and organelles. Extracellular vesicles are sometimes referred to by the term polydisperse because they are a population of particles with heterogeneous sizes, shapes, and components, as further described herein. The components of extracellular vesicles can vary substantially depending on factors including but not limited to tissue type, cell type, and physiological conditions. Although extracellular vesicles are believed to have the potential to treat a variety of conditions, it is unclear which extracellular vesicle compositions possess this surprising property. Because the components and functions of extracellular vesicles can vary between similar cell types even with minor modifications to their induction, it is important to identify the specific cells and conditions that are suitable for these compositions. An illustrative non-limiting example of the compositional diversity of extracellular vesicles, including but not limited to, extracellular vesicles derived from cardiac explant-derived cells prepared under physiological conditions, was reported to have an average size of 120 nm, whereas when prepared under standard conditions, the average extracellular vesicle size was 148 nm (Mount, Kanda et al. 2019). Additionally, the same study reported changes in 51 miRNA components under physiological conditions compared to standard conditions. Thus, determining the ideal composition of extracellular vesicles may be important in developing more effective treatments for atrial arrhythmias and other cardiac and non-cardiac diseases. Furthermore, once the effective composition of extracellular vesicles is determined, their properties, including constituent components, and size need to be determined.

[0072] Described herein are compositions comprising extracellular vesicles isolated from human cardiac cells, their uses and methods. It will be understood that the embodiments and examples are provided herein for illustrative purposes directed to those skilled in the art and are not intended to be limiting in any way.

[0073] As part of the studies detailed below, and without wishing to be bound by theory, results are provided that demonstrate, for what is believed to be the first time, that extracellular vesicles derived from human cardiac cells can ameliorate atrial arrhythmias, atrial fibrosis, atrial fibroblast proliferation, and atrial inflammation. These findings characterize the characteristics of extracellular vesicles derived from human cardiac cells. Specifically, the components, size, and ability to transport components to human cardiac cells, as well as the ability to reduce atrial fibrillation, atrial inflammation, atrial fibrosis, and fibroblast proliferation, of the extracellular vesicles were tested.

[0074] Here, we investigated the composition of extracellular vesicles derived from human cardiac cells and characterized the extracellular vesicles. Extracellular vesicles have diverse properties and therefore provide a useful platform for testing cardiac diseases such as atrial arrhythmias. To reduce the possibility of contamination with non-extracellular structures and therapeutically ineffective extracellular vesicles, the properties of isolated extracellular vesicles were first established.

[0075] Those skilled in the art will recognize that different methods for deriving extracellular vesicles may be applicable and may affect aspects of the extracellular vesicles. Those skilled in the art will be able to select a method suitable for a given application, given the teachings herein. Such methods include, but are not limited to, differential ultracentrifugation, size exclusion chromatography, density gradients, tangential flow filtration and variations thereof, microfiltration, ion exchange chromatography, immunoisolation, or combinations thereof (e.g., as discussed in (Konoshenko, Lekchnov et al. 2018)). In one embodiment, the extracellular vesicles may be derived from human cardiac cells by differential ultracentrifugation. In certain embodiments, it is contemplated that the extracellular vesicles may be derived from human cardiac cells by tangential flow filtration. Exemplary experimental methods for such determinations are provided in the examples described below. Those skilled in the art will understand that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting.

[0076] In one embodiment, provided herein is a composition comprising an extracellular vesicle and a biologically or pharma- ceutically acceptable adjuvant or carrier, wherein the extracellular vesicle may comprise one or more of the following characteristics:

[0077] Extracellular vesicles isolated from human cardiac cells, A polydisperse population of particles in the range of about 10 to about 1000 nm, or any value defining that range, such as, but not limited to, about 90 nm to about 500 nm, about 50 nm to about 250 nm, about 95 nm to about 170 nm, about 25 nm to about 200 nm, about 50 nm to about 750 nm, about 40 nm to about 600 nm, and ranges including and / or spanning the aforementioned values;

[0078] one or more cytoplasmic markers defined by ALIX, any ANXA polypeptide, any ACT polypeptide, TSG101, any CHMP polypeptide, PDCD6IP, VPS4A, VPS4B, ARRDC1, any CAV polypeptide, any EHD polypeptide, RHOA, HSPA8, HSPA1A, any actin polypeptide, any tubulin polypeptide, GAPDH, HSP90AB1, ARF6, SDCBP, MAPT, and TSG101, or a combination thereof;

[0079] one or more transmembrane markers defined by CD3, CD9, CD14, CD37, CD41, CD45, CD47, CD53, CD55, CD59, CD61, CD63, CD73, CD81, CD82, CD90, any GNA polypeptide, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DQ, any H2-A polypeptide, H2-K, H2-D, H2-Q, any ITGA polypeptide, any ITGB polypeptide, TFR2, LAMP1, LAMP2, any SDC polypeptide, BSG, ADAM10, SHH, TSPAN8, PECAM1, ERBB2, EPCAM, CDC42a, GYPA, AChE-S, AChE-E, AβA4, APP, ABCC1, FLOT1, FLOT2, ICAM1, EpCam, or a combination thereof;

[0080] substantially devoid of or devoid of one or more of the following groups: acetylcholinesterase activity, GM130, APOA1, APOA2, APOB, APOB100, ALB, ribosomal proteins, UMOD, and protein / nucleic acid aggregates; 1-1000 unique miRNA transcripts; and approximately 10 2 From 10 to 10 20 A unit dose of extracellular vesicles containing 1000 particles.

[0081] In certain embodiments of any of the above compositions or methods, the extracellular vesicles can be a polydisperse population comprising an average diameter of about 10 nm to about 500 nm, and any value defining that range can be, for example, 10 nm, 11 nm, 12 nm, 13 nm, 14 nm, 15 nm, 16 nm, 17 nm, 18 nm, 19 nm, 20 nm, 21 nm, 22 nm, 23 nm, 24 nm, 25 nm, 26 nm, 27 nm, 28 nm, 29 nm, 30 nm, 31 nm, 32 nm, 33 nm, 34 nm, 35 nm, 36 nm, 37 nm, 38 nm, 39 nm, 40 nm, 41 nm, 42 nm, 43 nm, 44 nm, 45 nm, 46 nm, 47 nm, 48 nm, 49 nm, 50 nm, 51 nm, 52 nm, 53 nm, 54 nm, 55 nm, 56 nm, 57 nm, 58 nm, 59 nm, 60 nm, 61 nm, 62 nm, 63 nm, 64 nm, 65 nm, 66 nm, 67 nm, 68 nm, 69 nm, 70 nm, 71 nm, 72 nm, 73 nm, 74 nm, 75 nm, 76 nm, 77 nm, 78 nm, 79 nm, 80 nm, 81 nm, 82 nm, 83 nm, 84 nm, 85 nm, 86 nm, 87 nm, 88 nm, 89 nm, 90 nm, 91 nm, 92 nm, 93 nm, 94 nm, 95 nm, 96 nm, 97 nm, 98 nm, 99 nm, 100 nm, 44nm, 45nm, 46nm, 47nm, 48nm, 49nm, 50nm, 51nm, 52nm, 53nm, 54nm, 55nm , 56nm, 57nm, 58nm, 59nm, 60nm, 61nm, 62nm, 63nm, 64nm, 65nm, 66nm, 67nm, 68 nm, 69nm, 70nm, 71nm, 72nm, 73nm, 74nm, 75nm, 76nm, 77nm, 78nm, 79nm, 80nm , 81nm, 82nm, 83nm, 84nm, 85nm, 86nm, 87nm, 88nm, 89nm, 90nm, 91nm, 92nm, 93 nm, 94nm, 95nm, 96nm, 97nm, 98nm, 99nm, 100nm, 101nm, 102nm, 103nm, 104nm , 105nm, 106nm, 107nm, 108nm, 109nm, 110nm, 111nm, 112nm, 113nm, 114nm, 11 5nm, 116nm, 117nm, 118nm, 119nm, 120nm, 121nm, 122nm, 123nm, 124nm, 125n m, 126nm, 127nm, 128nm, 129nm, 130nm, 131nm, 132nm, 133nm, 134nm, 135nm, 1 36nm, 137nm, 138nm, 139nm, 140nm, 141nm, 142nm, 143nm, 144nm, 145nm, 146 nm, 147nm, 148nm, 149nm, 150nm, 151nm, 152nm, 153nm, 154nm, 155nm, 156nm, 157nm, 158nm, 159nm, 160nm, 161nm, 162nm, 163nm, 164nm, 165nm, 166nm, 167 nm, 168nm, 169nm, 170nm, 171nm, 172nm, 173nm, 174nm, 175nm, 176nm, 177nm,<h2 style=";text-align:left;direction:ltr">178nm、179nm、180nm、181nm、182nm、183nm、184nm、185nm、186nm、187nm、18 8nm、189nm、190nm、191nm、192nm、193nm、194nm、195nm、196nm、197nm、198nm m、199nm、200nm、201nm、202nm、203nm、204nm、205nm、206nm、207nm、208nm、 209nm、210nm、211nm、212nm、213nm、214nm、215nm、216nm、217nm、218nm、219 nm, 220nm, 221nm, 222nm, 223nm, 224nm, 225nm, 226nm, 227nm, 228nm, 229nm, 230nm, 231nm, 232nm, 233nm, 234nm, 235nm, 236nm, 237nm, 238nm, 239nm, 2 40nm, 241nm, 242nm, 243nm, 244nm, 245nm, 246nm, 247nm, 248nm, 249nm, 250nm, 251nm, 252nm, 253nm, 254nm, 255nm, 256nm, 257nm, 258nm, 259nm, 260nm 261nm, 262nm, 263nm, 264nm, 265nm, 266nm, 267nm, 268nm, 269nm, 270nm, 271nm, 272nm, 273nm, 274nm, 275nm, 276nm, 277nm, 278nm, 279nm, 280nm, 281nm m、282nm、283nm、284nm、285nm、286nm、287nm、288nm、289nm、290nm、291nm、 292nm、293nm、294nm、295nm、296nm、297nm、298nm、299nm、300nm、301nm、302 nm、303nm、304nm、305nm、306nm、307nm、308nm、309nm、310nm、311nm、312nm 、313nm、314nm、315nm、316nm、317nm、318nm、319nm、320nm、321nm、322nm、3 23nm, 324nm, 325nm, 326nm, 327nm, 328nm, 329nm, 330nm, 331nm, 332nm, 333nm, 334nm, 335nm, 336nm, 337nm, 338nm, 339nm, 340nm, 341nm, 342nm, 343nm344nm, 345nm, 346nm, 347nm, 348nm, 349nm, 350nm, 351nm, 352nm, 353nm , 354nm, 355nm, 356nm, 357nm, 358nm, 359nm, 360nm, 361nm, 362nm, 363n m, 364nm, 365nm, 366nm, 367nm, 368nm, 369nm, 370nm, 371nm, 372nm, 373 nm, 374nm, 375nm, 376nm, 377nm, 378nm, 379nm, 380nm, 381nm, 382nm, 383 nm, 384nm, 385nm, 386nm, 387nm, 388nm, 389nm, 390nm, 391nm, 392nm, 39 3nm, 394nm, 395nm, 396nm, 397nm, 398nm, 399nm, 400nm, 401nm, 402nm, 4 03nm, 404nm, 405nm, 406nm, 407nm, 408nm, 409nm, 410nm, 411nm, 412nm, 413nm, 414nm, 415nm, 416nm, 417nm, 418nm, 419nm, 420nm, 421nm, 422nm, 423nm, 424nm, 425nm, 426nm, 427nm, 428nm, 429nm, 430nm, 431nm, 432nm , 433nm, 434nm, 435nm, 436nm, 437nm, 438nm, 439nm, 440nm, 441nm, 442n m, 443nm, 444nm, 445nm, 446nm, 447nm, 448nm, 449nm, 450nm, 451nm, 452 nm, 453nm, 454nm, 455nm, 456nm, 457nm, 458nm, 459nm, 460nm, 461nm, 462 nm, 463 nm, 464 nm, 465 nm, 466 nm, 467 nm, 468 nm, 469 nm, 470 nm, 471 nm, 472 nm, 473 nm, 474 nm, 475 nm, 476 nm, 477 nm, 478 nm, 479 nm, 480 nm, 481 nm, 482 nm, 483 nm, 484 nm, 485 nm, 486 nm, 487 nm, 488 nm, 489 nm, 490 nm, 491 nm, 492 nm, 493 nm, 494 nm, 495 nm, 496 nm, 497 nm, 498 nm, 499 nm, and 500 nm.

[0082] As taught in (Chiang and Chen 2019), extracellular vesicles from a single source are heterogeneous and have a distribution of sizes that characterize the population. A person skilled in the art will recognize that different methods for measuring the size and number of extracellular vesicles may be applicable. Such methods include, but are not limited to, nanoparticle tracking analysis, high-resolution flow cytometry, standard flow cytometry, resistive pulse sensing, atomic force microscopy, impedance-based detection, laser tweezers, Raman spectroscopy, dark-field microscopy, electron microscopy, transmission electron microscopy, and cryo-electron microscopy. A person skilled in the art will be able to select a method appropriate for a given application given the teachings herein. A person skilled in the art will also recognize that the number of extracellular vesicles may be indirectly measured by such methods, including quantification of total protein, total lipid, total RNA, acetylcholinesterase activity, or specific molecules. In one embodiment, the particle size and number of extracellular vesicles may be measured using nanoparticle tracking analysis. In a particular embodiment, the number of extracellular vesicle particles may be measured using the FluoroCet Exosome Quantification Kit. Exemplary experimental methods for such determinations are provided in the Examples set forth below. Those skilled in the art will appreciate that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these Examples, and that the following Examples are non-limiting.

[0083] The mammalian heart is divided into four chambers consisting of two ventricles (lower chambers) and two atria (upper chambers). The cardiac chambers are composed of five major cell types including cardiac fibroblasts, cardiomyocytes, cardiac progenitor cells, smooth muscle cells, and endothelial cells. All of said cells may be encompassed herein by the expression "human cardiac cells." In some embodiments, the human cardiac cells may be derived from a cardiac biopsy. In certain embodiments, the human cardiac cells may be derived from a cardiac biopsy that includes any combination of myocardial, epicardial, or endocardial tissue. In further embodiments, the cardiac biopsy may be the atrial appendage. In some embodiments, the human cardiac cells may be derived from ventricular tissue. In certain embodiments, the human cardiac cells may be derived from the whole heart. In a preferred embodiment, the cardiac biopsy may be the left atrial appendage. In a most preferred embodiment, the left atrial appendage biopsy includes cardiomyocytes and cardiac progenitor cells. Those skilled in the art will recognize that in certain embodiments, a ventricular or atrial biopsy is obtained by surgically removing, for example, the atrial appendage during open chest surgery, guiding a catheter into the heart, and taking a small bite from the cardiac tissue. Those skilled in the art will know the appropriate techniques for taking suitable biopsies or appendages. In some embodiments, cardiac-derived explant cells may be derived from a cardiac biopsy. Those skilled in the art will further recognize that cardiac explant-derived cells may represent a collection of different cell populations expressing markers of endothelial, mesenchymal, and stem cell identity. Without wishing to be bound by theory, such cells would likely be considered multipotent cells, or stem cells that have at least partially differentiated into cardiac tissue.

[0084] As described herein and recognized by those skilled in the art, immortalization of cells is a process or operation to increase the cell division capacity of cells in culture (in vitro), thereby increasing the time that the cells can be cultured. In certain embodiments of any of the above compositions or methods, the heart-derived explant cells can be immortalized using techniques including, but not limited to, genetic mutation, expression of viral genes, expression of viral gene products, expression of reverse telomerase, expression of transcriptase, expression of SV40, or equivalent techniques known to those skilled in the art.

[0085] As described herein and recognized by those skilled in the art, immortalization of cells is a process or manipulation to increase the cell division capacity of cells in culture (in vitro), thereby increasing the time the cells can be cultured. In certain embodiments of any of the above compositions or methods, cardiac-derived explant cells can be immortalized using techniques including, but not limited to, genetic mutation, expression of viral genes, expression of viral gene products, expression of reverse telomerase, expression of transcriptase, expression of SV40, or equivalent techniques known to those skilled in the art. Those skilled in the art will recognize that different methods for generating human cardiac cells may be possible (e.g., as discussed in (Balafkan, Mostafavi et al. 2020)). Those skilled in the art will be able to select the appropriate cell type for a given application given the teachings herein. Such methods may include cell vesicles using cardiac explant derived stem cells, cardiac explant derived stem cells, cardiac explant derived cells, cardiac explant derived stem cells, atrial explant derived stem cells, atrial explant derived cells, differentiation induced pluripotent stem cells, differentiating embryonic stem cells, any differentiating adult progenitor cells, differentiating adipose derived stem cells, differentiating mesenchymal stem cells, differentiating P19 cells, differentiating C2C12 cells, any cells capable of cardiac differentiation, or cells or tissues that generate equivalent extracellular composition.

[0086] In certain embodiments of any of the above compositions or methods, the human cardiac cells can be allogeneic to the recipient of the composition. In certain other embodiments, the human cardiac cells can be autologous to the recipient of the composition. In certain embodiments, the human cardiac cells can be cryopreserved between -1°C and -200°C, with any value defining the range, e.g., -200°C, -199°C, -198°C, -197°C, -196°C, -195°C, -194°C, -193°C, -192°C, -191°C, -190°C, -189°C, -188°C, -187°C, -186°C, -185°C, -184°C, -183°C, -182°C, -181°C, -180°C, -179°C, -178°C, -177°C, -176°C, -175°C, -174°C, -1 73℃, -172℃, -171℃, -170℃, -169℃, -168℃, -167℃, -166℃, -165℃, -164℃, -163℃, -162℃, -161℃, -160℃, -159℃, -158℃, -157℃, -156℃, -155℃, -154℃, -153℃, -152℃, -151℃, -150℃, -149℃, -148℃, -147℃, -146℃, -145℃, -144℃, -143℃, -142℃, -141℃, -140℃, -139℃, -138℃, -137℃, -136 ℃, -135℃, -134℃, -133℃, -132℃, -131℃, -130℃, -129℃, -128℃, -127℃, -126℃, -125℃, -124℃, -123℃, -122℃, -121℃, -120℃, -119℃, -118℃, -117℃, -116℃, -115℃, -114℃, -113℃, -112℃, -111℃, -110℃, -109℃, -108℃, -107℃, -106℃, -105℃, -104℃, -103℃, -102℃, -101℃, -100℃, -99℃, - 98℃, -97℃, -96℃, -95℃, -94℃, -93℃, -92℃, -91℃, -90℃, -89℃, -88℃, -87℃, -86℃, -85℃, -84℃, -83℃, -82℃, -81℃, -80℃, -79℃, -78℃, -77℃, -76℃, -75℃, -74℃, -73℃, -72℃, -71℃, -70℃, -69℃, -68℃, -67℃, -66℃, -65℃, -64℃, -63℃, -62℃, -61℃, -60℃, -59℃, -58℃, -57℃, -56℃, -55℃, -54℃,-53℃, -52℃, -51℃, -50℃, -49℃, -48℃, -47℃, -46℃, -45℃, -44℃, -43℃, -42℃, -41℃, -40℃, -39℃, -38℃, -37℃, -36℃, -35℃, -34℃, -33℃, -32℃, -31℃, -30℃, -29℃, -28℃, - These include 27°C, -26°C, -25°C, -24°C, -23°C, -22°C, -21°C, -20°C, -19°C, -18°C, -17°C, -16°C, -15°C, -14°C, -13°C, -12°C, -11°C, -10°C, -9°C, -8°C, -7°C, -6°C, -5°C, -4°C, -3°C, -2°C, and -1°C.

[0087] The International Society for Extracellular Vesicles (ISEV) teaches minimum information for the study of extracellular vesicles (Thery, Witwer et al. 2018). As taught at the time of filing, there is no consensus on specific markers for extracellular vesicle subtypes. It is further taught, therefore, that operational terms for extracellular vesicle subtypes that refer to physical characteristics such as size, biochemical composition such as protein content, condition of origin or cell of origin are recommended. ISEV further teaches that three categories of broad markers can be analyzed to demonstrate the presence of extracellular vesicles (categories 1 and 2) and to assess purity from contamination (category 3). ISEV also teaches markers that are generally limited to small extracellular vesicles (category 4) and markers of potential functional activity (category 5).

[0088] Category 1 is taught to include transmembrane or GPI-anchored proteins, the presence of which indicates the lipid bilayer structure characteristic of extracellular vesicles. The proteins may include: tetraspanins (CD63, CD81, CD82); tetraspanins (CD63, CD81, CD82); other multipass membrane proteins (CD47, GNA); MHC class I (HLA-A / B / C, H2-K / D / Q); integrins (ITGA, ITGB); transferrin receptor (TFR2); LAMP1 / 2, heparan sulfate proteoglycan (SDC); complement binding proteins (CD55, CD59); MHC class II (HLA-DR / DP / DQ, H2-A); BSG, ADAM10, CD73, SHH, TSPAN, CD37, CD53, CD9, PECAM1, ERBB2, EPCAM, CD90, CD45, CD41, CD42a, ICAM, GYPA, CD14, CD3, AChE-S, AChE-E, Aβ, APP, and ABCC1.

[0089] It is taught that category 2 includes cytoplasmic proteins, the presence of which indicates the ability of the preparation to encapsulate intracellular material. The proteins may include: ESCRT-I / II / III and accessory proteins (TSG101, CHMP): caveolin (CAV); enzymes (GAPDH); actin (ACT), tubulin (TUB); annexins (ANXA); heat shock proteins (HSC70, HSP70, HSPA1A HSPA8, HSP84, HSP90AB1); PDCD6IP, VPS4A / B; ARRDC1, FLOT1 / 2, EHD, RHOA, ARF6, SDCBP, MAPT. It is further taught that such cytosolic protein components of extracellular vesicles vary widely, and thus extracellular vesicles may contain additional cytosolic proteins.

[0090] It is taught that category 3 includes major components of non-extracellular vesicle structures that are often co-isolated with extracellular vesicles. The proteins may include lipoproteins (APOA1 / 2, APOB, APOB100, ALB) proteins and protein / nucleic acid aggregates, UMOD and ribosomal proteins. It is further taught that the purity of extracellular vesicle preparations is evaluated by evaluating the molecules in category 3.

[0091] It is taught that category 4 includes larger structures that are substantially devoid of small extracellular vesicles or are completely absent due to their size. The markers can include: nucleus (including histones, LMNA); mitochondria (including IMMT, CYC1, TOMM20); endoplasmic reticulum (including CANX, HSP90B1, HSPA5); Golgi apparatus (including GM130); autophagosome (including ATG9A); and cytoskeleton (including ACTN1 / 4, KRT18). Those skilled in the art will recognize that organelles and large intracellular structures can be identified with other markers. Those skilled in the art will also recognize the criteria for determining whether substantially devoid or absent based on a given application or methodology.

[0092] Category 5 teaches that functional components used to determine the binding mode with extracellular vesicles include proteins such as cytokines (including IFNG, IL); growth factors (including VEGFA, FGF1 / 2, PDGF, EGF, TGFB1 / 2); adhesion and extracellular matrix proteins (including FN1, COL, MFGE8, LGALS3BP, CD5L, AHSG).

[0093] Those skilled in the art will recognize that many protein markers are members of a family with similar or homologous proteins and may perform the same function.Thus, those skilled in the art will recognize that a protein marker may or may not apply to all proteins across a family or class.As a non-limiting example, ITGB broadly refers to the entire class of integrin β subunit proteins in humans, including ITGB1, ITGB2, ITGB3, ITGB4, ITGB5, ITGB6, ITGB7, and ITGB8.Those skilled in the art will recognize that homologs of said proteins may or may not have the same function.

[0094] ISEV further teaches that analytical approaches such as Western blot, high-resolution flow cytometry, proteomic arrays, or global proteomic analysis using mass spectrometry techniques can be used to identify proteins in categories 1-5. Those skilled in the art will recognize that additional methods can be used to determine the presence, absence, or levels of a given protein in an extracellular vesicle composition. Exemplary experimental methods for such determinations are provided in the Examples set forth below. Those skilled in the art will understand that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these Examples, and that the following Examples are non-limiting.

[0095] Furthermore, those skilled in the art will recognize that structures surrounded by lipid layers, such as the lipid bilayer of extracellular vesicles, are easily disrupted by detergent-containing solutions. Those skilled in the art will recognize this as another non-limiting example of determining and / or verifying the characteristics and / or presence of extracellular vesicles, where the addition of a detergent may reduce the number of extracellular vesicle particles compared to samples not treated with detergent. In another embodiment of any of the above compositions, the extracellular vesicles may be solubilized by the addition of a detergent, including a solution of about 0.01% to about 10.0% Triton™ X-100, any value defining the range, e.g., 0.01%, 0.05%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0. 9%, 0.95%, 1%, 1.05%, 1.1%, 1.15%, 1.2%, 1.25%, 1.3%, 1.35%, 1.4%, 1.45%, 1.5%, 1.55%, 1.6%, 1.65%, 1.7%, 1.75%, 1.8%, 1.85%, 1.9%, 1.95%, 2%, 2.05%, 2.1%, 2.15%, 2.2%, 2.25%, 2.3%, 2.35%, 2.4%, 2.45%, 2.5%, 2.55%, 2.6%, 2.65%, 2.7%, 2.75%, 2.8%, 2.85%, 2.9%, 2.95%, 3%, 3.05%, 3.1%, 3.15%, 3.2%, 3.25%, 3.3%, 3.35%, 3.4%, 3.45%, 3.5%, 3.55%, 3.6%, 3.65%, 3.7%, 3.75%, 3.8%, 3.85%, 3.9%, 3.95%, 4%, 4.05%, 4.1%, 4.15%, 4.2%, 4.25%, 4.3%, 4.35%, 4.4%, 4.45%, 4.5%, 4.55%, 4.6%, 4.65 %,4.7%,4.75%,4.8%,4.85%,4.9%,4.95%,5%,5.05%,5.1%,5.15%,5.2%,5.25%,5.3%,5.35%,5.4%,5.45%,5.5%,5.55%,5.6%,5.65%,5.7%,5.75%,5.8%,5.85%,5.9%,5.95%,6%,6.05%,6.1%,6.15%,6.2%,6.25%,6.3%,6.35%,6.4%,6.45%,6.5%,6.55%, 6.6%, 6.65%, 6.7%, 6.75%, 6.8%, 6.85%, 6.9%, 6.95%, 7%, 7.05%, 7.1%, 7.15%, 7.2%, 7.25%, 7.3%, 7.35%, 7.4%, 7.45%, 7.5%, 7.55%, 7.6%, 7.65%, 7.7%, 7.75%, 7.8%, 7.85%, 7.9%, 7.95%, 8%, 8.05%, 8.1%, 8.15%, 8.2%, 8.25%, 8.3%, 8.35%, 8.4%, 8.45%, 8.5%, 8.5 5%, 8.6%, 8.65%, 8.7%, 8.75%, 8.8%, 8.85%, 8.9%, 8.95%, 9%, 9.05%, 9.1%, 9.15%, 9.2%, 9.25%, 9.3%, 9.35%, 9.4%, 9.45%, 9.5%, 9.55%, 9.6%, 9.65%, 9.7%, 9.75%, 9.8%, 9.85%, 9.9%, 9.95% and 10%, where solubilization can be measured by a reduction in extracellular vesicle particle number compared to a sample not treated with detergent. Exemplary experimental methods for such determinations are provided in the Examples set forth below. Those skilled in the art will appreciate that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these Examples, and that the following Examples are non-limiting.

[0096] ISEV teaches the non-limiting nature of such aforesaid lists and recommends using them as a guide to define extracellular vesicles, as not all components are present or absent in all vesicle populations. ISEV further teaches that extracellular vesicle components not listed in any of categories 1-5 may be present in extracellular vesicles depending on factors including, but not limited to, tissue type, cell type, induction method, and physiological conditions. Given the above general knowledge, one of skill in the art will recognize that not all markers are present or absent on extracellular vesicles of a given cell or tissue type, and said differences in presence, absence, or presence or absence. The level of a particular component may serve as a defining characteristic of the resulting extracellular vesicles. One of skill in the art, given the teachings herein, will be able to select the appropriate method and threshold for determining "substantially deficient or absent" and "present" for extracellular vesicle components for a given application.

[0097] It is understood that certain subtypes of ribonucleic acid (RNA), including but not limited to microRNA (miRNA) and messenger RNA (mRNA), constitute part of the components of extracellular vesicles. miRNAs function by regulating post-transcriptional gene expression, generally through binding to complementary sequences on mRNA transcripts. Binding of miRNAs to complementary sequences can result in translational repression as well as mRNA degradation and gene silencing. miRNA activity can affect the heart in certain disease states, for example, U.S. Pat. No. 9,828,603 teaches that increasing levels of mir-146a reduced the infarct area in mice following myocardial infarction compared to animals treated with a control mimic miRNA. U.S. Pat. No. 9,828,603 further teaches that increasing the concentration of mir-210 transfected into cardiomyocytes increased survival after exposure to hydrogen peroxide by 10-fold. The miRNA profile of the extracellular vesicles can be determined by reverse transcription polymerase chain reaction (qRT-PCR), miRNA microarrays, multiplex fluorescent oligonucleotide-based miRNA detection, and RNA sequencing. In one embodiment, the miRNA profile of the extracellular vesicle composition derived from human cardiac cells can be determined by RNA sequencing.

[0098] In certain embodiments, the extracellular vesicles comprise from about 1 to about 1000 unique miRNA transcripts, with any value defining the range, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 102, 104, 105, 10 7, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 , 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 1 69, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 20 0, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231 , 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262,263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 82 2, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 92 82, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941 , 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999 or 100.

[0099] Exemplary experimental methods for such determination are provided in the Examples below. Those skilled in the art will understand that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these Examples, and that the following Examples are non-limiting. As used herein, unique miRNA transcripts refer to a population of miRNAs transcribed from unique loci.

[0100] In some embodiments of any of the above compositions or methods, the extracellular vesicles include various biomolecules such as nucleic acids and proteins. The extracellular vesicles include various types of RNA molecules as taught in (Zimta, Sigurjonsson et al. 2020) and various types of deoxyribonucleic acid (DNA) molecules as taught in (Hur and Lee 2021). In certain embodiments, the extracellular vesicles include DNA, DNA fragments, DNA plasmids, mRNA, tRNA, snRNA, piRNA, saRNA, miRNA, rRNA, ribozymes, double-stranded RNA, other non-coding RNA and coding RNA. In some embodiments, the extracellular vesicles include non-coding RNA (ncRNA), such as, but not limited to, long non-coding RNA (IncRNA), microRNA (miRNA), long intergenic non-coding RNA (lincRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), and Y RNA fragments.

[0101] Extracellular vesicles can be secreted into the extracellular space and transport their components to other cells by binding and fusing with cell membranes (Murphy, de Jong et al. 2019). Both components of the extracellular vesicle lipid bilayer and the extracellular vesicle cargo can be incorporated into the recipient cell. In one embodiment, transport of proteins from the extracellular vesicle to the recipient cell can determine the absorption of the extracellular vesicle components. In another embodiment, transport of lipids from the extracellular vesicle to the recipient cell can determine the absorption of the extracellular vesicle components. In certain embodiments, the human cardiac cells that absorb the extracellular vesicles can be immune cells, endothelial cells, myocytes, and / or fibroblasts. In certain embodiments, the human cardiac cells that absorb the extracellular vesicles can be in vitro. In certain embodiments, the human cardiac cells that absorb the extracellular vesicles can be in vivo. Exemplary experimental methods for such determinations are provided in the Examples described below. Those skilled in the art will appreciate that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting.

[0102] Examination of extracellular vesicle components has revealed several proteins and nucleic acids associated with cardiac conditions and diseases. As an example, overexpression of miR-24 improved cardiac function and reduced fibrosis in rodent models (Barile, Lionetti et al. 2014). One skilled in the art will further recognize that extracellular vesicle components may positively affect cardiac condition or function (e.g., (Quattrocelli, Crippa et al. 2013), (Yang, Qin et al. 2019), U.S. Patent No. 9,828,603) or adversely affect cardiac condition and function (e.g., (Adam, Lohfelm et al. 2012), (Cardin, Guasch et al. 2012), (Cao, Shi et al. 2017), (Zhi, Xu et al. 2019)). The findings described herein are somewhat surprising because several extracellular vesicle components reported herein as substantially absent or lacking have previously been clearly shown to have a positive effect on cardiac outcome (U.S. Pat. No. 9,828,603).

[0103] One of skill in the art given the teachings herein will further appreciate that it is contemplated that the compositions of extracellular vesicles described herein may be further tailored by genetic reprogramming / modification of human cardiac cells, including, but not limited to, increasing certain components (e.g., as discussed in (Hall, Prabhakar et al. 2016)), decreasing certain components (e.g., as discussed in (Pfeifer, Werner et al. 2015)), targeting extracellular vesicles to specific locations (e.g., as discussed in (Kooijmans, Schiffelers et al. 2016)), targeting extracellular vesicles to specific cells (e.g., as discussed in (Kooijmans, Schiffelers et al. 2016)), and increasing production of extracellular vesicles (e.g., as discussed in (Park, Bandeira et al. 2019)) to promote the function of extracellular vesicles, as described in the aforementioned references. For example, in certain embodiments, it is contemplated that human cardiac cells described herein can be genetically reprogrammed to overexpress the KCNN4 gene, which can promote extracellular vesicle production.Such approaches can include lentivirus reprogramming, CRISPR / Cas9 editing, or other methods known to those skilled in the art, such as minicircle DNA.

[0104] Inflammation may be a defensive response by the immune system to protect against harmful stimuli. However, prolonged inflammation may result in harmful conditions. Inflammation may be regulated by immune cells, which can infiltrate tissues, secrete factors, and destroy recognized harmful substances. Infiltration of inflammatory immune cells into atrial tissue may be observed in certain subjects with atrial arrhythmias (e.g., as described in (Zhou and Dudley 2020)), so the presence of inflammatory immune cells in tissues may indicate inflammation. Those skilled in the art will recognize that immune cells may infiltrate the heart. In certain embodiments, the phrase "human cardiac cells" may also include immune cells. Inflammasomes are receptors, also called sensors, that regulate inflammatory responses and serve as indicators of potential inflammation through markers of inflammasomes such as caspase-1 activation. Infiltration of inflammatory immune cells into atrial tissues of subjects with atrial arrhythmias indicates the possibility of immune cells absorbing extracellular vesicles. Immune cells may bind and / or secrete molecules, including but not limited to cytokines, interleukins, interferons, chemokines, complement proteins, or any equivalents, to induce inflammatory responses in surrounding tissues. Increased immune cell infiltration, secreted immune molecules, and inflammasome activation may indicate increased inflammation. Those skilled in the art will recognize that many techniques are possible for determining inflammation. Those skilled in the art will be able to select a suitable method for a given application, given the teachings herein. Exemplary experimental methods for such determinations are described in the examples described below. Those skilled in the art will understand that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting.

[0105] Fibrosis may cause thickening and / or scarring of affected tissues. Fibrosis may occur due to excessive deposition of extracellular matrix components, including but not limited to collagen, fibronectin and fibrin from fibroblasts, and may result from prolonged inflammation (Wynn 2008). In addition, it is believed that fibrosis may disrupt electrical activity in the heart, causing conditions including but not limited to atrial arrhythmias. Those skilled in the art will recognize that many techniques are possible to determine fibrosis, including but not limited to hydroxyproline and relative tissue content. Given the teachings herein, those skilled in the art will be able to select an appropriate method for a given application. Exemplary experimental methods for such determinations are provided in the Examples set forth below. Those skilled in the art will appreciate that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these Examples, and that the following Examples are non-limiting.

[0106] Those skilled in the art will recognize that increased proliferation of fibroblasts may promote fibrosis, as taught, for example, in (Kendall and Feghali-Bostwick 2014). Thus, those skilled in the art will recognize that changes in fibroblast proliferation may be a precursor to fibrosis and atrial arrhythmias, as further taught, for example, in (Ashihara, Haraguchi et al. 2012) and (Aguilar, Qi et al. 2014). Those skilled in the art will recognize that many techniques are possible to quantify fibroblast proliferation. Cell proliferation is controlled in part by transcriptional changes in genes that positively and / or negatively regulate the cell cycle (Liu, Chen et al. 2017). As used herein, a positive cell cycle regulatory gene may refer to a gene that, when expressed or activated, can increase cell division by promoting progression into and / or through cell cycle stages, including, but not limited to, cyclin D, cyclin E, cyclin A, and cyclin B. As used herein, a negative cell cycle regulatory gene may refer to a gene that, when expressed or activated, may reduce cell division by blocking progression into the cell cycle and / or by blocking progression through a cell cycle stage, including, but not limited to, p53, RB, p21, and cyclin-dependent kinase inhibitors (CKI). As taught, for example, in (Bretones, Delgado et al. 2015; Rubin, Sage et al. 2020), regulation of cell cycle genes is believed to be controlled, in part, by transcription factors, transcription factor families, and cofactors. This includes, but is not limited to, E2F, MYC, p53, RB, P107, P130, etc., which regulate the expression of gene families such as cyclins and cyclin-dependent kinases. Transcriptional control of the cell cycle results in complex changes in gene expression of factors that affect the transition from G0 or G1 to S phase of the cell cycle, and progression to G2 and M phases. One of ordinary skill in the art, given the teachings herein, will be able to select an appropriate method for a given application.Exemplary experimental methods for such determinations are provided in the Examples set forth below. Those skilled in the art will appreciate that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these Examples, and that the following Examples are non-limiting.

[0107] The derivation of extracellular vesicles can be performed from either bodily fluids (examples include, but are not limited to, blood, milk, urine) or conditioned cell culture medium. As bodily fluids may contain extracellular vesicles from many bodily sources, one skilled in the art will recognize that derivation of extracellular vesicles from cell culture medium minimizes heterogeneity of vesicle sources compared to bodily fluids. In some embodiments, the human cardiac cells can be grown in vitro. In certain embodiments, the human cardiac cells can be grown in vitro. As will be appreciated, the extracellular vesicle compositions, their uses and methods described herein can follow Good Manufacturing Practice (GMP) standards and / or other similar pharmaceutical industry standards. In some embodiments, GMP standards can be used to culture cardiac explant-derived cells, for example, as described in U.S. Pat. No. 11,083,756. Standard operating procedures (SOPs) can be developed for producing and using the extracellular vesicle compositions described herein, examples of which are provided in U.S. Pat. No. 11,083,756.

[0108] In certain embodiments, the human cardiac cells may be grown and expanded in vitro using GMP conditions. In certain embodiments, GMP conditions may include controlled physiological cell culture conditions, including a continuous atmosphere of about 1% to about 10% oxygen, and about 1% to about 10% carbon dioxide, a relative humidity of about 50% to about 90% RH, a temperature of about 32°C to about 42°C, serum-free, xeno-free growth medium, and fetal bovine serum that has been stripped of extracellular vesicles. In certain embodiments, the human cardiac cells may be grown in vitro using GMP-compliant enzymes to detach cells from a culture plate or dish, the GMP-compliant enzymes including one or more of TrypLE™ Select, collagenase I, and collagenase II, or a combination thereof. In certain embodiments, the extracellular vesicles are isolated after incubation for about 1 hour to about 196 hours or more, with any value defining the range, e.g., 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 ​​hours, 49 hours, 50 hours, 51 hours, 52 hours, 53 hours, 54 hours. , 55 hours, 56 hours, 57 hours, 58 hours, 59 hours, 60 hours, 61 hours, 62 hours, 63 hours, 64 hours, 65 hours, 66 hours, 67 hours, 68 hours, 69 hours, 70 hours, 71 hours, 72 hours, 73 hours, 74 hours, 75 hours, 76 hours, 77 hours, 78 hours, 79 hours, 80 hours, 81 hours, 82 hours, 83 hours, 84 hours, 85 hours, 86 hours, 87 hours Between, 88 hours, 89 hours, 90 hours, 91 hours, 92 hours, 93 hours, 94 hours, 95 hours, 96 hours, 97 hours, 98 hours, 99 hours, 100 hours, 101 hours, 102 hours, 103 hours, 104 hours, 105 hours, 106 hours, 107 hours, 108 hours, 109 hours, 110 hours, 111 hours, 112 hours, 113 hours, 114 hours, 115 hours, 116 hours,117 hours, 118 hours, 119 hours, 120 hours, 121 hours, 122 hours, 123 hours, 124 hours, 125 hours, 126 hours, 127 hours, 128 hours, 129 hours, 130 hours, 131 hours, 132 hours, 133 hours, 134 hours, 135 hours, 136 hours, 137 hours, 138 hours, 139 hours, 140 hours, 141 hours, 142 hours, 143 hours, 144 hours, 145 hours, 146 hours, 147 hours, 148 hours, 149 hours, 150 hours, 151 hours, 152 hours, 153 hours, 154 hours, 155 hours, 156 hours, 157 hours , 158 hours, 159 hours, 160 hours, 161 hours, 162 hours, 163 hours, 164 hours, 165 hours, 166 hours, 167 hours, 168 hours, 169 hours, 170 hours, 171 hours, 172 hours, 173 hours, 174 hours, 175 hours, 176 hours, 177 hours, 178 hours, 179 hours, 180 hours, 181 hours, 182 hours, 183 hours, 184 hours, 185 hours, 186 hours, 187 hours, 188 hours, 189 hours, 190 hours, 191 hours, 192 hours, 193 hours, 194 hours, 195 hours, 196 hours, or more. Those skilled in the art will appreciate that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting.

[0109] Allorecognition is the ability of an individual organism to distinguish its own tissue from that of other organisms, and surface antigens may determine the recognition of cells of non-self origin. Extracellular vesicles have different components, and one skilled in the art will recognize that each extracellular vesicle composition may or may not activate an immune response after allogeneic administration, which may be due to the diverse presence of surface antigens. The findings described herein are somewhat surprising, since extracellular vesicle compositions derived from human cardiac cells may not induce an immune response. The lack of a significant immune response may provide utility over other biological agents that may be hindered by immunogenicity, as taught, for example, in (Boehncke and Brembilla 2018). Furthermore, certain compositions of extracellular vesicles teach immunogenicity-promoting properties (Escudier, Dorval et al. 2005). In certain embodiments, substantially immunologically inert is determined by the lack of tolerance or response following xenotransplantation of any of the compositions of extracellular vesicles described above. In certain embodiments, the composition of the extracellular vesicles is derived from a xenogeneic source. In certain embodiments, it is contemplated that the extracellular vesicles are derived from a heterologous cell line. In certain embodiments, substantially immunologically inactive is determined by mixed lymphocyte reaction. Exemplary experimental methods for such determination are provided in the examples described below. Those skilled in the art will understand that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting.

[0110] Arrhythmias can be detected by analysis of an electrocardiogram, a test that monitors the electrical activity of the heart, providing a voltage versus time graph of the electrical activity of the heart, detecting small electrical changes in the heart resulting from depolarization and subsequent repolarization of the myocardium during each cardiac cycle (heart beat). An electrocardiogram can be performed in a clinic or sampled continuously (such as by a smart watch or hospitalized patient telemetry). Those skilled in the art will recognize that electrocardiography can be performed as an invasive or non-invasive procedure. Given the teachings herein, those skilled in the art will be able to select an appropriate method for a given application. Exemplary experimental methods for such determinations are provided in the examples described below. Those skilled in the art will understand that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting. Additional capture tests, including, but not limited to, electrocardiograms, blood pressure monitors, Holter monitors, event monitors, blood tests, echocardiograms, stress tests, inpatient telemetry, chest x-rays, smart watches, smart rings, wearable technology capable of measuring heart rate, any equivalent technology, or any combination thereof, may be used in the diagnosis and / or differential diagnosis of atrial arrhythmias.

[0111] Atrial arrhythmias as taught herein are a unique type of arrhythmia that differs in many ways from other arrhythmias, such as arrhythmias originating from the ventricles, including but not limited to etiology, pathology, symptoms, treatment options, patient outcomes and patient susceptibility, as discussed, for example, in (Ludhwani, Goyal et al. 2021) and (Nesheiwat, Goyal et al. 2021). Drugs that slow electrical conduction to prevent atrial fibrillation (such as but not limited to flecainide) are contraindicated in patients with ventricular arrhythmias because they induce arrhythmias and increase the risk of death (Ledan 2020). Furthermore, based on the teachings of (Rizvi, DeFranco et al. 2016), one skilled in the art will recognize that ventricular-specific differences exist in the mammalian heart, as atrial fibroblasts are different from ventricular fibroblasts.

[0112] Atrial arrhythmias include, but are not limited to, atrial fibrillation, postoperative atrial fibrillation, postinfarction atrial fibrillation, thyrotoxicosis, postviral atrial fibrillation, alcohol-related atrial fibrillation, drug-induced atrial fibrillation, viral atrial fibrillation, postviral atrial fibrillation, COVID-19 atrial fibrillation, post-COVID-19 atrial fibrillation, paroxysmal atrial fibrillation, permanent atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, atrial tachycardia, atrial flutter, familial atrial fibrillation, idiopathic atrial fibrillation, isolated atrial fibrillation, and orphan atrial arrhythmias. Atrial arrhythmias may cause symptoms such as, but are not limited to, general fatigue, elevated heart rate, irregular heartbeat, dizziness, shortness of breath, anxiety, fainting, heart failure, pounding in the neck, weakness, confusion, fainting, sweating, chest pain, chest pressure, chest pounding, or a combination thereof. In certain embodiments of any of the above compositions or methods, said composition of extracellular vesicles ameliorates one or more symptoms of atrial arrhythmia.

[0113] In certain embodiments, the composition of extracellular vesicles can reduce the duration of atrial fibrillation, where duration can refer to the length of time of a single episode of atrial fibrillation, including a reduction of 1 second or more, with any value defining the range, for example, 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, 11 seconds, 12 seconds, 13 seconds, 14 seconds, 15 seconds, 16 seconds, 17 seconds, 18 seconds, 19 seconds, 20 seconds, 21 seconds, 22 seconds, 23 seconds, 24 seconds, 25 seconds, 26 seconds, 27 seconds, 28 seconds, 29 seconds, 30 seconds, 31 seconds, 32 seconds, 33 seconds, 34 seconds, 35 seconds, 36 seconds, 37 seconds, 38 seconds, 39 seconds, 40 seconds, 41 seconds, 42 seconds, 43 seconds, 44 seconds, 45 seconds, 46 seconds, 47 seconds, 48 ​​seconds, 49 seconds, 50 seconds, 51 seconds, 52 seconds, 53 seconds, 54 seconds, 55 seconds, 56 seconds, 57 seconds, 58 seconds, 59 seconds, 60 seconds, 61 seconds, 62 seconds, 63 seconds, 64 seconds, 65 seconds, 66 seconds, 67 seconds, 68 seconds, 69 seconds, 70 seconds, 71 seconds, 72 seconds, 73 seconds, 74 seconds, 75 seconds, 76 seconds, 77 seconds, 78 seconds, 79 seconds, 80 seconds, 81 seconds, 82 seconds, 83 seconds, 84 seconds, 85 seconds, 86 seconds, 87 seconds, 88 seconds, 89 seconds, 90 seconds, 91 seconds 5 seconds, 26 seconds, 27 seconds, 28 seconds, 29 seconds, 30 seconds, 31 seconds, 32 seconds, 33 seconds, 34 seconds, 35 seconds, 36 seconds, 37 seconds, 38 seconds, 39 seconds, 40 seconds, 41 seconds, 42 seconds, 43 seconds, 44 seconds, 45 seconds, 46 seconds, 47 seconds, 48 ​​seconds, 49 seconds , 50 seconds, 51 seconds, 52 seconds, 53 seconds, 54 seconds, 55 seconds, 56 seconds, 57 seconds, 58 seconds, 59 seconds, 60 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes ,17 minutes,18 minutes,19 minutes,20 minutes,21 minutes,22 minutes,23 minutes,24 minutes,25 minutes,26 minutes,27 minutes,28 minutes,29 minutes,30 minutes,31 minutes,32 minutes,33 minutes,34 minutes,35 minutes,36 minutes,37 minutes,38 minutes,39 minutes,40 minutes,41 minutes,42 minutes,43 minutes,44 minutes,45 minutes,46 minutes,47 minutes,48 minutes,49 minutes,50 minutes,51 minutes,52 minutes,53 minutes,54 minutes,55 minutes,56 minutes,57 minutes,58 minutes,59 minutes,60 minutes,1 hour,2 hours,3 hours,4 hours,5 hours, Includes 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years or more.In certain embodiments, the composition of extracellular vesicles can reduce the incidence of atrial fibrillation, where incidence refers to the length of time between episodes of atrial fibrillation, including a reduction of 1 second or more, with any value defining the range, for example, 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, 11 seconds, 12 seconds, 13 seconds, 14 seconds, 15 seconds, 16 seconds, 17 seconds, 18 seconds, 19 seconds, 20 seconds, 21 seconds, 22 seconds, 23 seconds, 24 seconds, 25 seconds, 26 seconds, 27 seconds, 28 seconds, 29 seconds, 30 seconds, 31 seconds, 32 seconds, 33 seconds, 34 seconds, 35 seconds, 36 seconds, 37 seconds, 38 seconds, 39 seconds, 40 seconds, 41 seconds, 42 seconds, 43 seconds, 44 seconds, 45 seconds, 46 seconds, 47 seconds, 48 ​​seconds, 49 seconds, 50 seconds, 51 seconds, 52 seconds, 53 seconds, 54 seconds, 55 seconds, 56 seconds, 57 seconds, 58 seconds, 59 seconds, 60 seconds, 61 seconds, 62 seconds, 63 seconds, 64 seconds, 65 seconds, 66 seconds, 67 seconds, 68 seconds, 69 seconds, 70 seconds, 71 seconds, 72 seconds, 73 seconds, 74 seconds, 75 seconds, 76 seconds, 77 seconds, 78 seconds, 79 seconds, 80 seconds, 81 seconds, 82 seconds, 83 seconds, 84 seconds, 85 seconds, 86 seconds, 87 seconds, 88 seconds, 89 seconds, 90 seconds, 91 seconds, seconds, 28 seconds, 29 seconds, 30 seconds, 31 seconds, 32 seconds, 33 seconds, 34 seconds, 35 seconds, 36 seconds, 37 seconds, 38 seconds, 39 seconds, 40 seconds, 41 seconds, 42 seconds, 43 seconds, 44 seconds, 45 seconds, 46 seconds, 47 seconds, 48 ​​seconds, 49 seconds, 50 seconds, 51 seconds , 52 seconds, 53 seconds, 54 seconds, 55 seconds, 56 seconds, 57 seconds, 58 seconds, 59 seconds, 60 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 1 8 minutes, 19 minutes, 20 minutes, 21 minutes, 22 minutes, 23 minutes, 24 minutes, 25 minutes, 26 minutes, 27 minutes, 28 minutes, 29 minutes, 30 minutes, 31 minutes, 32 minutes, 33 minutes, 34 minutes, 35 minutes, 36 minutes, 37 minutes, 38 minutes, 39 minutes, 40 minutes, 41 minutes, 42 minutes, 43 minutes, 44 minutes, 45 minutes, 46 minutes, 47 minutes, 48 ​​minutes, 49 minutes, 50 minutes, 51 minutes, 52 minutes, 53 minutes, 54 minutes, 55 minutes, 56 minutes, 57 minutes, 58 minutes, 59 minutes, 60 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours , 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more. Exemplary experimental methods for such determination are provided in the examples described below. Those skilled in the art will understand that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting.

[0114] The administration forms include, but are not limited to, injections, catheters, solutions, creams, gels, implants, pumps, ointments, emulsions, suspensions, microspheres, particles, microparticles, nanoparticles, liposomes, pastes, patches, tablets, capsules, transdermal delivery devices, sprays, aerosols, or other means well known to those skilled in the art. Exemplary experimental methods for such determination are provided in the examples described below. Those skilled in the art will understand that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting. Those skilled in the art will be able to select the appropriate administration method that fits the needs of a particular application and / or a particular subject.

[0115] In another embodiment of any of the above compositions or methods, the extracellular vesicles can be administered by single or multiple injections, and the number of injections can be determined as a ratio of the total surface area of ​​the tissue to be injected. Without wishing to be bound by theory, a non-limiting example is an injection of about 0.01 cm 2 From about 10.00 cm 2 The injections per minute are listed, and arbitrary values ​​define the range, e.g., 0.01 cm 2 From 0.05cm 2 , 0.05cm 2 From 0.10cm 2 , 0.15cm 2 From 0.20cm 2 , 0.25cm 2 From 0.30 cm 2 , 0.30cm 2 From 0.35 cm 2 , 0.35cm 2 From 0.40 cm 2 , 0.40cm 2 From 0.45 cm 2 , 0.50cm 2 From 0.55cm 2 , 0.55cm 2 From 0.60cm 2 , 0.60cm 2 From 0.65cm 2 , 0.65cm 2 From 0.70cm2 , 0.70cm 2 From 0.75cm 2 , 0.75cm 2 From 0.80cm 2 , 0.85cm 2 From 0.90cm 2 , 0.90cm 2 From 0.95 cm 2 , 0.95cm 2 From 1.00cm 2 , 1.00cm 2 From 1.10cm 2 , 1.10cm 2 From 1.20cm 2 , 1.20cm 2 From 1.30 cm 2 , 1.30cm 2 From 1.40 cm 2 , 1.40cm 2 From 1.50 cm 2 , 1.50cm 2 From 1.60cm 2 , 1.60cm 2 From 1.70cm 2 , 1.70cm 2 From 1.80cm 2 , 1.80cm 2 From 1.90cm 2 , 1.90cm 2 From 2.00cm 2 , 2.00cm 2 From 2.10cm 2 , 2.10cm 2 From 2.20cm 2 , 2.20cm 2 From 2.30 cm 2 , 2.30cm 2 From 2.40 cm 2 , 2.40cm 2 From 2.50 cm 2 , 2.50cm 2 From 2.60cm 2 , 2.60cm 2 From 2.70cm 2 , 2.70cm 2 From 2.80cm 2 , 2.80cm 2 From 2.90cm 2, 2.90cm 2 From 3.00cm 2 , 3.00cm 2 From 3.10cm 2 , 3.10cm 2 From 3.20cm 2 , 3.20cm 2 From 3.30 cm 2 , 3.30cm 2 From 3.40 cm 2 , 3.40cm 2 From 3.50 cm 2 , 3.50cm 2 From 3.60cm 2 , 3.60cm 2 From 3.70cm 2 , 3.70cm 2 From 3.80cm 2 , 3.80cm 2 From 3.90cm 2 , 3.90cm 2 From 4.00cm 2 , 4.00cm 2 From 4.10cm 2 , 4.10cm 2 From 4.20cm 2 , 4.20cm 2 From 4.30 cm 2 , 4.30cm 2 From 4.40cm 2 , 4.40cm 2 From 4.50 cm 2 , 4.50cm 2 From 4.60cm 2 , 4.60cm 2 From 4.70cm 2 , 4.70cm 2 From 4.80cm 2 , 4.80cm 2 From 4.90cm 2 , 4.90cm 2 From 5.00cm 2 , 5.00cm 2 From 5.10cm 2 , 5.10cm 2 From 5.20cm 2 , 5.20cm 2 From 5.30 cm 2 , 5.30cm2 From 5.40 cm 2 , 5.40cm 2 From 5.50 cm 2 , 5.50cm 2 From 5.60cm 2 , 5.60cm 2 From 5.70cm 2 , 5.70cm 2 From 5.80cm 2 , 5.80cm 2 From 5.90cm 2 , 5.90cm 2 From 6.00cm 2 , 6.00cm 2 From 6.10cm 2 , 6.10cm 2 From 6.20cm 2 , 6.20cm 2 From 6.30 cm 2 , 6.30cm 2 From 6.40 cm 2 , 6.40cm 2 From 6.50 cm 2 , 6.50cm 2 From 6.60cm 2 , 6.60cm 2 From 6.70cm 2 , 6.70cm 2 From 6.80cm 2 , 6.80cm 2 From 6.90cm 2 , 6.90cm 2 From 7.00cm 2 , 7.00cm 2 From 7.10cm 2 , 7.10cm 2 From 7.20cm 2 , 7.20cm 2 From 7.30 cm 2 , 7.30cm 2 From 7.40cm 2 , 7.40cm 2 From 7.50 cm 2 , 7.50cm 2 From 7.60cm 2 , 7.60cm 2 From 7.70cm 2 , 7.70cm 2From 7.80cm 2 , 7.80cm 2 From 7.90cm 2 , 7.90cm 2 From 8.00cm 2 , 8.00cm 2 From 8.10cm 2 , 8.10cm 2 From 8.20cm 2 , 8.20cm 2 From 8.30 cm 2 , 8.30cm 2 From 8.40cm 2 , 8.40cm 2 From 8.50cm 2 , 8.50cm 2 From 8.60cm 2 , 8.60cm 2 From 8.70cm 2 , 8.70cm 2 From 8.80cm 2 , 8.80cm 2 From 8.90cm 2 , 8.90cm 2 From 9.00cm 2 , 9.00cm 2 From 9.10cm 2 , 9.10cm 2 From 9.20cm 2 , 9.20cm 2 From 9.30 cm 2 , 9.30cm 2 From 9.40cm 2 , 9.40cm 2 From 9.50cm 2 , 9.50cm 2 From 9.60cm 2 , 9.60cm 2 From 9.70cm 2 , 9.70cm 2 From 9.80cm 2 , 9.80cm 2 From 9.90cm 2 , and 9.90 cm 2 From 10.00cm 2 Includes.

[0116] In another embodiment, the injections may include from 1 to about 500 injections, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 , 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113 , 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 1 76, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 20 7, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238 , 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269,270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, ​​383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, and 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 49 or 100 times. Exemplary experimental methods for such determinations are provided in the Examples set forth below. Those skilled in the art will appreciate thatIt will be understood that various modifications, alternative techniques, or substitutions can be made to the experimental methods provided in these examples, and that the following examples are non-limiting.

[0117] In another embodiment of any of the above compositions or methods, the extracellular vesicle composition may be administered by a dosage form in a syringe. In certain embodiments, the dose of the extracellular vesicle composition may be related to the number of particles in a unit volume, for example, the number of particles per milliliter. In certain embodiments, the dose of the extracellular vesicle composition is about 10 2 From about 10 particles / mL 20 particles / mL, and any value defining the range may be, for example, 1×10 2 Particles / mL to 5 x 10 2 particles / mL, 5×10 2 Particles / mL to 1 x 10 3 particles / mL, 1×10 3 Particles / mL to 5 x 10 3 particles / mL, 5×10 3 Particles / mL to 1 x 10 4 particles / mL, 1×10 4 Particles / mL to 5 x 10 4 particles / mL, 5×10 4 Particles / mL to 1 x 10 5 particles / mL, 1×10 5 Particles / mL to 5 x 10 5 particles / mL, 5×10 5 Particles / mL to 1 x 10 6 particles / mL, 1×10 6 Particles / mL to 5 x 10 6 particles / mL, 5×10 6 Particles / mL to 1 x 10 7 particles / mL, 1×10 7 Particles / mL to 5 x 10 7 particles / mL, 5×10 7 Particles / mL to 1 x 10 8 particles / mL, 1×10 8 Particles / mL to 5 x 10 8 particles / mL, 5×10 8 Particles / mL to 1 x 10 9 particles / mL, 1×10 9Particles / mL to 5 x 10 9 particles / mL, 5×10 9 Particles / mL to 1 x 10 10 particles / mL, 1×10 10 Particles / mL to 5 x 10 10 particles / mL, 5×10 10 Particles / mL to 1 x 10 11 particles / mL, 1×10 11 Particles / mL to 5 x 10 11 particles / mL, 5×10 11 Particles / mL to 1 x 10 12 particles / mL, 1×10 12 Particles / mL to 5 x 10 12 particles / mL, 5×10 12 Particles / mL to 1 x 10 13 particles / mL, 1×10 13 Particles / mL to 5 x 10 13 particles / mL, 5×10 13 Particles / mL to 1 x 10 14 particles / mL, 1×10 14 Particles / mL to 5 x 10 14 particles / mL, 5×10 14 Particles / mL to 1 x 10 15 particles / mL, 1×10 15 Particles / mL to 5 x 10 15 particles / mL, 5×10 15 Particles / mL to 1 x 10 16 particles / mL, 1×10 16 Particles / mL to 5 x 10 16 particles / mL, 5×10 16 Particles / mL to 1 x 10 17 particles / mL, 1×10 17 Particles / mL to 5 x 10 17 particles / mL, 5×10 17 Particles / mL to 1 x 10 18 particles / mL, 1×10 18 Particles / mL to 5 x 10 18 particles / mL, 5×10 18 Particles / mL to 1 x 10 19 particles / mL, 1×10 19 Particles / mL to 5 x 10 19 particles / mL and 5×10 19 Particles / mL to 1 x 1020 Contains particles / mL.

[0118] In another embodiment of any of the above compositions or methods, the dose of the extracellular vesicle composition is about 10 2 Particles ~ approx. 10 20 particles, and any value defining the range is, for example, 1×10 2 5×10 from particles 2 Particles, 5×10 2 1×10 particles 3 Particles, 1×10 3 5×10 from particles 3 Particles, 5×10 3 1×10 particles 4 Particles, 1×10 4 5×10 from particles 4 Particles, 5×10 4 1×10 particles 5 Particles, 1×10 5 5×10 from particles 5 Particles, 5×10 5 1×10 particles 6 Particles, 1×10 6 5×10 from particles 6 Particles, 5×10 6 1×10 particles 7 Particles, 1×10 7 5×10 from particles 7 , 5×10 7 1×10 particles 8 Particles, 1×10 8 5×10 from particles 8 Particles, 5×10 8 1×10 particles 9 Particles, 1×10 9 5×10 from particles 9 Particles, 5×10 9 1×10 particles 10 Particles, 1×10 10 5×10 from particles 10 Particles, 5×10 10 1×10 particles 11 Particles, 1×10 11 5×10 from particles 11 Particles, 5×10 11 1×10 particles 12 Particles, 1×10 125×10 from particles 12 Particles, 5×10 12 1×10 particles 13 Particles, 1×10 13 5×10 from particles 13 Particles, 5×10 13 1×10 particles 14 Particles, 1×10 14 5×10 from particles 14 Particles, 5×10 14 1×10 particles 15 Particles, 1×10 15 5×10 from particles 15 Particles, 5×10 15 1×10 particles 16 Particles, 1×10 16 5×10 from particles 16 Particles, 5×10 16 1×10 particles 17 Particles, 1×10 17 5×10 from particles 17 Particles, 5×10 17 1×10 particles 18 Particles, 1×10 18 5×10 from particles 18 Particles, 5×10 18 1×10 particles 19 Particles, 1×10 19 5×10 from particles 19 particles and 5×10 19 1×10 particles 20 In certain embodiments, the dose of the extracellular vesicle composition may relate to the total number of particles received. In other embodiments, the dose of the extracellular vesicle composition may relate to the number of particles received in each individual injection. In certain other embodiments, the dose of the extracellular vesicle composition may relate to the sum of the extracellular vesicles received in multiple injections, which may be received at the same time or at different times.

[0119] The pharmaceutical formulations of the present invention can be prepared by procedures known in the art using well-known and readily available ingredients. For example, the compounds can be formulated with common excipients, diluents, or carriers to form tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers suitable for such formulations include: binders (e.g., carboxymethylcellulose and other cellulose derivatives, alginates, gelatin, and polyvinylpyrrolidone); humectants (e.g., glycerol); disintegrants (e.g., paraffin); resorption promoters (e.g., quaternary ammonium compounds); surfactants (e.g., cetyl alcohol, glycerol monostearate); adsorbent carriers (such as kaolin and bentonite); emulsifiers; preservatives; sweeteners; stabilizers; colorants; fragrances; flavorings; lubricants (e.g., talc, calcium stearate, and magnesium stearate); solid polyethyl glycols. and mixtures thereof.

[0120] Those skilled in the art will understand that the biomolecules and / or compounds described herein can be provided in pharmaceutical compositions with pharma- ceutically acceptable diluents, carriers, or excipients, and / or with one or more separate active agents or drugs as part of a pharmaceutical combination or pharmaceutical composition.In certain embodiments, the biomolecules, compounds, and / or pharmaceutical compositions can be administered simultaneously, sequentially, or in combination with other drugs or pharmaceutical compositions, individually, or as a combined preparation or combination in a treatment regimen.In certain embodiments, the extracellular vesicle compositions can be administered simultaneously, sequentially, or in combination with other drugs, pharmaceutical compositions, or treatments, individually, or as a combined preparation or combination in a treatment regimen to treat or prevent atrial arrhythmia. In certain embodiments, the extracellular vesicle compositions may be administered individually or as combined formulations or combinations in a therapeutic regimen simultaneously, sequentially, or in combination with rhythm control drugs (e.g., including but not limited to, flecainide, propafenone, quinidine, sotalol, amiodarone, and dronedarone), rate control drugs (including but not limited to, beta-blockers, calcium channel blockers, cardiac glycosides, etc.) or surgical treatments (including but not limited to, cardioversion, catheter ablation, pacemaker insertion, defibrillator implantation, Maze procedure, etc.) to treat or prevent atrial arrhythmias.

[0121] The composition can be configured to release the active ingredient only or preferably at a specific location or cell type, and / or optionally over a period of time (i.e., sustained release formulations). Such combinations provide additional mechanisms for controlling release kinetics and distribution. Coatings, envelopes, and protective matrices can be made, for example, from polymeric substances or waxes and pharma- ceutically acceptable carriers. In certain further embodiments of any of the above compositions or methods, the extracellular vesicles are modified to limit their absorption to only fibroblasts, cardiomyocytes, endothelial cells, and / or immune cells, or any desired cell or tissue type.

[0122] As used herein, the term "differentially expressed" may refer to, but is not limited to, a change in expression or level of a given factor, such as a protein, RNA, mRNA, miRNA, biomolecule, or any bioactive cellular component, when comparing one sample to another. The samples examined for differential expression may be different cell types, different experimental conditions, different genetic manipulations, or changes in other parameters known to those skilled in the art. In certain embodiments, the term "differentially expressed" may refer to any increase or decrease in expression in a protein, RNA, miRNA, mRNA, or other biomolecule or bioactive cellular component, such as a protein, RNA, miRNA, mRNA, or other protein, RNA, miRNA, mRNA, or equivalent bioactive component known to those skilled in the art. In certain embodiments, the term "differentially expressed" may refer to a significant increase or decrease in expression in a cellular component, such as, but not limited to, a protein, RNA, miRNA, mRNA, or any equivalent bioactive component known to those skilled in the art. In certain embodiments, the term "differentially expressed" may refer to an increase or decrease in expression of a bioactive cellular component, such as, but not limited to, a protein, RNA, miRNA, mRNA, or any equivalent component known to one of skill in the art, of a log2 fold > or < 1.5 and a p-value < 0.05.

[0123] In certain embodiments, the differentially expressed miRNA may also include the mRNA targets of the differentially expressed miRNA. As known to those skilled in the art, miRNAs generally function by regulating post-transcriptional gene expression through binding to complementary sequences on mRNA transcripts. Thus, in certain embodiments described herein, it is contemplated that the "differentially expressed miRNA" may include an mRNA that may have a putative or predicted miRNA binding site or consensus site of a differentially expressed miRNA, and may also include a protein encoded by an mRNA that may contain a putative or predicted miRNA binding site of a differentially expressed miRNA. In view of the teachings herein, the skilled artisan will be able to select an appropriate technique or algorithm, such as, but not limited to, miRWalk (Sticht, De La Torre, et al. 2018), which may provide a list of mRNA target sequences of a particular miRNA. In certain embodiments, the algorithm or technique for determining the mRNA targets of a differentially expressed miRNA may include analysis of the 3'UTR and 5'UTR of an mRNA for miRNA consensus or binding sites. In certain embodiments, the algorithm or technique for determining the mRNA targets of the differentially expressed miRNA may include analysis of the 3'UTR of the mRNA for miRNA consensus or binding sites. In certain embodiments, the differentially expressed miRNA may be provided to a miRWalk to determine the differentially expressed mRNA.

[0124] In certain embodiments, without wishing to be bound by theory, it is contemplated that one or more differentially expressed components comprising cardiac-derived extracellular vesicles may mediate their activity. In certain embodiments, without wishing to be bound by theory, it is contemplated that multiple differentially expressed components comprising cardiac-derived extracellular vesicles may mediate their activity.

[0125] As used herein, the term "native" may include one or more factors that are present in one state and not present in another state, or that are present in minimal amounts in another state. In certain embodiments, the term "native" may refer to a group of factors, such as, for example, biomolecules, bioactive components, proteins, mRNAs, miRNAs, etc., present in the extracellular vesicles or extracellular vesicle cargo. For example, it is contemplated that a unique miRNA may include multiple unique miRNAs in combination, or a unique protein may include multiple unique proteins in combination. In certain embodiments, the term "native" may refer to the absence of a particular factor, such as, for example, a bioactive component, protein, mRNA, miRNA, etc., present in the extracellular vesicles or extracellular vesicle cargo. In certain embodiments, the composition of the extracellular vesicles may include one or more unique proteins. In certain embodiments, the composition of the extracellular vesicles may include one or more unique proteins, as compared to extracellular vesicles isolated from a source that does not include human heart tissue.

[0126] Those skilled in the art, given the teachings herein, will appreciate that atrial arrhythmias can be induced, precipitated, and / or caused by many factors. Those skilled in the art will appreciate that models such as, but not limited to, aseptic pericarditis, ventricular dysfunction, infarction, and coronary artery ligation can induce atrial arrhythmias or increase the likelihood of developing atrial arrhythmias.

[0127] In certain embodiments, it is contemplated that human heart-derived extracellular vesicles can be applied or delivered to a subject in a gel. In certain embodiments, the gel can be a biomaterial gel. As used herein, "biomaterial gel" can refer to a gel that is substantially composed of one or more biomaterials. In certain embodiments, the gel can be an agarose gel. In certain embodiments, the biomaterial gel can be impregnated with human heart-derived extracellular vesicles. As used herein, "impregnation" can refer to the insertion or application of extracellular vesicles to another object or material, such as a gel. Impregnation of a material results in a substantially uniform distribution of the extracellular vesicles throughout the material, resulting in an approximately equal concentration of vesicles throughout the material. Given the teachings herein, one of skill in the art will be able to select appropriate conditions, such as, but not limited to, the type of agarose or the agarose concentration, to achieve a human heart-derived extracellular vesicles-impregnated gel.

[0128] As used herein, the term "payload" may refer to a component that constitutes an extracellular vesicle, such as its cargo. As used herein, the terms "component", "cargo", and "payload" may be used interchangeably to refer to factors that constitute an extracellular vesicle. As known to those skilled in the art, EV cargo, such as proteins and RNA, may depend on tissue cell source, and methodological factors, such as but not limited to different media, EV collection conditions, protein quantification techniques, RNA quantification techniques, techniques for protein quantification analysis, and techniques for RNA quantification analysis. Those skilled in the art will appreciate that comparisons made between samples, such as samples containing extracellular vesicles, may be more consistent with fewer variables being altered. Thus, comparisons between EV cargo from different tissues require that EVs be derived, quantified, and analyzed using substantially similar techniques to ensure the most accurate results for determining variable-specific expression level changes or differential expression analysis.

[0129] The following examples are offered for illustrative purposes and are intended for those of ordinary skill in the art. These examples are provided to demonstrate certain embodiments described herein and should not be construed as limiting in any way.

[0130] Working Example Example 1 Materials and Methods Cardiac explant-derived cell (EDC) culture and extracellular vesicles (EV) isolation Human cardiac explant-derived cells (EDCs) were obtained from left atrial appendages donated by patients undergoing clinically indicated cardiac surgery after informed consent under a protocol approved by the University of Ottawa Heart Institute Research Ethics Board. EDCs were cultured as previously described (Davis, Kizana et al. 2010;Latham, Ye et al. 2013;Mount,Kanda et al. 2019). Briefly, cardiac biopsies were minced and digested with appropriate enzymes, including but not limited to a GMP grade blend of collagenase I / II (Roche), and plated in Nutristem® medium (Biological Industries) exposed to physiological (5%) oxygen in a GMP cell manufacturing facility (Mount,Kanda et al. 2019). EDCs were harvested from plated tissues using TrypLE® Select (Thermo Fischer Scientific) for direct experimentation once a week for approximately 4 weeks.

[0131] Conditioned media was collected after 48 h of culture in 1% EV-depleted serum (System Biosciences) and 1% oxygen and centrifugation at 10,000g for 30 min and 100,000g for 3 h to pellet EVs (Kanda, Alarcon et al. 2018; Villanueva, Michie et al. 2019). Extracellular vesicle (EV) content, size, and surface marker expression were analyzed using acetylcholinesterase activity (Fluoro-Cet, Systems Biosciences), nanoparticle tracking (Nanosight), and candidate antibody array (Exo-Check®, Systems Biosciences) analysis.

[0132] EV miRNA and proteome analysis miRNA content within EDC EVs was profiled using multiplex fluorescent oligonucleotide-based miRNA detection (Human v3, Nanostring) as previously described (Kanda, Alarcon et al. 2018; Villanueva, Michie et al. 2019). Briefly, prior to profiling (Counter Human V3 miRNA Expression Assay), RNA was extracted (QIAGEN) and quantified (Agilent 2100 Bioanalyzer, Agilent). Image quality was assessed (nSolver®) and samples were discarded if the field of view percent and sample binding density exceeded pre-specified criteria. Background subtraction was performed using the mean and two standard deviations of the negative controls. Counts were normalized using the trimmed mean of M-values, and differentially expressed miRNAs were identified using a generalized linear model likelihood ratio test.

[0133] EDC EVs were lysed (8 M urea, 100 mM HEPES, 5% glycerol, and 0.5% n-dodecyl β-d-maltoside; Thermo Fischer Scientific), reduced (tris(2-carboxyethyl)phosphine alkylated with iodoacetamide), digested (1.5 μL of 0.3 μg / μL trypsin / Lys-C solution; Promega) before formic acid treatment, desalting (C18 TopTips; Glygen) and vacuum drying. Protein samples were analyzed using an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific) coupled to an UltiMate 3000 nanoRSLC (Dionex, Thermo Fisher Scientific) as previously described (Risha, Minic et al. 2020). Peptides were searched against the human Uniprot FASTA database using MaxQuant software with a false discovery rate of 1% (Cox and Mann 2008). Pathway analysis terms were extracted from the Reactome database (Sidiropoulos, Viteri et al. 2017) for network analysis (Cytoscape) (Merico, Isserlin et al. 2010). Only proteins found in at least two biological replicates were included in the analysis. Flow cytometry was performed on EVs individually labeled for CD9 (312106, BioLegend), CD63 (353004, BioLegend), or CD81 (349506, BioLegend) using a CytoFLEX S Beckman Coulter flow cytometer (Welsh, Jones et al. 2020). Light scatter was calibrated using National Institute of Standards and Technology traceable size standards (Thermo Fisher Scientific) and fluorescence was calibrated using soluble fluorophore equivalent beads (BD Biosciences) for analysis using FCMPASS (v3.07, National Cancer Institute) and FlowJo (V10.7, BD Biosciences) (Welsh and Jones 2020).

[0134] Isolation of atrial fibroblasts Primary cultures of rat atrial fibroblasts were isolated from the hearts of 8-9 week-old Sprague-Dawley rats using enzymatic digestion (collagenase type II, Worthington Biochemical) at 37 °C. Cells were cultured in Dulbecco's modified Eagle's high glucose medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% glutamine, and 1% penicillin-streptomycin (Thermo Fischer Scientific) at 5% CO2. Second or third generation fibroblasts were used in all subsequent experiments.

[0135] In vitro uptake of EVs EV uptake in cardiac cells was assessed in a range of cell lines using flow cytometry. Rat atrial fibroblasts, neonatal rat ventricular cardiomyocytes and human umbilical vein endothelial cells (HUVECs; Lonza) were cultured with 108 EVs labeled with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil). Neonatal rat ventricular myocytes (NRVMs) were prepared from 2-day-old Sprague-Dawley rats (Harlan) as described (Kapoor, Liang et al. 2013; Liang, Yuan et al. 2015). HUVECs were cultured according to the manufacturer's instructions.

[0136] In vivo efficacy testing Male and female Sprague-Dawley rats (6 months old, Charles River) were subjected to induction of sterile pericarditis or sham surgery based on a protocol approved by the University of Ottawa Animal Care Committee. The detailed protocol was preregistered within the Open Science Framework. A one-way study was designed to test whether intramyocardial injection of EDC EVs at the time of induction of sterile pericarditis significantly reduces the incidence of AF by invasive electrophysiological testing (primary outcome). A rat model of sterile pericarditis after talc application was used (Huang, Chen et al. 2016). To increase the rigor and reproducibility of the study on postoperative atrial fibrillation (POAF), 6-month-old female and male rats were studied. We hypothesized that the incidence of atrial fibrillation after talc treatment was 0.6 and that EV treatment would reduce the incidence of atrial fibrillation to 0.2. Gender is not thought to alter the incidence of induced atrial fibrillation. Based on these assumptions, a group sample size of 34 rats (17 females + 17 males) would achieve 83% power to detect dominance using a two-tailed Mann-Whitney test (probability of a false positive result (α error) = 0.05).

[0137] Rats were fed rat chow and kept at 21°C, 50% humidity, and under a 12:12-h light-dark cycle. All animals had free access to tap water and chow. After preoperative administration of buprenorphine (0.03 mg / kg subcutaneously), rats were anesthetized with 3% isoflurane, intubated, and ventilated. The chest was shaved and sterilized with 2% w / v chlorhexidine gluconate in 70% v / v isopropyl alcohol. Animals were then divided into sham (n=24; 12 females, 12 males), atrial EV10 8 Animals randomized to sterile pericarditis were subjected to open-chest surgery and the atrial surface was liberally dusted with sterile talcum powder (Thermo Fischer Scientific). Animals randomized to sham surgery underwent a superficial incision that was closed in a manner indistinguishable from animals that underwent open-chest surgery. Intramyocardial injections were performed using a Hamilton microsyringe (31-gauge needle) to inject a total volume of 100 μL into five separate injection points in the left atrial wall (Cardin, Guasch et al. 2012). After surgery, animals were placed in an incubator at 30 °C with supplemental oxygen and moist food until they returned to physiological conditions. Additional doses of buprenorphine (0.03 mg / kg subcutaneously) were administered 6 and 12 hours postoperatively. Animal care technicians from the University of Ottawa observed the animals twice daily for 2 days following surgery. Laboratory staff were blinded to the treatments received, and analyses were performed by individuals blinded to group assignments. Group assignments were kept in a separate password-protected list for unblinding after analysis of the primary study outcomes was completed. 96 rats underwent surgery, and all completed the study without adverse events or protocol deviations (Figure 22).

[0138] Three days after surgery, all rats underwent invasive electrophysiological testing (Cardin, Guasch et al. 2012). After intraperitoneal injection of sodium pentobarbital (40 mg / kg), a 1.6 F octapolar catheter (Millar) with an interelectrode spacing of 1 mm was inserted into the right atrium via the jugular vein for stimulation and recording. Surface and intracardiac electrocardiograms were continuously monitored (AD Instruments). The refractory period of the atrioventricular node was determined as the longest S1-S2 interval that failed to be conducted to the ventricle using a 2-times threshold, 2-ms square wave pulse after a 10-stimulus drive train (S1, cycle length 100 ms) followed by S2 decremented at 2-ms intervals. If it failed to induce AF, atrial burst pacing of 10–30 s was performed with cycle lengths ranging from 20–80 ms. AF was defined as rapid and fragmented atrial electrograms, lack of discernible P waves on the surface electrocardiogram, and an irregular ventricular rhythm lasting at least 500 ms (Kapoor, Liang et al. 2013). The total time of AF episodes was defined as the sum of AF durations from the longest AF episode recorded. At the end of the study, rats were sacrificed by exsanguination under pentobarbital anesthesia after demonstrating a lack of withdrawal reflex upon toe pinch.

[0139] Histological analysis and quantification of fibrosis Atria were collected, fixed and sectioned for histological analysis of inflammatory infiltrates (hematoxylin and eosin (H&E), activated T lymphocytes (CD3 (ab16669, Abcam) and CD4 (ab237722, Abcam), macrophage infiltration / polarization (CD68 (ab125212, Abcam) and CD163 (ab182422, Abcam) and neutrophils (CD11b (ab133357, Abcam)). Hematoxylin and eosin staining was quantified using freely available ImageJ software with a color deconvolution plugin that allows separation of hematoxylin and eosin components and quantification of each stain individually. Total tissue area was determined throughout the section and the area of ​​infiltrates was determined using H&E color deconvolution. The area was determined using ImageJ thresholding obtained after deconvolution, which allowed calculation of the percentage of infiltrate (infiltrate divided by total area). Collagen content in the left atrium was quantified using an unbiased measure that reflects the overall degree of myocardial fibrosis (Jamall, Finelli et al. 1981; He, Gao et al. 2011).

[0140] Transcriptome analysis of atrial fibroblasts The impact of EV treatment on atrial gene expression was assessed using RNA sequencing (RNAseq). After atrial RNA isolation, rRNA was removed for preparation of cDNA libraries (Ribo-Zero rRNA Removal Kit, Illumina) followed by sequencing (45 million reads per sample). Prior to quantification of gene expression, reads were first mapped using Bowtie2 (RSEM v1.2.15. TMM). Genes with expression changes of 1.5-fold (p<0.05) were considered differentially expressed in Ingenuity pathway and network analysis (Qiagen).

[0141] Inflammatory cytokines Atrial tissue was minced and homogenized using a tissue homogenizer (TissueRuptor, Qiagen) according to the manufacturer's protocol. Inflammatory cytokines and chemokines were measured using a multiplex Luminex-based assay (LXSARM, R&D Systems). Each sample was run in duplicate in a 96-well plate. Four analytes (IL1, IL2, IL18, TNF) were measured using the MAGPIX system (C4447b). The acquired mean fluorescence data were analyzed and calculated by xPONENT software. IL-6 (ERA32RB, Invitrogen), PDGF-AB (ab213906, abcam), and MCP-1 (ab100778, abcam) were quantified using commercially available enzyme-linked immunosorbent assay (ELISA) assays.

[0142] Fibroblast proliferation Postoperative atrial fibrillation (POAF) was modeled by exposing normal rat atrial fibroblasts to interleukin-6 (IL-6) or transforming growth factor β1 (TGFβ1) to recapitulate an inflammatory in vivo environment (Narikawa, Umemura et al. 2018). Atrial fibroblast proliferation without treatment and after treatment with IL6, TGFβ1, and / or EDC EVs was assessed by staining for nuclear incorporation with the thymidine analog 5-ethynyl-2'-deoxyuridine (EdU) (17-10525; Millipore) and DAPI. Manual cell counts were performed to confirm findings. Population doubling times were measured using the WST-8 assay (Dojindo). Cell cycle distribution was assessed using flow cytometry according to the manufacturer's instructions (4500-0220, Guava). Briefly, fibroblasts were cultured in serum-free medium for 24 h, followed by 10 days of culture, which was used as a G1 cell arrest control or vehicle. 8Atrial fibroblasts were cultured for 24 h in EDC-EVs, IL-6, TGFβ1, and aphidicolin (APC) (Sigma). Flow cytometry was performed to quantify populations within the G0 / G1, S, and G2 / M phases of the cell cycle for each treatment (Guava, Millipore Sigma). To further explore the effects of EDC-EVs on atrial fibroblasts, commercially available enzyme-linked immunosorbent assay (ELISA) assays were performed to examine molecular regulators of cell cycle progression. Briefly, atrial fibroblasts were lysed according to the manufacturer's instructions and ELISAs were performed for cyclin A2 (MBS7211946, MyBioSource), cyclin B1 (MBS9328611, MyBioSource), cyclin D (MBS721009, MyBioSource), and cyclin E (MBS1600300, MyBioSource).

[0143] statistical analysis All statistical tests used and graphical representations of data (means and error bars, or box plots) are defined within the figure legends of the respective data panels. All data are presented as mean ± standard error of the mean. To determine whether differences existed within groups, data were analyzed by one-way ANOVA or repeated measures ANOVA (SPSS v20.0.0). If such differences existed, Bonferroni's corrected t-test was used to determine which groups differed. In all cases, variances were assumed to be equal and normality was confirmed before further post-hoc testing. Differences in categorical measurements were analyzed using chi-square tests. A final value of P ≤ 0.05 was considered significant for all analyses.

[0144] result Human atrial EVs contain anti-fibrotic / anti-inflammatory transcripts and proteins. Human EDCs were cultured in a clinical cell manufacturing facility from atrial appendage biopsies using serum-free and xeno-free culture conditions (Mount, Kanda et al. 2019). EVs were isolated from conditioned medium after 48 h in 1% oxygen, basal medium conditions (Kanda, Alarcon et al. 2018; Mount, Kanda et al. 2019). Following accepted definitions, EDC EVs represent a polydisperse population of particles ranging from 95 to 170 nm (132 ± 7 nm). These microparticles contained transmembrane (CD63, CD81, FLOT1, ICAM1, EpCam) and cytosolic markers (ALIX, ANXA5, TSG101) indicative of EV identity (Lotvall, Hill et al. 2014), but no evidence of cellular contaminants (GM130; Figure 2). Flow cytometry demonstrated significant enrichment of microparticles containing typical EV markers CD9, CD63, and CD81 (Figures 3-4). Interestingly, fewer particles expressed CD81 (approximately two-fold lower vs. CD9 or CD63, p<0.05), and smaller particles were more likely to express CD63 (p<0.05 vs. CD9 or CD81) (Figure 3B-C). Acetylcholinesterase activity was also present and correlated with nanoparticle tracking content. Thus, the presence of a functional extracellular membrane-bound protein associated with EVs is confirmed, providing a rapid means of confirming EV concentration.

[0145] The cargo within EDC EVs was enriched with 83 miRNA transcripts associated with reducing inflammation, stimulating angiogenesis, and inhibiting fibrosis (Figure 5, Table 1). Interestingly, the most abundant miRNAs (counts >1000) were associated with altered cell division / proliferation (let-7a, miR23a, miR-199a) and fibrosis (let-7a and miR-199a). EDC EVs contained the transcript miR-21, known to promote fibrosis and AF susceptibility (Cardin, Guasch et al. 2012), but lacked all other known pathological transcripts (miR-1 (Girmatsion, Biliczki et al. 2009)), miR-133 (Tsopolis, Fazio et al. 2018), miR-328 (Small, Frost et al. 2010), and miR-590 (Shan, Zhang et al. 2009)), and contained miRNAs associated with reduced fibrotic atrial remodeling (miR-26 (Luo, Pan et al. 2013) and miR-29 (van Rooij, Sutherland et al. 2008)). Of the 811 proteins identified in EDC EVs ( Figures 6 – 7 ), the proteome was enriched with 196 proteins associated with inflammation (Wilcoxon rank sum test p < 0.003). These directly affected both chemotaxis (i.e., annexin A1 and annexin-5) ((Lim, Solito et al. 1998;Ewing, de Vries et al. 2011;Burgmaier, Schutters et al. 2014;Vital, Becker et al. 2016;de Jong, Pluijmert et al. 2018) and macrophage function (i.e., galectin-1, hemopexin and thioredoxin) (Correa, Sotomayor et al. 2003;Liang, Lin et al. 2009;El Hadri, Mahmood et al. 2012;Jung, Kwak et al. 2017;Canesi, Mateo et al. 2019).Among 28 proteins implicated in fibrosis, decorin (transforming growth factor 1β (TGF-β1) inhibitor) and matrix metalloproteinase 2 were highly expressed (Onozuka, Kakinuma et al. 2011;Radbill, Gupta et al. 2011;Baghy, Iozzo et al. 2012;Parichatikanond, Luangmonkong et al. 2020). Enrichment mapping of the EV proteome predicted important roles in cell cycle control, inflammation, and cell signaling.

[0146] Taken together, the data support the notion that EDCs produce defined EV products containing anti-fibrotic, anti-inflammatory cargo that may alter the underlying drivers of POAF.

[0147] Table 1 shows exemplary miRNAs identified using multiplex fluorescent oligonucleotide-based miRNA detection in extracellular vesicles derived from cardiac explant-derived cells. hsa, Homo sapiens

[0148] [Table 1]

[0149] Intramyocardial injection of human EVs reduces inflammation, fibrosis, and atrial fibrillation in a rat model of aseptic pericarditis The antiarrhythmic potential of EDC EVs was investigated using a rat model of aseptic pericarditis (Huang, Chen et al. 2016), whereby all animals underwent open-chest surgery before being randomized to epicardial application of talc or epicardial application without talc. Immediately after epicardial application of talc, animals were again randomly assigned to intra-atrial injection of EVs or vehicle (saline; Figure 9). As outlined in Figure 22, all animals survived the first surgery, but three animals treated with vehicle died from anesthesia overdose before the second surgery. Three days after open-chest surgery, treatment with EVs reduced the probability of inducing AF by 40% (p<0.01 vs. vehicle alone, Figures 10-11). Recipient sex did not alter this effect. In animals that experienced AF, neither EV treatment nor recipient sex significantly altered AF duration (Figure 12). However, this observation may be due to the small number of sham- and EV-treated animals that experienced AF, as well as the nonparametric distribution of AF duration. Pericarditis, EV treatment, and recipient gender did not affect electrocardiographic or electrophysiological measures of cardiac function (Table 2). As shown in Figure 13, EV treatment prevented atrial fibrosis (45 ± 19% reduction in hydroxyproline content, p = 0.01 vs. vehicle alone) and enlargement (41 ± 15% reduction in atria / body weight, p = 0.01 vs. vehicle alone).

[0150] Table 2 shows the effects of EVs on electrocardiographic and electrophysiological functions. AVERP, atrioventricular nodal refractory period; EV, extracellular vesicles; veh, vehicle.

[0151] [Table 2]

[0152] EVs prevent inflammation Open chest surgery results in loss of pericardial mesothelial cells, leading to an inflammatory infiltrate and subsequent fibrinogenous reaction. The impact of human EVs on inflammation was first evaluated using atrial histology in EV-treated mice. As shown in Figure 14, sterile pericarditis markedly increased the inflammatory infiltrate detected in atrial sections (6 ± 1-fold increase over baseline, p < 0.001). EV injection attenuated the inflammatory effect of talc, as the inflammatory infiltrate was halved (45 ± 24% reduction; p < 0.001 vs. vehicle treatment). This reduction mirrored the reduction in proinflammatory cytokines seen in treated atria (Figure 15). Sterile pericarditis alone produced a typical increase in the proinflammatory cytokines IL1β, IL2, IL6, IL18, MCP1, PDGF-AB, and TNFα. Intramyocardial injection of EVs prevented the increase in a number of these cytokines (IL2, IL6, PDGF-AB, and TNFα) while attenuating the observed increase in other cytokines (IL1β, IL18).

[0153] EVs directly inhibit the malignant transformation of atrial fibroblasts Fibroblasts comprise nearly 75% of cells in the heart (Yue, Xie et al. 2011). When fibroblasts are activated by profibrotic stimuli, they can proliferate and differentiate into myofibroblasts, adversely affecting atrial structure and electrophysiological function. Given that interfering with atrial fibroblast proliferation reduces the burden of fibrosis and atrial fibrillation (McRae, Kapoor et al. 2019), we investigated the effects of EVs on atrial fibroblast proliferation. POAF was modeled by exposing normal rat atrial fibroblasts to interleukin-6 (IL6) or transforming growth factor β1 (TGFβ1) (Narikawa, Umemura et al. 2018). As shown in Figures 16-18, IL6 and TGFβ1 increased proliferation as evidenced by manually measured cell counts and increased 5-ethynyl-2'-deoxyuridine (EdU) incorporation. Application of EVs during IL6 / TGFβ1 exposure reduced fibroblast proliferation to baseline.

[0154] Next, we used flow cytometry to profile the impact of EVs on cell cycle kinetics (Figure 19). Fibroblasts grown in high serum conditions showed progression through the cell cycle (G0 / G1, S, and G2 / M phases). Anaphase promoting complex (APC) promoted the degradation of cell cycle proteins and cells accumulated in G0 / G1 phase. IL6 and TGFβ1 decreased the percentage of fibroblasts within G0 / G1 phase by 15±4% (p=0.004 vs. baseline) and 15±8% (p=0.005 vs. baseline), while increasing the percentage of cells in proliferative S+. G2M phase by 24±7% (p=0.01 vs. baseline) and 24±12% (p=0.01 vs. baseline), respectively. Coadministration of EVs abolished the effect of each cytokine on the proportional change in G0 / G1 and S+G2M fibroblasts (p=ns vs. baseline). Fibroblast cultures were next investigated to identify which cyclins within the regulatory machinery underlying cell cycle progression were modulated by EV treatment. As shown in Figure 20, treatment with IL6 or TGFβ1 increased the content of cyclins A2, B1, and E, while decreasing the content of cyclin D well below baseline expression. Co-administration with EDC EVs mitigated these effects, with cyclin levels normalizing in many cases after treatment. Interestingly, EV treatment reduced the expression of cyclin B1 below baseline, consistent with the observed effects on proliferation.

[0155] Example 2 Materials and Methods Explant-derived cells were cultured from human atrial appendages in a clinical-grade cell manufacturing facility using serum-free and xeno-free culture conditions. Upon talc application, increasing doses of EVs (10, 10, 10 or 10, n=10–17 / group) or vehicle control (n=17) were injected into the atria of middle-aged male Sprague-Dawley rats (6 months old). A sham control group was included to demonstrate background inducibility (n=12). Three days after surgery, all rats underwent invasive electrophysiological testing before sacrifice. Atrial fibrosis was assessed using hydroxyproline and inflammation was quantified using candidate cytokine profiling.

[0156] result Pericarditis increased the likelihood of inducing AF (p,0.05 vs. sham). All doses reduced the probability of inducing AF with the greatest effect seen after treatment with the highest dose (10 9 , p<0.05 vs. vehicle; Fig. 24A). Pericarditis increased atrial fibrosis, but EV treatment limited the effect of pericarditis on atrial fibrosis, with a maximal effect at 10 8 or 10 9 A decrease in the proinflammatory cytokine content was seen after treatment with EVs (Figure 24B). Enzyme-linked immunoassay-based analysis of atrial tissue lysates revealed that increasing EV doses were associated with a progressive decrease in proinflammatory cytokine content (Figure 24C).

[0157] Example 3 Materials and Methods Middle-aged female Sprague-Dawley rats (6 months of age) were treated with either sham surgery (n=17) or induction of aseptic pericarditis followed by treatment with 0.1 mg / kg colchicine daily (n=15), 0.5 mg / kg colchicine daily (n=15), or 10 mg / kg colchicine daily (n=15). 9Rats were randomized to receive a single intra-atrial injection of human EVs (n=17) or a single intra-atrial injection of vehicle alone (n=12). Treatment with colchicine was initiated 1 day before pericardiotomy and continued daily until sacrifice. Explant-derived cells were cultured from human atrial appendages using serum-free and xeno-free culture conditions in a clinical-grade cell manufacturing facility. Three days after surgery, all rats underwent invasive electrophysiological testing before sacrifice. Atrial fibrosis was assessed using hydroxyproline and inflammation was quantified using candidate cytokine profiling. Homogenized atrial tissue was used for cytokine and hydroxyproline measurements.

[0158] result Pericarditis increased the likelihood of inducing AF (p<0.05 vs. sham). All doses reduced the probability of inducing AF with the greatest effect seen after treatment with the highest dose (10 9 , p<0.05 vs. vehicle; Fig. 25A). Pericarditis increased atrial fibrosis, but EV treatment limited the effect of pericarditis on atrial fibrosis, with a maximal effect at 10 8 or 10 9 A decrease in the proinflammatory cytokine content (IL-6 and MCP-1) was seen after treatment with EVs (Figure 25B). Enzyme-linked immunoassay-based analysis of atrial tissue lysates revealed that increasing EV dose was associated with a progressive decrease in the proinflammatory cytokine content (IL-6 and MCP-1) (Figure 25C).

[0159] Example 4 Materials and Methods Female Sprague Dawley rats were randomized to undergo left coronary artery (LCA) ligation, which resulted in progressive left ventricular dysfunction, reduced contractility, left atrial dilation, fibrosis, prolonged refractoriness, and AF promotion compared to sham (Cardin, Guasch et al. 2012). After 4 weeks, rats with large infarcts were selected using echocardiography (Cardin, Guasch et al. 2012). Left ventricular regional wall motion was scored in the LV short axis as follows for six segments in this figure: (1) normal, (2) hypokinetic, (3) akinetic, (4) dyskinetic, and (5) aneurysmal. The wall motion score index (WMSI) is the average of all scores. Rats with a WMSI <1.65 2 weeks post-MI were excluded from the study (approximately 25% of the initial cohort) (Cardin, Guasch et al. 2012). All animals were then randomized to receive 1) vehicle (saline) alone or 2) epicardial atrial injection of EV. 9 EVs were injected into five sites in the left atrium (Cardin, Guasch et al. 2012). Laboratory staff were blinded to the treatments received and all analyses were performed by individuals blinded to group allocation. Group allocation was kept in a separate password-protected list for unblinding after analysis of study results was completed. Eight weeks after LCA ligation, invasive hemodynamics were measured using a standard Millar catheter / recording system ((Tilokee, Latham, et al. 2016), (Jackson, Tilokee et al. 2015)) before electrophysiological testing. For electrophysiological testing, an octapolar catheter was inserted into the right atrium via the jugular vein to stimulate and record atrial effective refractory period, Wenckebach cycle length, and corrected sinus node recovery time using square wave pulses at twice the threshold (2 ms). AF was induced with up to three external stimuli at 100 ms cycle length and, if that failed, with atrial burst pacing. AF was defined as a rapid, irregular atrial rate (>500 beats / min) with altered electrogram morphology (Cardin, Guasch et al. 2012). After electrophysiological testing, animals were sacrificed and hearts were harvested for mechanistic studies.

[0160] result EV treatment after LCA ligation significantly reduced atrial fibrillation compared to control treatment (Figure 26).

[0161] Example 5 Materials and Methods Male C57 mice were fed mouse chow and housed at 21°C with 50% humidity under a 12:12-h light-dark cycle. All animals had free access to tap water and chow. Before and after surgery, mice were anesthetized with 2–3% isoflurane, intubated, and ventilated. The thorax was shaved and sterilized with 2% w / v chlorhexidine gluconate in 70% v / v isopropyl alcohol. Animals then had aseptic pericarditis induced by dusting the atrial surface with sterile talc powder (Thermo Fischer Scientific), followed by application of inert agarose gel (n=6) or agarose gel impregnated with EVs (n=6) to the atrial epicardium using a sealed envelope approach. After surgery, animals were placed in an incubator at 30°C supplemented with oxygen and moist chow until they returned to physiological conditions. An additional dose of buprenorphine was administered 6 and 12 hours postoperatively. Animal care technicians from the University of Ottawa observed the animals twice daily for 2 days after surgery. Analyses were performed by individuals blinded to laboratory treatments and blinded to group assignments. Group assignments were kept in a separate, password-protected list for unblinding purposes after analysis of the primary study outcomes was completed.

[0162] Three days after surgery, mice were sacrificed by exsanguination under pentobarbital anesthesia after showing a lack of withdrawal reflex to toe pinching. Atria were fixed and sectioned for histological analysis of fibrosis by staining with Masson's trichrome (Sigma). Left atrial collagen (n=3) was quantified based on hydroxyproline content measurement (K555-100, BioVision).

[0163] result EV treatment with biomaterial gel significantly reduced atrial hydroxyproline content (54 ± 11 μg vs. 135 ± 12 μg, p = 0.01 vs. gel alone) and showed a strong trend towards reduced Masson's Trichrome scar (23 ± 5 vs. 35 ± 4 mean % cross-sectional area, p = 0.10, n = 3) and atrial mass (left atrial-to-body mass ratio of 0.10 ± 0.01 vs. 0.18 ± 0.04, p = 0.06, n = 6).

[0164] Example 6 Materials and Methods Conditioned medium from explant-derived cells cultured for 48 hours in 1% oxygen, 1% EV-depleted serum (System Biosciences) was used to isolate EVs using ultracentrifugation (Kanda, Alarcon et al. 2018; Villanueva, Michie et al. 2019). EVs were labeled by treating with EDC with the lipophilic carbocyanine dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine (DiD, Sigma) prior to generating conditioned medium.

[0165] Cells were seeded in 6-well plates and incubated at 37°C and 5% oxygen. When cells reached 70-80% confluency, they were cultured for 10 min. 8 EVs were added to the cells and the plates were returned to the incubator for a set period of time (10 min, 1 h, 3 h, or 24 h). After incubation, cells were gently washed with PBS, trypsinized, and resuspended in a final volume of 200 μL PBS. The suspension was always kept on ice until analysis. For each replicate, a control point was added consisting of cells incubated in the same conditions without the addition of EVs. Flow cytometry measurements were performed using a Guava® easyCyte flow cytometer and data were analyzed using guavaSoft2.7. The percentage of positive cells was defined using the control wells as baseline.

[0166] result To examine evidence of differential uptake, we assessed the rate and extent of DiD-labeled EV uptake in atrial fibroblasts (AF), cardiomyocytes, endothelial cells, and macrophages at baseline in vitro (Figure 27). Potential off-target effects were investigated using brain, kidney, lung, and liver cells. Flow cytometry revealed that mouse macrophages avidly took up DiD-labeled EVs, with 18±10% staining positive for DiD after 10 min of exposure. Interestingly, this uptake plateaued rapidly, with only 69±2% staining positive for DiD after 24 h. In contrast, primary rat AF and HUVECs also showed vigorous uptake of DiD-labeled EVs (62±8% and 73±10%, respectively, at 3 h), which increased to 96±4% and 95±4%, respectively, after 24 h. Pulmonary microvascular endothelial cells showed negligible EV uptake after 3 h, but this increased to 83±8% after 24 h of continuous exposure. NRVM showed a slow and gradual uptake in the first 3 h (25 ± 4%), peaking at 44 ± 11% after 24 h exposure. Kidney HEK cells showed negligible uptake at 1 h, reaching 72 ± 11% after 24 h. Liver HepG2 cells showed little uptake (<1%) in the first hour, with less than 46 ± 11% of cells taking up EVs after 24 h exposure.

[0167] Example 7 Materials and Methods Cell culture and EV isolation BM-MSCs were isolated from bone marrow samples collected from healthy volunteers enrolled in the Cellular Immunotherapy for Septic Shock (CISS) trial based on a protocol approved by the Ottawa Hospital Research Ethics Board (McIntyre, Stewart, et al. 2018). HDCs were isolated from atrial appendage tissue collected from patients undergoing clinically indicated surgery based on a protocol approved by the University of Ottawa Heart Institute Research Ethics Board (Mount, Kanda, et al. 2019; Latham, Ye, et al. 2013; Davis, Kizana, et al. 2010). UC-MSCs were isolated from primary UC cell isolates based on a protocol approved by the Ottawa Hospital Research Ethics Board in collaboration with the Centre for Regenerative Therapy in Dresden (McIntyre, Stewart, et al. 2018). All cell products were manufactured according to clinical grade release standards at the Biospherix unit of the Ottawa Hospital Cell Manufacturing Facility. BM-MSCs were cultured in NutriStem XF medium (Sartorius) under 21% oxygen conditions (McIntyre, Stewart, et al. 2018). HDCs were cultured in NutriStem XF medium under 5% oxygen conditions (Mount, Kanda, et al. 2019). UC-MSCs were cultured in Dulbecco's Modified Eagle Medium (ThermoFisher Scientific) containing 10% clinical grade platelet lysate (Mill Creek Life Sciences) under 5% oxygen conditions. When cells reached 70% confluence, the medium was replaced with conditioned medium (BM-MSCs and HDCs: NutriStem XF basal medium, UC-MSCs: Dulbecco's Modified Eagle Medium with high glucose and 1% platelet lysate). After conditioning for 48 h with 1% oxygen, the medium was collected for EV isolation. EVs were isolated using ultracentrifugation (10,000g × 30 min and 100,000g × 3 h) (Villaneuva, Michie, et al. 2019; Kanda, Benavente-Babace, et al. 2020).

[0168] Nanoparticle Tracking System The size and concentration of EV specimens were analyzed using a NanoSight LM10 equipped with a blue laser (488 nm, 70 mW) and a sCMOS camera. Briefly, 1 μL of the final pellet suspension was diluted 1:1000 in saline and 500 μL was loaded into the sample chamber. Three 60-s videos were recorded for each sample. Data analysis was performed using NTA3.0 software (Nanosight).

[0169] EV Proteomic Antibody Array EV markers were characterized using a proteomic array (EXORAY200A; System Biosciences) according to the manufacturer's recommendations. Briefly, 50 μg of EV lysate was incubated with labeling reagent for 30 min, followed by incubation with membranes precoated with antibodies against eight known EV markers. After overnight incubation, detection buffer was added before the membranes were washed and scanned with an X-ray imager.

[0170] MicroRNA expression assay MicroRNAs were isolated from EVs using an appropriate miRNA isolation kit (Qiagen). One hundred nanograms of miRNA was used for the nCounter miRNA sample preparation reaction. Sample preparation was performed according to the manufacturer's instructions. All hybridization reactions were incubated for a minimum of 18 hours at 65 degrees Celsius. Hybridized probes were purified and counted with an nCounter Prep Station and Digital Analyzer. For each assay, a high-density scan (600 fields of view) was performed. Count data obtained from Nanostring were analyzed with ROSALIND (https: / / rosalind.bio / ). Background subtraction was performed based on the POS_A probe correction factor and normalization was performed using the geometric mean of each code set from the positive control normalization and code set normalization.

[0171] After normalization, fold changes were calculated and comparisons between the two EV types were assessed using the ROSALIND t-test method. P-value adjustment was performed using the Benjamini-Hochberg method of estimating the false discovery rate (FDR). Log2 fold changes, p-values, and normalized Log2 count data were exported from ROSALIND and volcano plots and heatmaps were constructed using GraphPad Prism v.9.1 and RStudio (pheatmap package), respectively. miRNAs were considered differentially expressed with a log2 fold change ≥1.5 or ≤1.5 and a p-value <0.05.

[0172] Functional enrichment analysis of microRNAs was analyzed using TAM2.0 (http: / / www.lirmed.com, (Lu, Shi, et al. 2010; Li, Han, et al. 2018)). A list of mature miRNA names from normalized ROSALIND data was used as input (over-represented, p ≤ 0.05). Three functional enrichment categories (i.e., functional, tissue-specific, and transcription factors) were extracted to estimate the functional importance of miRNA cargo found within EVs. To delineate functional differences associated with miRNA cargo across all three EV types, enrichment analysis was performed using TAM2.0 using the list of all differentially expressed and all upregulated miRNAs.

[0173] Target network and enrichment analysis was restricted to validated 3'-UTR targets. The list of differentially expressed miRNAs was used as input to miRWalk v3 (http: / / mirwalk.umm.uni-heidelberg.de / , (Sticht, De La Torre, et al. 2018)) to obtain miRNA-mRNA target networks with an interaction probability score of 0.95 (miRTarBase). Cytoscape was then used to visualize the network and perform enrichment analysis (Sticht, De La Torre, et al. 2018). Gene ontology enrichment analysis was performed using the Cytoscape plugin BINGO (overrepresentation, hypergeometric test with Benjamini&Hochberg False Discovery Rate correction, p-value 0.05).

[0174] EV proteomic analysis EV isolates containing 25 μg of protein were lysed using a solubilization buffer consisting of 8 M urea, 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 5% glycerol, and 0.5% n-dodecyl β-d-maltoside (DDS). Samples were reduced using tris(2-carboxyethyl)phosphine (1.6 mM) and then alkylated with iodoacetamide (8 mM) for 55 min at room temperature. Proteins were digested using 0.45 μg of trypsin / Lys-C solution (Promega) for 20 h at room temperature. Two microliters of formic acid were then added to the samples, which were desalted using a C18 TopTips (Glygen) column and finally dried under vacuum. Five micrograms of protein were then analyzed by Orbitrap Fusion mass spectrometry (Thermo Fisher Scientific) (Risha, Minic, et al. 2020). Peptides were separated by in-house packed columns (Polymicro Technology) using a gradient of water / acetonitrile / 0.1% formic acid. Samples were loaded onto the column for 105 min at a flow rate of 0.30 μL / min. Peptides were separated using a stepwise cycle of acetonitrile concentrations from 2 to 90% every 10 min. Peptides were eluted using positive electrospray ionization in the ion source and sprayed into the mass spectrometer. Peptide mass spectrometry spectra (m / z 350–2000) were acquired at a resolution of 60,000. Precursor ions were filtered according to monoisotopic precursor selection and dynamic exclusion (30 s ± 10 ppm window). Fragmentation was performed using collision-induced dissociation in a linear ion trap. Precursors were isolated using an isolation window of 2 m / z and fragmented at a normalized collision energy of 35%.

[0175] Differential protein expression analysis was performed using Perseus (https: / / maxquant.net / , Tyanova, Temu, et al. 2016). Label-free quantification values ​​were log2 transformed for visual inspection using histogram distribution plots for each sample. Proteins identified in at least two out of three replicates were included in the analysis. Two-tailed Student's t-test with permutation-based FDR was used to calculate statistical significance between the two EV types. The log2 fold difference, p-values, and log2 label-free quantification values ​​were used to generate volcano plots and heatmaps using GraphPad Prism v.9.1 and RStudio (pheatmap package), respectively. Proteins were considered differentially expressed with a p-value <0.05.

[0176] Functional annotation and pathway enrichment analysis of the whole proteome and differentially expressed proteins were performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID, v6.8, https: / / david.ncifcrf.gov / , Sherman, Hao, et al. 2022; da Huang, Sherman, et al. 2009) and the Homo sapiens proteome as background. Significantly enriched terms were extracted using Fisher's exact test with multiple testing by the Benjamini-Hochberg method with an adjusted p-value of 0.05. The top 10 functional GO terms of biological process, cellular component, molecular function, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were extracted by enrichment analysis performed separately for all proteins and upregulated regulatory proteins.

[0177] Protein-protein interaction analysis of differentially expressed proteins was performed using the Search for Interacting Genes tool (STRING, v11.5, https: / / string-db.org / cgi / input.pl, Szklarczyk, Gable, et al. 2019) with a medium confidence score of 0.4. Cluster and enrichment analysis was then performed using Cytoscape. Cluster and enrichment analysis (degree cutoff=2, cluster search=haircut, node score cutoff=0.2, K core=2, max depth=100) was performed using the Cytoscape plugin MCODE, and hub genes were identified using the cytoHubb plugin.

[0178] statistical analysis All statistical tests and graphical representations of data are defined within the respective methods sections. All data are presented as mean ± standard error of the mean unless otherwise stated. To determine whether differences existed in EV size and concentration between cell types, data were analyzed by one-way analysis of variance (ANOVA; GraphPad Prism v.9.1) with post hoc testing using Tukey's multiple comparison test. A final value of P ≤ 0.05 was considered significant for all analyses.

[0179] result Cell culture and EV characterization A schematic of the experimental method is shown in Figure 28. As previously described, all three cell products were manufactured according to clinical release standards (McIntyre, Stewart, et al. 2018; Schlosser, Wang, et al. 2019; Vaka, Khan, et al. 2022). These cell isolates were previously characterized for surface marker identity (Vaka, Khan, et al. 2022) and trilineage differentiation (English, Fergusson, et al. 2021), so cell characterization was not repeated in the current study. Differential ultracentrifugation was used to isolate EVs from conditioned media collected from cultured cells. The size of EVs isolated from all three cell lines was not different (Figure 29A-B), presenting an accepted definition for EV identity with no differences attributed to the producer cell line (Lotvall, Hill, et al. 2014). BM-MSCs and HDCs produced similar amounts of EVs, whereas UC-MSCs produced two-fold more EVs (p<0.05 vs. BM-MSCs or HDCs). All three EV preparations expressed common EV surface markers (ALIX, ANXAS, CD81, CD63, EPCAM, FLOT-1, TSG101, ICAM) without evidence of cellular contamination (GM130; Figure 30).

[0180] EVmiRNA and protein cargo profiling within bone marrow, heart and umbilical cord EVs As shown in Figure 31A,C, 757 miRNAs were commonly expressed by all three EVs. Interestingly, UC-MSCs were found to express the most distinctive EVs with 18 unique miRNAs. Among the highly expressed miRNAs (i.e., expression above the 99th percentile), four miRNAs were found to be commonly expressed by all three EVs (miR-199a+miR-199b, miR-23a, miR-4454+miR-7975, miR-125b-5p). Two miRNAs (let-7a, let-7b) were shared between BM-MSC and HDC EVs, while one miRNA (miR-100) was found in both HDC and UC-MSC EVs (Figure 31B).

[0181] As shown in Figure 32A,C, 420 proteins were expressed in all three cell types. In contrast to the few miRNAs that were uniquely expressed, all three EVs were found to contain several unique proteins (i.e., more than 100), including the most common proteins in BM-MSCs and HDCs. UC-MSCs expressed the most unique proteins. When ranked as highly expressed proteins, only ACTG1 protein was shared above the 99th percentile in EVs from the three cell types, while ANXA2 and FN1 were shared between BM-MSCs and HDC EVs (Figure 32B).

[0182] Differential expression of microRNAs or proteins in bone marrow, heart and umbilical cord EVs To examine miRNA stoichiometry for differences in expression patterns, differential miRNA expression was compared using a 1.5x Log2 threshold (Figures 33-35 and Tables 3-5). Expression of miRNAs in BM-MSC EVs and HDC EVs was largely similar with only 56 differentially regulated transcripts. In contrast, expression in UC-MSC EVs was significantly different with 176 and 314 differentially expressed miRNAs compared to BM-MSC EVs and HDC EVs, respectively. Analysis of protein expression showed a similar pattern with only 23 proteins differentially expressed when comparing BM-MSC EVs to HDC EVs (Figures 36-38 and Tables 6-8). UC-MSC EVs had 305 and 260 differentially expressed proteins compared to BM-MSC EVs and HDC EVs, respectively.

[0183] Functional analysis of miRNA expression in bone marrow, heart, and umbilical cord EVs As shown in Figures 39, 41, and 43, HDC EVs expressed miRNA transcripts involved in apoptosis, collagen formation, osteoblast differentiation, and cell proliferation when compared to EVs from BM-MSCs. GO enrichment analysis demonstrated that miRNA-mRNA targets were significantly enriched in pigment biosynthesis, mRNA catabolism, and RNA processing. Highly expressed microRNAs in HDC EVs were associated with differentiation, cardiac regeneration, and differentiation, while highly expressed miRNAs in BM-MSC EVs were involved in collagen formation, cell proliferation, and cell death.

[0184] EVs from BM-MSCs were enriched for transcripts involved in apoptosis, hematopoiesis, and retinal development compared to EVs from UC-MSCs. GO analysis of transcripts from BM-MSC EVs suggests involvement in glucose metabolism, protein transport, RNA processing, and vacuolar trafficking. MicroRNAs upregulated in BM-MSC EVs were involved in apoptosis, cell migration, and osteogenesis, while miRNAs enriched in UC-MSCs were involved in senescence, cardiac regeneration, and proliferation.

[0185] When comparing HDC EVs to UC-MSC EVs, miRNAs were found to be involved in development, immune regulation, and proliferation. GO analysis of transcripts from HDC EVs suggested that they were involved in glucose metabolism, protein transport, RNA processing, and vacuolar trafficking. Highly expressed miRNAs in HDC EVs were involved in mesenchymal to epithelial transition, NFκB regulation, and development, while highly expressed miRNAs in UC-MSCs were involved in senescence, inflammation, and proliferation. The downstream transcription factors and organization associated with these functions for EVs from all three producer cell lines are shown in Figures 40, 42, and 44.

[0186] Functional analysis of protein expression in bone marrow, heart, and umbilical cord EVs Enrichment analysis of protein cargo within EVs revealed several terms related to biological processes, cellular components, molecular functions, and KEGG pathways for each cell source. The top 10 biological processes, cellular components, and KEGG pathways are shown in Figures 46, 48, 50, and 53-55. Many of the top terms were shared and related to EV biology or cell binding (i.e., cell adhesion, extracellular exosomes, focal adhesions, cadherin binding, protein binding). When comparing EVs from different cell types, each producer cell line contributed several unique terms that shared the highest homology between BM-MSC EVs and HDC EVs. When comparing HDC EVs to BM-MSC EVs, functional pathways were primarily involved in calcium ion binding, cell binding, and extracellular matrix assembly (Figure 45). Proteins overexpressed in EVs produced by BM-MSCs were more likely to be involved in heparin or integrin binding. When comparing BM-MSC EVs to UC-MSC EVs, differentially expressed proteins were involved in actin organization, cadherin binding, and cell adhesion (Figure 47). Highly expressed proteins in BM-MSC EVs were involved in protein+RNA binding, while UC-MSC EVs had highly expressed proteins in extracellular matrix binding / structure and LDL receptor biology. When comparing HDC EVs to UC-MSC EVs, proteins were found to be involved in calcium-protein binding (Figure 49).

[0187] Protein-protein interactions mediated by bone marrow, heart, and umbilical cord EVs Proteins regulate biological processes through functional or physical interactions with other proteins. Protein-protein interaction network analysis was used to explore potential interactions between differentially expressed proteins. As shown in Figures 51 and 52, this analysis revealed several nodes and interaction pairs with the highest degree of homology shared between HDC EVs and BM-MSC EVs. The key nodes were then used to extract hub genes for cluster analysis, resulting in one cluster from the HDC vs. BM-MSC EV network, nine clusters from the BM-MSC vs. UC-MSC EV network, and seven clusters from the HDC vs. UC-MSC EV network.

[0188] Using a topological scoring system (Bandettini, Kellman, et al. 2012), the HDC vs. BM-MSC EV network was found to contain no significant clusters, indicating a high degree of homology. Two significant clusters were found within the comparison between BM-MSC EVs and UC-MSC EVs (topological score = 19.36, 20 nodes, 184 interaction pairs). Analysis of cluster 1 revealed hub genes related to chaperone-containing proteins (CCT3, degree = 32; CCT7, degree = 34; CCT8, degree = 26) and ribosomal protein subunits (RPS3, degree = 28; RPL11, degree = 25; Figure 51). String enrichment analysis showed that the top biological processes were related to protein localization to telomeres (GO:1904851), protein localization to Cajal bodies (GO:1904871), and telomerase localization to Cajal bodies (GO:1904874). Cluster 2 contained 57 nodes and 668 interacting pairs, and the top five hub genes were related to chaperone-containing proteins (CCT3, degree = 32; CCT4, degree = 33; CCT7, degree = 34), nucleotide-binding proteins (GNB2L1, degree = 34), and translational elongation factor (EEFF2, degree = 39). The top two identified biological process terms showed to be related to cellular localization (GO:0051649) and interspecies interactions between organisms (GO:0006810).

[0189] Comparing HDC EVs and UC-MSC EVs, two clusters were obtained, cluster 1 (score = 17.6) contained 31 nodes and 264 interaction pairs (Figure 52). The top five hub genes in cluster 1 were related to copper binding (CP, degree = 22), iron binding transport (TF, degree = 22), thyroid hormone binding (TTR, degree = 22), and vitamin D transport (GC, degree = 22). The top biological process terms in cluster 1 were related to exocytosis (GO:0045055), platelet degranulation (GO:0002576), and vesicle transport (GO:0016192). Cluster 2 contained 30 nodes and 169 interaction pairs. Top hub genes within this cluster were related to collagen (COL1A1, degree = 8; COL1A2, degree = 17), glycoprotein (THBS1, degree = 17), and matrix metallopeptidase (MMP2, degree = 19; MMP14, degree = 16). String enrichment analysis within this cluster indicated that proteins mediate cell adhesion (GO:0007155), extracellular matrix organization (GO:0030198), and primary germ layer formation (GO:0001704).

[0190] Table 3 shows a list of exemplary miRNA cargoes differentially expressed in HDC vs. BM-MSC EVs. hsa, Homo sapiens

[0191] [Table 3] TIFF2024543456000005.tif66166

[0192] Table 4 shows a list of exemplary miRNA cargoes differentially expressed in BM-MSC vs. UC-MSC EVs. hsa, Homo sapiens

[0193] [Table 4] TIFF2024543456000007.tif253165 TIFF2024543456000008.tif252164 TIFF2024543456000009.tif205164

[0194] Table 5 shows a list of exemplary miRNA cargoes differentially expressed in HDC vs. UC-MSC EVs. hsa, Homo sapiens

[0195] [Table 5] TIFF2024543456000011.tif248159 TIFF2024543456000012.tif248159 TIFF2024543456000013.tif250160 TIFF2024543456000014.tif247158 TIFF2024543456000015.tif248159 TIFF2024543456000016.tif190162

[0196] Table 6 shows a list of examples of protein cargoes that are differentially expressed in HDC versus BM-MSC EVs.

[0197] [Table 6]

[0198] Table 7 shows a list of exemplary cargo proteins that are differentially expressed in BM-MSC versus UC-MSC EVs.

[0199] [Table 7] TIFF2024543456000019.tif254164 TIFF2024543456000020.tif250164 TIFF2024543456000021.tif252163 TIFF2024543456000022.tif249163 TIFF2024543456000023.tif245161 TIFF2024543456000024.tif248161 TIFF2024543456000025.tif247163 TIFF2024543456000026.tif250164 TIFF2024543456000027.tif252163 TIFF2024543456000028.tif126164

[0200] Table 8 shows a list of exemplary cargo proteins that are differentially expressed in HDC versus UC-MSC EVs.

[0201] [Table 8] TIFF2024543456000030.tif253166 TIFF2024543456000031.tif254165 TIFF2024543456000032.tif250162 TIFF2024543456000033.tif251163 TIFF2024543456000034.tif250162 TIFF2024543456000035.tif248160 TIFF2024543456000036.tif246160 TIFF2024543456000037.tif248160 TIFF2024543456000038.tif251163 TIFF2024543456000039.tif94163

[0202] Table 9 shows the top 10 BP GO enrichment terms of HDC EV protein cargo.

[0203] [Table 9]

[0204] Table 10 shows the top 10 BP GO enrichment terms for BM MSC protein cargo.

[0205] [Table 10]

[0206] Table 11 shows the top 10 BP GO enrichment terms of UC MSC EV protein cargo.

[0207] [Table 11]

[0208] Table 12 shows a comparison of GO enrichment terms of BM-MSC, HDC, and UC-MSC EV protein cargo.

[0209] [Table 12]

[0210] As used herein, the term "about" refers to about a + / - 10% variation from a given value. It is to be understood that such a variation is always included in any value provided herein, whether or not specifically stated.

[0211] As used herein, the term "substantially" refers to about a + / - 5% variation from a given value. If no value is used, "substantially" means nearly complete, but possibly including some variation, contamination, and / or additional components. In some embodiments, "substantially" may include complete.

[0212] All references cited herein are incorporated by reference in their entirety.

[0213] Thus, the present disclosure is well adapted to achieve the objects and advantages mentioned, as well as those inherent therein. The specific embodiments disclosed above are merely exemplary, and the disclosure may be modified and implemented in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Although individual embodiments are described, the disclosure covers all combinations of all such embodiments. Moreover, no limitations are intended to the details of construction or design shown herein, except as set forth in the claims. Furthermore, terms in the claims have their plain ordinary meaning unless expressly and clearly defined by the patent owner. Thus, it is apparent that the specific exemplary embodiments disclosed above may be altered or modified, and all such variations are deemed to be within the scope and spirit of the present disclosure. In the event of any inconsistency in the usage of a word or term in this specification and in one or more patents or other documents which may be incorporated herein by reference, the consistent definition in this specification should be adopted.

[0214] One or more exemplary embodiments have been described by way of example, and those skilled in the art will appreciate that many variations and modifications can be made without departing from the scope of the invention, as defined in the claims.

[0215] References Adam, O., B. Lohfelm, et al. (2012). "Role of miR-21 in the pathogenesis of atrial fibrosis." Basic Res Cardiol 107(5): 278. Aguilar, M., X. Y. Qi, et al. (2014). "Fibroblast electrical remodeling in heart failure and potential effects on atrial fibrillation." Biophys J 107(10): 2444-2455. Ashihara, T., R. Haraguchi, et al. (2012). "The role of fibroblasts in complex fractionated electrograms during persistent / permanent atrial fibrillation: implications for electrogram-based catheter ablation." Circulation 110(2): 275-284. Baghy, K., R. V. Iozzo, et al. (2012). "Decorin-TGFbeta axis in hepatic fibrosis and cirrhosis." J Histochem Cytochem 60(4): 262-268. Balafkan, N., S. Mostafavi, et al. (2020). "A method for differentiating human induced pluripotent stem cells toward functional cardiomyocytes in 96-well microplates." SciRep 10(1): 18498. Barile, L., V. Lionetti, et al. (2014). "Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction." Cardiovascular Res 103(4): 530-541. Benjamin, E. J., D. Levy, et al. (1994). "Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study." JAMA 271(11): 840-844. Boehncke, W. H. and N. C. Brembilla (2018). "Immunogenicity of biologic therapies: causes and consequences." Expert Rev Clin Immunol 14(6): 513-523. Bretones, G., M. D. Delgado, et al. (2015). "Myc and cell cycle control." Biochim Biophys Acta 1849(5): 506-516. Burgmaier, M., K. Schutters, et al. (2014). "AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(- / -) mice." J Cell Mol Med 18(10): 2117-2124. Canesi, F., V. Mateo, et al. (2019). "A thioredoxin-mimetic peptide exerts potent anti-inflammatory, antioxidant, and atheroprotective effects in ApoE2.Ki mice fed high fat diet." Cardiovascular Res 115(2): 292-301. Cao, W., P. Shi, et al. (2017). "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1 / STAT3 pathway." BMC Cardiovasc Disord 17(1): 88. Cardin, S., E. Guasch, et al. (2012). "Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure." Circulation Arrhythm Electrophysiology 5(5): 1027-1035. Chiang, C. Y. and C. Chen (2019). "Toward characterizing extracellular vesicles at a single-particle level." J Biomed Sci 26(1): 9. Ciferri, M. C., R. Quarto, et al. (2021). "Extracellular Vesicles as Biomarkers and Therapeutic Tools: From Pre-Clinical to Clinical Applications." Biology (Basel) 10(5). Correa, S. G., C. E. Sotomayor, et al. (2003). "Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages." Glycobiology 13(2): 119-128. Cox, J. and M. Mann (2008). "MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification." Nat Biotechnol 26(12): 1367-1372. Davis, D. R., E. Kizana, et al. (2010). "Isolation and expansion of functionally-competent cardiac progenitor cells directly from heart biopsies." J Mol Cell Cardiol 49(2): 312-321. de Jong, R. C. M., N. J. Pluijmert, et al. (2018). "Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response." Sci Rep 8(1): 6753. El Hadri, K., D. F. Mahmood, et al. (2012). "Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis." Arterioscler Thromb Vasc Biol 32(6): 1445-1452. El Harane, N., Kervadec, A., et al. (2018). " Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors". Eur Heart J 39(20):1835-1847 Escudier, B., T. Dorval, et al. (2005). "Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial." J Transl Med 3(1): 10. Ewing, M. M., M. R. de Vries, et al. (2011). "Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice." Arterioscler Thromb Vasc Biol 31(1): 95-101. Friberg, L. (2018). "Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs." Am Heart J 205: 118-127. Furberg, C. D., B. M. Psaty, et al. (1994). "Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)." Am J Cardiol 74(3): 236-241. Girmatsion, Z., P. Biliczki, et al. (2009). "Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation." Heart Rhythm 6(12): 1802-1809. Gray, A., Wright, A., et al. (2015). " Quantification of histochemical stains using whole slide imaging: development of a method and demonstration of its usefulness in laboratory quality control." J Clin Pathol 68(3):192-9. Go, A. S., E. M. Hylek, et al. (2001). "Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study." JAMA 285(18): 2370-2375. Hall, J., S. Prabhakar, et al. (2016). "Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma." Cell Mol Neurobiol 36(3): 417-427. He, X., X. Gao, et al. (2011). "Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7." Circ Res 108(2): 164-175. Huang, Z., X. J. Chen, et al. (2016). "Signal Transducer and Activator of Transcription 3 / MicroRNA-21 Feedback Loop Contributes to Atrial Fibrillation by Promoting Atrial Fibrosis in a Rat Sterile Pericarditis Model." Circ Arrhythm Electrophysiol 9(7). Hur, J. Y. and K. Y. Lee (2021). "Characteristics and Clinical Application of Extracellular Vesicle-Derived DNA." Cancers (Basel) 13(15). Jamall, I. S., V. N. Finelli, et al. (1981). "A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues." Anal Biochem 112(1): 70-75. Jost, N., T. Christ, et al. (2021). "New Strategies for the Treatment of Atrial Fibrillation." Pharmaceuticals (Basel) 14(9). Jung, J. Y., Y. H. Kwak, et al. (2017). "Protective effect of hemopexin on systemic inflammation and acute lung injury in an endotoxemia model." J Surg Res 212: 15-21. Kanda, P., E. I. Alarcon, et al. (2018). "Deterministic Encapsulation of Human Cardiac Stem Cells in Variable Composition Nanoporous Gel Cocoons To Enhance Therapeutic Repair of Injured Myocardium." ACS Nano 12(5): 4338-4350. Kanda, P., E. I. Alarcon, et al. (2018). "Deterministic Encapsulation of Human Cardiac Stem Cells in Variable Composition Nanoporous Gel Cocoons To Enhance Therapeutic Repair of Injured Myocardium." ACS Nano . Kapoor, N., W. Liang, et al. (2013). "Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18." Nat Biotechnol 31(1): 54-62. Kendall, R. T. and C. A. Feghali-Bostwick (2014). "Fibroblasts in fibrosis: novel roles and mediators." Front Pharmacol 5: 123. Konoshenko, M. Y., E. A. Lekchnov, et al. (2018). "Isolation of Extracellular Vesicles: General Methodologies and Latest Trends." Biomed Res Int 2018: 8545347. Kooijmans, S. A. A., R. M. Schiffelers, et al. (2016). "Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment." Pharmacol Res 111: 487-500. Latham, N., B. Ye, et al. (2013). "Human blood and cardiac stem cells synergize to enhance cardiac repair when cotransplanted into ischemic myocardium." Circulation 128(11 Suppl 1): S105-112. Ledan S (2020). "Antiarrhythmic Treatment in Atrial Fibrillation." US Pharm . 45(2):24-27. Liang, X., T. Lin, et al. (2009). "Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages." J Leukoc Biol 86(2): 229-235. Liang, Y., Yuan, W., et al. (2015). " Macrophage migration inhibitory factor promotes expression of GLUT4 glucose transporter through MEF2 and Zac1 in cardiomyocytes." Metabolism 64(12):1682-93. Lim, L. H., E. Solito, et al. (1998). "Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1." Proc Natl Acad Sci U S A 95(24): 14535-14539. Liu, Y., S. Chen, et al. (2017). "Transcriptional landscape of the human cell cycle." Proc Natl Acad Sci U S A 114(13): 3473-3478. Lotvall, J., A. F. Hill, et al. (2014). "Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles." J Extracell Vesicles 3: 26913. Ludhwani, D., A. Goyal, et al. (2021). "Ventricular Fibrillation." Luo, X., Z. Pan, et al. (2013). "MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation." J Clin Invest 123(5): 1939-1951. Lycke, M., L. O'Neill, et al. (2021). "How Close Are We toward an Optimal Balance in Safety and Efficacy in Catheter Ablation of Atrial Fibrillation? Lessons from the CLOSE Protocol." J Clin Med 10(18). McRae, C., A. Kapoor, et al. (2019). "Systematic review of biological therapies for atrial fibrillation." Heart Rhythm 16(9): 1399-1407. Merico, D., R. Isserlin, et al. (2010). "Enrichment map: a network-based method for gene-set enrichment visualization and interpretation." PLoS One 5(11): e13984. Mount, S., P. Kanda, et al. (2019). "Physiologic expansion of human heart-derived cells enhances therapeutic repair of injured myocardium." Stem Cell Res Ther 10(1): 316. Murphy, D. E., O. G. de Jong, et al. (2019). "Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking." Exp Mol Med 51(3): 1-12. Narikawa, M., M. Umemura, et al. (2018). "Acute Hyperthermia Inhibits TGF-beta1-induced Cardiac Fibroblast Activation via Suppression of Akt Signaling." Sci Rep 8(1): 6277. Nesheiwat, Z., A. Goyal, et al. (2021). "Atrial Fibrillation." Onozuka, I., S. Kakinuma, et al. (2011). "Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice." Biochem Biophys Res Commun 406(1): 134-140. Parichatikanond, W., T. Luangmonkong, et al. (2020). "Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-beta Signaling." Front Cardiovasc Med 7: 34. Park, K. S., E. Bandeira, et al. (2019). "Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles." Stem Cell Res Ther 10(1): 288. Pfeifer, P., N. Werner, et al. (2015). "Role and Function of MicroRNAs in Extracellular Vesicles in Cardiovascular Biology." Biomed Res Int 2015: 161393. Quattrocelli, M., S. Crippa, et al. (2013). "Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice." J Am Heart Assoc 2(4): e000284. Radbill, B. D., R. Gupta, et al. (2011). "Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression." Dig Dis Sci 56(2): 406-416. Risha, Y., Z. Minic, et al. (2020). "The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers." Sci Rep 10(1): 13572. Rizvi, F., A. DeFranco, et al. (2016). "Chamber-specific differences in human cardiac fibroblast proliferation and responsiveness toward simvastatin." Am J Physiol Cell Physiol 311(2): C330-339. Rubin, S. M., J. Sage, et al. (2020). "Integrating Old and New Paradigms of G1 / S Control." Mol Cell 80(2): 183-192. Seo, C., C. Michie, et al. (2020). "Systematic review of pre-clinical therapies for post-operative atrial fibrillation." PLoS One 15(11): e0241643. Shan, H., Y. Zhang, et al. (2009). "Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines." Cardiovasc Res 83(3): 465-472. Sidiropoulos, K., G. Viteri, et al. (2017). "Reactome enhanced pathway visualization." Bioinformatics 33(21): 3461-3467. Small, E. M., R. J. Frost, et al. (2010). "MicroRNAs add a new dimension to cardiovascular disease." Circulation 121(8): 1022-1032. Suetsugu, A., K. Honma, et al. (2013). "Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models." Adv Drug Deliv Rev 65(3): 383-390. Thery, C., K. W. Witwer, et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines." J Extracell Vesicles 7(1): 1535750. Tsoporis, J. N., A. Fazio, et al. (2018). "Increased right atrial appendage apoptosis is associated with differential regulation of candidate MicroRNAs 1 and 133A in patients who developed atrial fibrillation after cardiac surgery." J Mol Cell Cardiol 121: 25-32. van Rooij, E., L. B. Sutherland, et al. (2008). "Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis." Proc Natl Acad Sci U S A 105(35): 13027-13032. Villanueva, M., C. Michie, et al. (2019). "Glyoxalase 1 Prevents Chronic Hyperglycemia Induced Heart-Explant Derived Cell Dysfunction." Theranostics 9(19): 5720-5730. Vital, S. A., F. Becker, et al. (2016). "Formyl-Peptide Receptor 2 / 3 / Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease." Circulation 133(22): 2169-2179. Welsh, J. A. and J. C. Jones (2020). "Small Particle Fluorescence and Light Scatter Calibration Using FCMPASS Software." Curr Protoc Cytom 94(1): e79. Welsh, J. A., J. C. Jones, et al. (2020). "Fluorescence and Light Scatter Calibration Allow Comparisons of Small Particle Data in Standard Units across Different Flow Cytometry Platforms and Detector Settings." Cytometry A 97(6): 592-601. Wynn, T. A. (2008). "Cellular and molecular mechanisms of fibrosis." J Pathol 214(2): 199-210. Yang, H., X. Qin, et al. (2019). "An in Vivo miRNA Delivery System for Restoring Infarcted Myocardium." ACS Nano 13(9): 9880-9894. Yue, L., J. Xie, et al. (2011). "Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation." Cardiovasc Res 89(4): 744-753. Zhi, Y., C. Xu, et al. (2019). "Effective Delivery of Hypertrophic miRNA Inhibitor by Cholesterol-Containing Nanocarriers for Preventing Pressure Overload Induced Cardiac Hypertrophy." Adv Sci (Weinh) 6(11): 1900023. Zhou, X. and S. C. Dudley, Jr. (2020). "Evidence for Inflammation as a Driver of Atrial Fibrillation." Front Cardiovasc Med 7: 62. Zimta, A. A., O. E. Sigurjonsson, et al. (2020). "The Malignant Role of Exosomes as Nanocarriers of Rare RNA Species." Int J Mol Sci 21(16). Lu M, Shi B, Wang J, Cao Q and Cui Q. TAM: a method for enrichment and depletion analysis of a microRNA category in a list of microRNAs. BMC Bioinformatics. 2010;11:419. Li J, Han X, Wan Y, Zhang S, Zhao Y, Fan R, Cui Q and Zhou Y. TAM 2.0: tool for MicroRNA set analysis. Nucleic Acids Res. 2018;46:W180-w185. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T and Chang W. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50:W216-21. Huang da W, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57. Sticht C, De La Torre C, Parveen A and Gretz N. miRWalk: An online resource for prediction of microRNA binding sites. PLoS One. 2018;13:e0206239. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607-d613. Kanda P, Benavente-Babace A, Parent S, Connor M, Soucy N, Steeves A, Lu A, Cober ND, Courtman D, Variola F, et al. Deterministic paracrine repair of injured myocardium using microfluidic-based cocooning of heart explant-derived cells. Biomaterials. 2020;247:120010. McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, Marshall J, Dos Santos C, Walley KR, Winston BW, et al. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. Am J Respir Crit Care Med. 2018;197:337-347. Schlosser K, Wang JP, Dos Santos C, Walley KR, Marshall J, Fergusson DA, Winston BW, Granton J, Watpool I, Stewart DJ, et al. Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients. Crit Care Med. 2019;47:918-925. Vaka R, Khan S, Ye B, Risha Y, Parent S, Courtman D, Stewart DJ and Davis DR. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury. Stem Cell Res Ther. 2022;13:20. English S, Fergusson D, Lalu M, Thebaud B, Watpool I, Champagne J, Sobh M, Courtman DW, Khan S, Jamieson M, et al. Results of the cellular immuno-therapy for covid-19 related acute respiratory distress syndrome (circa-phase i trial: Cytotherapy. 2021 May;23(5):S22. doi: 10.1016 / S1465324921002796. Epub 2021 May 11. Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and Arai AE. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14:83. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox, J. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016 Sep;13(9):731-40. doi: 10.1038 / nmeth.3901. Epub 2016 Jun 27. Tilokee EL, Latham N, Jackson R, Mayfield AE, Ye B, Mount S, Lam BK, Suuronen EJ, Ruel M, Stewart DJ, Davis DR, Paracrine Engineering of Human Explant-Derived Cardiac Stem Cells to Over-Express Stromal-Cell Derived Factor 1alpha Enhances Myocardial Repair. Stem Cells. 2016.Jul;34(7):1826-35. doi: 10.1002 / stem.2373. Epub 2016 Apr 21. Jackson R, Tilokee EL, Latham N, Mount S, Rafatian G, Strydhorst J, Ye B, Boodhwani M, Chan V, Ruel M, Ruddy TD, Suuronen EJ, Stewart DJ, Davis DR, Paracrine Engineering of Human Cardiac Stem Cells With Insulin-Like Growth Factor 1 Enhances Myocardial Repair. J Am Heart Assoc. 2015;4.J Am Heart Assoc. 2015 Sep 11;4(9):e002104. doi: 10.1161 / JAHA.115.002104.

Claims

1. A composition comprising extracellular vesicles and a biologically or pharma- ceutically acceptable adjuvant or carrier, wherein the extracellular vesicles comprise one or more of the following characteristics: (a) Extracellular vesicles isolated from human cardiac cells; (b) a polydisperse population of particles having diameters ranging from about 10 to about 500 nm; (c) one or more cytoplasmic markers defined by ALIX, any ANXA polypeptide, any ACT polypeptide, TSG101, any CHMP polypeptide, PDCD6IP, VPS4A, VPS4B, ARRDC1, any CAV polypeptide, any EHD polypeptide, RHOA, HSPA8, HSPA1A, any actin polypeptide, any tubulin polypeptide, GAPDH, HSP90AB1, ARF6, SDCBP, MAPT, HSC70, HSP70, HSP84, and TSG101, or a combination thereof; (d) CD3, CD9, CD14, CD37, CD41, CD45, CD47, CD53, CD55, CD59, CD61, CD63, CD73, CD81, CD82, CD90, any GNA polypeptide, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DQ, any H2-A polypeptide, H2-K, H2-D, H2-Q, any ITGA polypeptide, any I one or more transmembrane markers defined by a TGB polypeptide, TFR2, LAMP1, LAMP2, any SDC polypeptide, BSG, ADAM10, SHH, TSPAN8, PECAM1, ERBB2, EPCAM, CDC42a, GYPA, AChE-S, AChE-E, AβA4, APP, ABCC1, FLOT1, FLOT2, ICAM1, EpCam, or a combination thereof; (e) acetylcholinesterase activity, (f) substantially lacking or lacking one or more of the group consisting of GM130, APOA1, APOA2, APOB, APOB100, ALB, ribosomal proteins, UMOD, and protein / nucleic acid aggregates; (g) 1 to 1000 unique miRNA transcripts; and (h) 10 per milliliter 2 ~10 20 A unit dose of extracellular vesicles containing 1000 particles.

2. The composition of claim 1 , wherein the human cardiac cells are autologous or allogeneic cells.

3. The composition of claim 1 , wherein the extracellular vesicles are taken up by immune cells.

4. The composition of claim 3 , wherein the immune cell is a macrophage.

5. The composition of any one of claims 1 to 4, wherein the extracellular vesicles reduce inflammasome activation.

6. The composition of claim 5, wherein the extracellular vesicles reduce macrophage inflammasome activation.

7. The composition of claim 1 , wherein the extracellular vesicles are absorbed into human cardiac cells.

8. The composition of claim 7, wherein the uptake by the human cardiac cells is determined by transport of a protein from the extracellular vesicle to the human cardiac cells.

9. The composition of claim 7, wherein the transport of proteins from the extracellular vesicles to human cardiac cells comprises transport of one or more of an exogenous protein, a fluorescent protein, a luminescent protein, a protein capable of producing a colorimetric reaction, a protein tagged with a fluorescent group, a protein tagged with a luminescent group, a protein tagged with a colorimetric reaction group, a protein that is undetectable or absent in human cardiac cells, or any combination thereof.

10. The composition of claim 9, wherein the protein tagged with a fluorogenic group is CD63.

11. The composition of claim 7, wherein the absorption by the human cardiac cells is determined by the transport of membrane lipids from extracellular vesicles to the human cardiac cells.

12. 12. The composition of claim 11, wherein the transport of membrane lipids from the extracellular vesicles to human cardiac cells is measured using one or more techniques including 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil), PKH67 PKH26, any membrane-localizable fluorescent dye, any membrane-localizable luminescent dye, any membrane-localizable colorimetric dye, any functional equivalent, and any combination thereof.

13. The composition of claim 11, wherein the transport of membrane lipids from extracellular vesicles to human cardiac cells is measured using DiI.

14. The composition of any one of claims 1 to 13, wherein the human cardiac cells are endothelial cells, myocytes, immune cells and / or fibroblasts.

15. The composition of claim 1 , wherein the human cardiac cells are derived from a cardiac biopsy.

16. 16. The composition of claim 15, wherein the biopsy comprises one or more of the cardiac layers, endocardium, myocardium, epicardium, or any combination thereof.

17. The composition of claim 16 , wherein the human cardiac cells are derived from myocardial tissue.

18. The composition of claim 17 , wherein the human cardiac cells are derived from the atrium.

19. The composition of claim 18 , wherein the human cardiac cells are derived from the left atrial appendage.

20. The composition of claim 16 , wherein the human cardiac cells are derived from ventricular tissue.

21. The composition of claim 15 , wherein the human cardiac cells are derived from a whole human heart.

22. 2. The composition of claim 1, wherein the extracellular vesicles are isolated from one or more of the following: (a) cardiac explant-derived stem cells; (b) cardiac explant-derived cells; (c) cardiac cells differentiated from induced pluripotent stem cells; (d) cardiac cells differentiated from ES cells; or (e) Cardiac cells derived from any cell type capable of differentiating into cardiac cells.

23. 23. The composition of claim 22, wherein the extracellular vesicles are isolated from immortalized cardiac explant-derived cells.

24. 24. The composition of claim 23, wherein the cardiac explant-derived cells are immortalized using one or more of the following techniques: viral genes, viral gene products, genetic mutations, telomerase reverse transcriptase expression, SV40, or equivalent techniques.

25. The composition of claim 1 , wherein the human cardiac cells are cryopreserved.

26. The composition of claim 1 , wherein the human cardiac cells are expanded in vitro.

27. The composition of claim 26 , wherein the human cardiac cells are expanded in vitro.

28. 27. The composition of claim 26, wherein the human cardiac cells are grown in vitro using Good Manufacturing Practice (GMP) conditions.

29. 29. The composition of claim 28, wherein the GMP conditions include: (a) controlled physiological cell culture conditions, said conditions comprising a continuous atmosphere of about 5% oxygen, about 5% carbon dioxide, a relative humidity of about 80%, and a temperature of about 37° C.; (b) a serum-free, xeno-free growth medium, and (c) Fetal bovine serum depleted of extracellular vesicles.

30. 28. The composition of claim 27, wherein the human cardiac cells are grown in vitro using GMP conditions.

31. 31. The composition of any one of claims 26 to 30, wherein the human cardiac cells are grown in vitro using GMP-compliant enzymes to detach the cells from the culture plate.

32. 32. The composition of claim 31 , wherein the GMP compliant enzyme is TrypLE™ Select.

33. 32. The composition of claim 31, wherein the GMP compliant enzyme is one or more of collagenase I and collagenase II, or a combination thereof.

34. 34. The composition of any one of claims 26 to 33, wherein the extracellular vesicles are isolated after about 12 hours to about 72 hours of incubation.

35. 35. The composition of any one of claims 26 to 34, wherein the extracellular vesicles are isolated after incubation for about 48 hours or more.

36. The composition of claim 1 , which is substantially immunologically inactive.

37. The composition of claim 1, wherein the extracellular vesicles comprise a polydisperse population of particles having diameters ranging from about 95 nm to about 170 nm.

38. The composition of claim 1, wherein the extracellular vesicles comprise a polydisperse population comprising an average diameter of about 125 nm to about 140 nm.

39. The composition of claim 1, wherein the extracellular vesicles comprise a polydisperse population comprising an average diameter of about 132 nm.

40. The composition of claim 1 , wherein the one or more cytoplasmic markers are defined by ALIX, ANXA5, and TSG101, or any combination thereof.

41. 2. The composition of claim 1, wherein the one or more transmembrane markers are defined by CD9, CD61, CD63, CD81, FLOT1, ICAM1, EpCam, or any combination thereof.

42. The composition of claim 41, wherein CD81 is expressed on an equal or fewer number of particles than particles expressing CD9 or CD63.

43. The composition of claim 42, wherein CD81 is expressed on approximately half or less of the number of particles compared to the number of particles expressing CD63.

44. 2. The composition of claim 1, wherein the acetylcholinesterase activity is measured using a Fluorocet exosome quantification kit or equivalent methodology.

45. 2. The composition of claim 1, which is substantially devoid of or devoid of GM130.

46. The composition of claim 1, wherein the miRNA comprises between 10 and 100 unique transcripts.

47. The composition of claim 1, wherein the miRNA comprises 60-85 unique transcripts.

48. The composition according to claim 1, comprising one or more of the following: miR-23a-3p, miR-199a-3p + miR-199b-3p, miR-4454 + miR-7975, let-7a-5p, let-7b-5p, miR-125b-5p, miR-100-5p, miR-29b-3p, miR-21-5p, miR-191-5p, miR-199b-5p, miR-29a-3p, miR-22-3p, let-7i-5p, miR-181a-5p, miR-25-3p, miR-127-3p, let-7g-5p, miR-15b-5p, miR-320e, miR-221-3p, let-7d-5p, miR-16-5p, miR-424-5p, miR-3180, miR-374a-5p, miR-15a-5p, miR-130a-3p, miR-376a-3p, miR-199a-5p, miR-222-3p, miR-4286, miR-4516, miR-34a-5p, miR-1255a, miR-365a-3p + miR-365b-3p, miR-323a-3p, let-7c-5p, miR-27b-3p, miR-134-3p, miR-451a, miR-23b-3p, miR-423-5p, miR-28-5p, miR-125a-5p, miR-24-3p, miR-382-5p, miR-1228-3p, miR-20a-5p + miR-20b-5p, let-7e-5p, miR-18a-5p, miR-337-5p, miR-320e, miR-106a-5p + miR-17-5p, miR-19b-3p, miR-140-5p, let-7f-5p, miR-323a-5p, miR-148a-3p, miR-132-3p, miR-136-5p, miR-376c-3p, miR-379-5p, miR-26a-5p, miR-202-3p, miR-1290, miR-154-5p, miR-214-3p, miR-377-3p, miR-381-3p, miR-188-5p, miR-26b-5p, miR-363-3p, miR-337-3p, miR-137, miR-1973, miR-193a-5p + miR-193b-5p, miR-411-5p, functional equivalents, or combinations thereof.

49. 49. The composition of any one of claims 1 to 48, wherein the miRNA transcript is substantially devoid of or devoid of one or more of miR-1, miR-133, miR-328, miR-590, or any combination thereof.

50. 50. The composition of any one of claims 1-49, wherein the miRNA transcript is substantially devoid of, or devoid of, one or more of miR-210, miR-146a, or a combination thereof.

51. The unit dose of the extracellular vesicles is 10 per milliliter 8 ~10 12 The composition of claim 1 comprising particles.

52. The unit dose of the extracellular vesicles is 10 per milliliter 10 The composition of claim 1 comprising particles.

53. 53. A composition according to any one of claims 1 to 52 for use in the treatment of atrial arrhythmia.

54. 54. The composition of claim 53, wherein the atrial arrhythmia is selected from the group consisting of atrial fibrillation, atrial fibrillation, post-operative atrial fibrillation, post-infarction atrial fibrillation, thyrotoxicosis, post-viral atrial fibrillation, alcohol-related atrial fibrillation, drug-related atrial fibrillation, induced atrial fibrillation, viral atrial fibrillation, viral atrial fibrillation, COVID-19 atrial fibrillation, post-COVID-19 atrial fibrillation, paroxysmal atrial fibrillation, permanent atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, atrial tachycardia, atrial flutter, familial atrial fibrillation, idiopathic atrial fibrillation, isolated atrial fibrillation, and orphan atrial arrhythmia.

55. 55. The composition of any one of claims 1 to 54, wherein the extracellular vesicles are delivered systemically.

56. 55. The composition of any one of claims 1 to 54, wherein the extracellular vesicles are delivered locally.

57. 57. The composition of claim 56, wherein the extracellular vesicles are delivered intramyocardium.

58. 58. The composition of claim 57, wherein the extracellular vesicles are delivered into the atrium.

59. 59. The composition of any one of claims 1 to 58, wherein the extracellular vesicles are delivered by catheter.

60. 60. The composition of claim 59, wherein the extracellular vesicles are delivered by a central venous access device.

61. 60. The composition of claim 59, wherein the extracellular vesicles are delivered by a peripherally inserted central catheter.

62. 62. The composition of any one of claims 1 to 61, wherein the extracellular vesicles reduce or prevent atrial inflammation.

63. 63. The composition of claim 62, wherein the reduction in atrial inflammation is quantified histologically and comprises a reduction in the number of inflammatory cells in the atria of the heart compared to untreated controls.

64. 64. The composition of claim 63, wherein the number of inflammatory cells in the atrium is quantified using one or more markers including hematoxylin and eosin staining, activated T lymphocytes, macrophage infiltration, macrophage polarization, mast cells, neutrophils, or any combination thereof.

65. 65. The composition of any one of claims 63 to 64, wherein the histological reduction in the number of inflammatory cells in the atrium comprises a reduction ranging from about 1% to about 100% of inflammatory cells in the atrium when compared to untreated subjects.

66. 63. The composition of claim 62, wherein the reduction in atrial inflammation is a reduction in cytokine levels in the heart compared to an untreated subject.

67. 67. The composition of claim 66, wherein the one or more cytokines comprise IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-11, IL-13, IL-16, IL-17, IL-18, G-CSF, GM-CSF, MCP-1, PDGF-AB, TNF-α, any Type I IFN, any Type II IFN, any Type III IFN, or any combination thereof.

68. 67. The composition of claim 66, wherein the one or more cytokines comprise IL-1β, IL-2, IL-6, IL-10, IL-18, PDGF-AB, MCP-1, TNF-α, or any combination thereof.

69. 69. The composition of any one of claims 66-68, wherein the reduction in cytokine levels is quantified using a multiplex Luminex™ assay and comprises about a 1% to about 100% reduction in one or more cytokines compared to an untreated subject.

70. 69. The composition of any one of claims 66 to 68, wherein the reduction in cytokine levels is quantified using an enzyme-linked immunosorbent assay (ELISA) and comprises about a 1% to about 100% reduction in one or more cytokines compared to an untreated subject.

71. 71. The composition of any one of claims 1 to 70, wherein the extracellular vesicles reduce or prevent atrial fibrosis.

72. 72. The composition of claim 71, wherein the composition reduces atrial fibrosis by decreasing atrial collagen levels as compared to untreated subjects.

73. 73. The composition of claim 72, wherein atrial collagen levels are quantified using hydroxyproline.

74. 74. The composition of claim 73, comprising about a 1% to about a 100% decrease in hydroxyproline levels compared to an untreated subject.

75. 74. The composition of claim 73, comprising about a 25% to about a 75% decrease in hydroxyproline levels compared to an untreated subject.

76. 74. The composition of claim 73, comprising about a 40% to about 60% decrease in hydroxyproline levels compared to an untreated subject.

77. 77. The composition of any one of claims 1 to 76, wherein the extracellular vesicles reduce proliferation of atrial fibroblasts.

78. 78. The composition of claim 77, wherein the reduction in atrial fibroblast proliferation is a relative reduction in atrial fibroblast numbers over time compared to untreated controls.

79. 79. The composition of any one of claims 77 to 78, comprising a reduction in relative atrial fibroblast numbers over time of about 1% to about 100% when compared to untreated subjects.

80. 78. The composition of claim 77, wherein the reduction in atrial fibroblast proliferation comprises a reduction in the number of cells in the S phase of the cell cycle compared to untreated subjects.

81. 81. The composition of claim 80, wherein the number of cells in S phase of the cell cycle is measured using one or more of flow cytometry, Western blot, ELISA, bromodeoxyuridine (BrDU), 5-ethynyl-2'deoxyuridine (EdU), any nucleoside analogue, phosphorylation of retinoblastoma protein, cyclin D, cyclin E, cyclin A, cyclin B, any equivalent method, or any combination thereof.

82. 82. The composition of claim 81, wherein the number of cells in the S phase of the cell cycle is measured using EdU.

83. 83. The composition of any one of claims 80 to 82, comprising about a 1% to about 100% reduction in the number of cells in the S phase of the cell cycle when compared to an untreated subject.

84. 78. The composition of claim 77, wherein the reduction in atrial fibroblast proliferation is an increase in the number of cells in G0 or G1 of the cell cycle compared to an untreated subject.

85. 85. The composition of claim 84, wherein the number of cells in G0 or G1 of the cell cycle is measured using one or more of the following: flow cytometry, Western blot, ELISA, Ki67, BrDU, EdU, propidium iodide, phosphorylation of retinoblastoma protein, cyclin D, cyclin E, any equivalent method, or a combination thereof.

86. The composition of claim 84, wherein the number of cells in G0 or G1 of the cell cycle is measured using flow cytometry.

87. 87. The composition of any one of claims 84 to 86, wherein the increase in cell number in G0 or G1 of the cell cycle comprises an increase of about 1% to about 100% or more compared to an untreated subject.

88. 78. The composition of claim 77, wherein the reduction in atrial fibroblast proliferation comprises a reduction in the number of cells in the G2 or M phase of the cell cycle compared to an untreated subject.

89. The composition of claim 88, wherein the reduction in the number of cells in the G2 or M phase of the cell cycle compared to an untreated subject is measured using one or more of the following: flow cytometry, Western blot, ELISA, phosphorylation of histone H3, propidium iodide, cyclin B, cyclin E, cyclin A, cyclin D, CDK1, CDK2, DAPI, Hoechst, Ki67, any equivalent method, or a combination thereof.

90. 90. The composition of any one of claims 88 to 89, wherein the reduction in cell number in the G2 or M phase of the cell cycle is measured using flow cytometry.

91. 91. The composition of any one of claims 88 to 90, wherein the reduction in the number of cells in G2 or M of the cell cycle comprises a reduction of about 1% to about 100% when compared to an untreated subject.

92. 78. The composition of claim 77, wherein the reduction in atrial fibroblast proliferation comprises a reduction in transcription of one or more positive cell cycle regulatory genes compared to untreated subjects.

93. 93. The composition of claim 92, wherein the genes that positively regulate the cell cycle include one or more of cyclin D, cyclin E, cyclin A, and cyclin B.

94. 77. The composition of claim 76, wherein the reduction in atrial fibroblast proliferation comprises an increase in transcription of one or more negative cell cycle regulatory genes compared to untreated subjects.

95. The composition of any one of claims 1 to 94, wherein the extracellular vesicles reduce the relative mass of the atria when compared to an untreated subject, comprising comparing the ratio of atrial mass to total body weight (relative mass = atrial mass / total body weight) between a subject treated with extracellular vesicles and an untreated subject.

96. 96. The composition of claim 95, wherein the reduction in relative atrial mass compared to an untreated subject comprises a reduction in relative mass of about 1% to about 100%.

97. The composition of claim 1 , wherein the biologically or pharma- ceutically acceptable adjuvant or carrier is suitable for systemic delivery.

98. The composition of claim 1 , wherein the biologically or pharma- ceutically acceptable adjuvant or carrier is suitable for local delivery.

99. 99. The composition of claim 98, wherein the biologically or pharma- ceutically acceptable adjuvant or carrier is suitable for intramyocardial delivery.

100. 100. The composition of claim 99, wherein the biologically or pharma- ceutically acceptable adjuvant or carrier is suitable for intra-atrial delivery.

101. 101. The composition of claim 100, wherein the biologically or pharma- ceutical acceptable adjuvant or carrier is suitable for catheter delivery.

102. 102. The composition of any one of claims 1 to 101, wherein the extracellular vesicles improve one or more symptoms including general fatigue, rapid heartbeat, irregular heartbeat, dizziness, shortness of breath, anxiety, fainting, heart failure, pounding in the neck, weakness, confusion, fainting, sweating, chest pain, chest pressure, pounding in the chest, or any combination thereof.

103. 103. The composition of any one of claims 1 to 102, wherein the extracellular vesicles reduce the duration of atrial fibrillation.

104. The composition of claim 103, wherein the reduction in the duration of atrial fibrillation is determined using an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or a combination thereof.

105. The composition of any one of claims 1 to 104, wherein the extracellular vesicles reduce the incidence of atrial fibrillation.

106. The composition of claim 105, wherein the reduction in incidence of atrial fibrillation is determined using an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or a combination thereof.

107. The composition of claim 1 , wherein the extracellular vesicles are solubilized by the addition of a detergent.

108. 108. The composition of claim 107, wherein the surfactant comprises a solution of about 0.1% Triton™ X-100.

109. The composition of claim 108, wherein solubilization is measured by a reduction in the number of extracellular vesicle particles compared to a sample that has not been treated with a detergent.

110. 110. A method for the treatment or prevention of atrial arrhythmia comprising administering to a subject in need thereof a composition according to any one of claims 1 to 109.

111. 110. A method for the treatment or prevention of atrial fibrosis comprising administering to a subject in need thereof a composition according to any one of claims 1 to 109.

112. 110. A method for the treatment or prevention of atrial inflammation comprising administering to a subject in need thereof a composition according to any one of claims 1 to 109.

113. 110. A method for the treatment or prevention of atrial fibroblast proliferation comprising administering to a subject in need thereof a composition according to any one of claims 1 to 109.

114. The method of claim 110, wherein the atrial arrhythmia is selected from the group consisting of atrial fibrillation, post-operative atrial fibrillation, post-infarction atrial fibrillation, thyrotoxicosis, post-viral atrial fibrillation, alcohol-related atrial fibrillation, drug-induced atrial fibrillation, viral atrial fibrillation, viral atrial fibrillation, COVID-19 atrial fibrillation, post-COVID-19 atrial fibrillation, paroxysmal atrial fibrillation, permanent atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, atrial tachycardia, atrial flutter, familial atrial fibrillation, idiopathic atrial fibrillation, isolated atrial fibrillation, and orphan atrial arrhythmia.

115. 115. The method of claim 114, wherein the atrial arrhythmia is diagnosed by one or more technologies including an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or any combination thereof.

116. The method of claim 115, wherein the subject with atrial arrhythmia has one or more symptoms including general fatigue, rapid heartbeat, irregular heartbeat, dizziness, shortness of breath, anxiety, fainting, heart failure, pounding in the neck, weakness, confusion, fainting, sweating, chest pain, chest pressure, pounding in the chest, or a combination thereof.

117. 117. The method of any one of claims 110 to 116, wherein the administration comprises systemic administration.

118. 117. The method of any one of claims 110 to 116, wherein the administration comprises topical administration.

119. 119. The method of claim 118, wherein the administration comprises intramyocardial administration.

120. 120. The method of claim 119, wherein the administration comprises intra-atrial administration.

121. 121. The method of any one of claims 118 to 120, wherein the local administration comprises injection.

122. 122. The method of claim 121, wherein the local administration comprises injections, including from about 1 to about 500 injections.

123. The local administration, including injection, is 2 Approximately 10.00 cm from each 2 123. The method of any one of claims 121 to 122, comprising an injection every 24 hours.

124. 120. The method of claim 119, wherein the intramyocardial administration comprises injection.

125. 125. The method of claim 124, wherein the intramyocardial administration comprising injections comprises from about 1 to about 500 injections.

126. The intramyocardial administration, including injection, is 2 Approximately 10.00 cm from each 2 126. The method of claim 125, comprising one injection per

127. 121. The method of claim 120, wherein the intra-atrial administration comprises an injection.

128. 128. The method of claim 127, wherein the intra-atrial administration comprising injections comprises from about 1 to about 500 injections.

129. The intra-atrial administration, including injection, is performed in an amount of about 0.10 cm 2 of atrial surface area. 2 Approximately 10.00 cm from each 2 129. The method of claim 128, comprising one injection per

130. 121. The method of any one of claims 110 to 120, wherein the extracellular vesicles are administered by catheter.

131. 131. The method of any one of claims 110 to 130, wherein the extracellular vesicles reduce atrial inflammation.

132. 132. The method of claim 131, wherein the reduction in atrial inflammation is quantified histologically and comprises a reduction in the number of inflammatory cells in the atria of the heart compared to untreated subjects.

133. 133. The method of claim 132, wherein the number of inflammatory cells in the atrium is quantified using one or more markers including hematoxylin and eosin staining, activated T lymphocytes, macrophage infiltration, macrophage polarization, mast cells, neutrophils, or any combination thereof.

134. 134. The method of any one of claims 132 to 133, wherein the histological reduction in the number of inflammatory cells in the atrium comprises a reduction of about 1% to about 100% of inflammatory cells in the atrium compared to an untreated subject.

135. 132. The method of claim 131, wherein the reduction in atrial inflammation is a reduction in cytokine levels in the heart compared to an untreated subject.

136. 136. The method of claim 135, wherein the one or more cytokines comprise IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-11, IL-13, IL-16, IL-17, IL-18, G-CSF, GM-CSF, MCP-1, PDGF-AB, TNF-α, any type I IFN, any type II IFN, any type III IFN, or any combination thereof.

137. 136. The method of claim 135, wherein the one or more cytokines comprise IL-1β, IL-2, IL-6, IL-10, IL-18, PDGF-AB, TNF-α, or any combination thereof.

138. 138. The method of any one of claims 135-137, wherein the reduction in cytokine levels is quantified using a multiplex Luminex assay and comprises a reduction of about 1% to about 100% in one or more cytokines compared to an untreated subject.

139. 139. The method of any one of claims 110 to 138, wherein the extracellular vesicles reduce atrial fibrosis.

140. 140. The method of claim 139, wherein atrial fibrosis is reduced by reducing atrial collagen.

141. 141. The method of claim 140, wherein atrial collagen levels are quantified using hydroxyproline, any equivalent, or any combination thereof.

142. 142. The method of claim 141, comprising reducing hydroxyproline levels by about 1% to about 100% when compared to an untreated subject.

143. The method of any one of claims 110 to 142, wherein the extracellular vesicles reduce proliferation of atrial fibroblasts.

144. The method of claim 143, wherein the reduction in atrial fibroblast proliferation comprises a reduction in the number of cells in the S phase of the cell cycle compared to untreated subjects.

145. 145. The method of claim 144, wherein the number of cells in S phase of the cell cycle is measured using one or more of flow cytometry, Western blot, ELISA, bromodeoxyuridine (BrDU), 5-ethynyl-2'deoxyuridine (EdU), any nucleoside analogue, Ki67, phosphorylation of retinoblastoma protein, cyclin D, cyclin E, cyclin A, cyclin B, any equivalent method, or any combination thereof.

146. 146. The method of claim 145, wherein the number of cells in the S phase of the cell cycle is measured using EdU.

147. 147. The method of any one of claims 144 to 146, comprising reducing the number of cells in the S phase of the cell cycle by about 1% to about 100% when compared to an untreated subject.

148. 144. The method of claim 143, wherein the decrease in atrial fibroblast proliferation is an increase in the number of cells in G0 or G1 of the cell cycle compared to an untreated subject.

149. 149. The method of claim 148, wherein the number of cells in G0 or G1 of the cell cycle is measured using one or more of flow cytometry, Western blot, ELISA, Ki67, BrDU, EdU, propidium iodide, phosphorylation of retinoblastoma protein, cyclin D, cyclin E, any equivalent method, or any combination thereof.

150. The method of claim 148, wherein the number of cells in G0 or G1 of the cell cycle is measured using flow cytometry.

151. 151. The method of any one of claims 148 to 150, wherein the increase in cell number in G0 or G1 of the cell cycle comprises an increase of about 1% to about 100% or more compared to an untreated subject.

152. 144. The method of claim 143, wherein the reduction in atrial fibroblast proliferation comprises a reduction in the number of cells in the G2 or M phase of the cell cycle compared to an untreated subject.

153. The method of claim 152, wherein the reduction in cell number in the G2 or M phase of the cell cycle is measured using one or more of the following: flow cytometry, Western blot, ELISA, Ki67, phosphorylation of histone H3, propidium iodide, cyclin B, cyclin B, cyclin A, cyclin D, CDK1, CDK2, DAPI, Hoechst, Ki67, any equivalent method, or a combination thereof.

154. The method of claim 152, wherein the reduction in the number of cells in the G2 or M phase of the cell cycle compared to an untreated subject is measured using flow cytometry.

155. 155. The method of any one of claims 152 to 154, wherein the reduction in the number of cells in G2 or M of the cell cycle comprises a reduction of about 1% to about 100% when compared to an untreated subject.

156. The method of claim 143, wherein said reduction in atrial fibroblast proliferation comprises a reduction in transcription of one or more positive cell cycle regulatory genes compared to untreated subjects.

157. 157. The method of claim 156, wherein the genes that positively regulate the cell cycle include one or more of cyclin D, cyclin E, cyclin A, and cyclin B.

158. The method of claim 143, wherein said reduction in atrial fibroblast proliferation comprises an increase in transcription of one or more negative cell cycle regulatory genes compared to untreated subjects.

159. 159. The method of any one of claims 110 to 158, wherein the extracellular vesicles improve one or more symptoms including general fatigue, rapid heartbeat, irregular heartbeat, dizziness, shortness of breath, anxiety, weakness, confusion, fainting, sweating, chest pain, chest pressure, chest pounding, or a combination thereof.

160. 160. The method of any one of claims 110 to 159, wherein the extracellular vesicles reduce the duration of atrial fibrillation.

161. The method of claim 160, wherein the reduction in the duration of atrial fibrillation is determined using an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or a combination thereof.

162. The method of any one of claims 110 to 161, wherein the extracellular vesicles reduce the incidence of atrial fibrillation.

163. 163. The method of claim 162, wherein the reduction in incidence of atrial fibrillation is determined using an electrocardiogram, a continuous electrocardiogram monitor, a blood pressure monitor, a Holter monitor, an event monitor, a blood test, an echocardiogram, a stress test, a chest x-ray, a smart watch, a smart ring, wearable technology capable of measuring heart rate, equivalent technology, or a combination thereof.

Citation Information

Patent Citations

  • Cardiosphere-derived cells and their extracellular vesicles for the treatment and prevention of cancer

    JP2020529477A

  • CDC-derived exosomes for treatment of ventricular tachyarrythmias

    US20190160111A1

  • Engineered stem cells and cellular products produced and secreted by such cells, methods of preparing, and uses thereof

    US20200172871A1